Protocol Number: VXA -NVV -201 
 
Official Title:  A Phase 2b Double -blinded, Randomized, Placebo -Controlled, Human Norovirus GI.1 
(Norwalk Virus Inoculum) Challenge Study Following Administration of an Oral, Single -dose 
Norovirus Vaccine expressing GI.[ADDRESS_366122] Norovirus 
Gastroenteritis (NVG) in Healthy Adult Volunteers  
 
Study ID: [REMOVED]  
 
Document Date: 25 May 2023   
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 3 of 114 
Date: 25 May 2023  
 TABLE OF CONTENTS:  
SIGNATURE [CONTACT_1783]/STATEMENT OF COMPLIANCE  ................................ ................... [ADDRESS_366123] OF ABBREVIATIONS AND ACRONYMS  ................................ .............................  8 
CLINICAL PROTOCOL SYNOPSIS  ................................ ................................ ................  10 
Primary Endpoint  ................................ ................................ ................................ ................. 19 
Secondary Endpoints  ................................ ................................ ................................ ...........19 
1 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  ................................ ................................ ................................ ........................  22 
1.1 Background  ................................ ................................ ................................ ............22 
1.2 Norovirus vaccine: General Properties & Pharmacodynamics  ............................. [ADDRESS_366124] Description  ................................ ................................ .....24 
1.3 Summary of Nonclinical Studies  ................................ ................................ ...........24 
1.4 Summary of Clinical Studies with Vaxart Oral Vaccine Platform  ........................ 25 
 Norovirus Phase 1 Study VXA -G11-101 ................................ .............................. 25 
 Norovirus Phase 1 Dose Optimization Study VXA -G11-102 ............................... 28 
 Clinical Study VXA -NVV-103 with VXA -G1.1-NN and VXA -G2.4-NS ...........30 
Summary of Safety  ................................ ................................ ................................ ............. 31 
Summary of Immunogenicity Analysis  ................................ ................................ .............. 32 
1.5 Norovirus Human Challenge Model ................................ ................................ ......33 
1.6 NV Challenge Dose Titration Study and Dose Justification  ................................ .36 
1.7 Summary of Clinical Experience with Vaxart Oral Vaccine Platform  ................. 38 
1.8 Rationale for GI.1 Human Challenge Study (VXA -NVV-201) ............................ 39 
1.9 Potential Risks and Benefits  ................................ ................................ .................. 39 
 Vaccine Risks  ................................ ................................ ................................ ........39 
 Norovirus Challenge Risks  ................................ ................................ .................... 40 
 Risk of Blood Draw  ................................ ................................ ............................... 40 
 Known Potential Benefits  ................................ ................................ ...................... 40 
2 HYPOTHESIS, OBJECTIVES AND PURPOSE  ................................ ......................  40 
2.1 Study Hypothesis  ................................ ................................ ................................ ...40 
2.2 Study Objectives  ................................ ................................ ................................ ....40 
 Primary Objective  ................................ ................................ ................................ ..40 
 Secondary Objectives  ................................ ................................ ............................ 40 
 Exploratory Objectives  ................................ ................................ .......................... 41 
3 STUDY DESIGN AND ENDPOINTS  ................................ ................................ ......... 41 
3.1 Description of Study Design ................................ ................................ .................. 41 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 4 of 114 
Date: [ADDRESS_366125] Withdrawals or Termination  ................................ ................ 47 
5 STUDY DRUG  ................................ ................................ ................................ .............. 48 
5.1 Study Drug(s) and Control Description  ................................ ................................ .[ADDRESS_366126] Dosage Preparation and Administration  ................................ .........49 
 Study Drug Accountability  ................................ ................................ .................... 49 
6 NV CHALLENGE INOCULUM ................................ ................................ .................  50 
6.1 Formulation, Packaging, and Labeling of NV Challenge Virus  ............................ 50 
6.2 Storage and Stability of NV Challenge Virus  ................................ ....................... 50 
6.3 Preparation and Administration of NV Challenge Virus  ................................ .......51 
7 STUDY PROCEDURES AND SCHEDULE  ................................ ..............................  51 
7.1 Pre-Screening Period (Day -90 to Screening)  ................................ ....................... 51 
7.2 Visit 00: Screening Visit (Study Day -45 to -1) ................................ .................... 52 
7.3 Visit 01: Study Day 1, Study Drug Administration ................................ ...............52 
7.4 Visit 02: Study Day 8  ................................ ................................ ............................ 53 
7.5 Visit 03: Study Day 28, 1 day prior to challenge [+3 days for visit window and 
+30 days window for repeat Visit 03]  ................................ ................................ ................. 53 
7.6 Visit 04: Study Day 29 (Challenge Day)  ................................ ............................... 55 
 Pre-challenge Assessments  ................................ ................................ .................... 55 
 Viral Challenge Eligibility ................................ ................................ ..................... 55 
 Viral Challenge Administration  ................................ ................................ .............56 
 Visits 04 – 08: Post-Challenge Observation Period  (Day 29 – Day 33 [+ 3 Days])
 56 
7.7 Visit 09: Study Day 36 ([ADDRESS_366127] challenge)  ................................ ................... 57 
7.8 Visit 10: Study Day 57 ([ADDRESS_366128] challenge ± 3 days)  ................................ ...58 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 5 of 114 
Date: 25 May 2023  
 7.9 Visit 11 (Day 120) – Visit 14 (Day 300) Safety Follow -up Contacts  ................... 58 
7.10  Visit 15: Study Day 365 ([ADDRESS_366129] challenge + 1 week)  End of Study 
Contact 58 
7.11  Early Termination  ................................ ................................ ................................ ..59 
 Early Termination (Day 1 – Day 28; Vaccine Phase)  ................................ ...........59 
 Early Termination ( –ay 29 - Day 57;  Challenge Phase)  ................................ .......59 
 Early Termination (Day 58 to Day 365 – Safety Follow -Up Period)  ................... 59 
7.12  Unscheduled Visit(s)  ................................ ................................ ............................. 60 
7.13  Immunogenicity Assessments  ................................ ................................ ...............60 
7.14  Assessment of Clinical Illness  ................................ ................................ ...............60 
7.15  Norwalk Virus Infection  ................................ ................................ ........................ 60 
7.16  Microbiological Assessments  ................................ ................................ ................ 61 
8 MANAGEMENT OF EXPECTED NOROVIRUS ILLNESS  ................................ .. 61 
8.1 Clinical Evaluation  ................................ ................................ ................................ 61 
8.2 Study Definitions  ................................ ................................ ................................ ...61 
8.3 Measurement of Diarrhea and Vomitus  ................................ ................................ .61 
8.4 Management of Fluid Loss  ................................ ................................ .................... 62 
8.5 Indications for Concomitant Medications  ................................ ............................. 62 
8.6 Prohibited and Controlled Medications/Treatments  ................................ ..............[ADDRESS_366130] (AESI)  ................................ ..........66 
9.4 Definition of New Onset of Chronic Illness (NOCI)  ................................ ............66 
9.5 Study Halting Rules  ................................ ................................ ............................... 67 
9.6 Safety Oversight  ................................ ................................ ................................ ....67 
9.7 Safety Monitoring Committee (SMC)  ................................ ................................ ...67 
10 CLINICAL MONITORING  ................................ ................................ ........................  68 
11 STATISTICAL CONSIDERATIONS  ................................ ................................ ........ 68 
11.1  Study Hypothesis  ................................ ................................ ................................ ...68 
11.2  Sample Size Determination  ................................ ................................ ................... 69 
11.3  Treatment Assignment Procedures  ................................ ................................ ........69 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 6 of 114 
Date: 25 May 2023  
 
 Randomization Procedures  ................................ ................................ .................... 69 
 Blinding Procedures  ................................ ................................ .............................. 70 
11.4  Final Analysis Plan  ................................ ................................ ................................ 70 
11.5  Missing Values and Outliers  ................................ ................................ .................. 70 
11.6  Interim Analysis  ................................ ................................ ................................ ....71 
11.7 Exploratory Analysis  ................................ ................................ ............................. 71 
12 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .. 72 
12.1  Source Documentation  ................................ ................................ .......................... 72 
12.2  Data Management  ................................ ................................ ................................ ..72 
13 QUALITY ASSURANCE AND QUALITY CONTROL  ................................ .......... 72 
14 ETHICAL CONSIDERATIONS (AND INFORMED CONSENT)  .........................  [ADDRESS_366131]  ................................ ................................ .................... 73 
14.3  Informed Consent Process  ................................ ................................ ..................... 73 
14.4  Exclusion of Women, Minorities, and Children (Special Populations)  ................ [ADDRESS_366132] Confidentiality  ................................ ................................ .......................... 74 
15 REFERENCES  ................................ ................................ ................................ .............. 74 
APPENDIX A:        SCHEDULE OF EVENTS  ................................ ................................  77 
APPENDIX B:   CHALLENGE VIRUS PREPARATION  ................................ ............... 78 
APPENDIX C:  GRADING OF SIGNS AND SYMPTOM S OF ACUTE      
GASTROENTERITIS  ................................ ................................ ................  82 
APPENDIX D:   MODIFIED VESIKARI SCALE (17 POINTS)  ................................ ..... 83 
APPENDIX E:      LIST OF ADVERSE EVENTS OF SPECIAL INTEREST (AESIs)  .. 84 
APPENDIX F:  Preparation of NV Challenge Inoculum  ................................ .....................  87 
APPENDIX G:      SUMMARY OF CHANGES TO PROTOCOL  ................................ ... 91 
 
TABLES AND FIGURES  
 
Table 1:  VXA-G1.1-NN Product Description  ................................ ................................ ....................  24 
Table 2:  Subject Enrollment in Study VXA -G11-101 ................................ ................................ ....... 26 
Table 3:  Solicited Symptoms (Solicited TEAEs in Study VXA -G1.1-101) ................................ ...... 26 
Table 4:  Geometric Mean Titer (GMT), GM Fold Rise (GMFR) and Statistical Significance  
for Leb and H1 BT 50 assay in Study VXA -G11-101 ................................ ...........................  27 
Table 5:  Treatment Groups and Dosing Regimens in Study VXA -G11-102 ................................ ..... 28 
Table 6:  Solicited Adverse Events in Study VXA -G11-102 ................................ ..............................  29 
Table 7:  Comparison of BT 50 Antibody Results Among Groups in the  
VXA-G11-101 and VXA -G11-102 Trials  ................................ ................................ ........... 29 
Table 8:    Design of Study VXA -NVV-103……………………………………………………… ….30 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 7 of 114 
Date: 25 May 2023  
 Table 9:   Summary of Solicited Symptoms of Reactogenicity (Study VXA -NVV-103)……………31  
Table 10: Norwalk Virus Infection and Illness Rates after Challenge with NV 8fIIa (Atmar Study)  . 33 
Table 11: Dose respon se for Norwalk strain 8fIIa and 8fIIb (Teunis Study)  ................................ ....... 34 
Table 12: Summary of Norovirus Challenge Studies – C. Moe’s Lab; Emory University  ..................  34 
Table 13: Symptoms Re ported After Challenge with Norwalk Strain 8fIIb  ................................ ........ 35 
Table 14: Description of illness after challenge with two different doses of Norwalk virus  
(Study VXA -G11-201.1) ................................ ................................ ................................ .... 36 
Table 15: Summary of  the correlation between acute  gastroenteritis and NV positive by [CONTACT_9084]…...  37 
Table 16: Characterization of diarrhea in subjects with acute gastroenteritis and NV positivity by 
[CONTACT_9084] (by [CONTACT_8477] )…………………………………………………………………………...37  
Table 17: Clinical Studies Co mpleted Using Vaxart Oral Ad5 Vaccine Platform, 2011 -2017 ........... 38 
Table 18: Study Design and Vaccine Groups (Study VXA -NVV-201) ................................ ............... 42 
Table 19: Active Product Description (VXA -G1.1-NN) ................................ ................................ ..... 48 
Table 20: SOLICITED SYMPTOM REACTOGENICITY TABLE  ………………………………   60  
Table 21: Power Calculations  ……………………………………………………………….. 69 
 
Figure 1:  VP1-Specific Antibody Secreting Cells Measured 7 Days After Immunization  
(Study VXA -G1.1-101)................................ ................................ ................................ ........ 27 
Figure 2: Overall IgA ASC Response Rate After Either One or Two Doses  
(Study VXA -G1.1-102)................................ ................................ ................................ ........ 30 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 8 of 114 
Date: [ADDRESS_366133]  
IU  Infectious unit(s)  
IV  Intravenous  
MedDRA  Medical Dictionary for Regulatory Activities  
MLF  Mucosal lining fluid  
MM  Medical Monitor  
Nab  Neutralizing antibody  
NOCI  New Onset of Chronic Illness  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 9 of 114 
Date: 25 May 2023  
 NoV  Norovirus  
NV  Norwalk Virus  
NVG  Norovirus gastroenteritis  
OHRP  Office for Human Research Protections  
PBMC  Peripheral Blood Mononuclear Cells  
PI  [INVESTIGATOR_299974]4   Platelet Factor 4 antibody ELISA  
QA  Quality Assurance  
QC  Quality Control  
rAd5  recombinant Ad5  
qRT-PCR Quantitative Reverse Transcriptase Polymerase Chain Reaction  
SAE  Serious Adverse Event/Serious Adverse Experience  
SAM  Synthetic absorption matrix  
SigA  Secretory IgA  
SMC  Safety Monitoring Committee  
SOP  Standard Operating Procedure  
TTS  Thrombolytic and thrombocytopenic syndrom e 
US  [LOCATION_002]  
USDA  [LOCATION_002] Department of Agriculture  
US EPA [LOCATION_002] Environmental Protection Agency  
VLP  Virus-like Particle  
VP1  Viral protein 1, major capsid or surface protein of viruses  
WHO-DD World Health Organization Drug Dictionary  
  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 10 of 114 
Date: 25 May 2023  
 CLINICAL PROTOCOL SYNOPSIS  
Study Title A Phase 2b Double -Blinded, Randomized, Placebo -Controlled, Human 
Norovirus GI.1 (Norwalk Virus Inoculum ) Challenge Study Following 
Administration of an Oral, Single -dose Norovirus Vaccine expressing GI.[ADDRESS_366134] Norovirus Gastroenteritis 
(NVG) in Healthy Adult Volunteers  
Protocol Number  VXA-NVV-201 
Sponsor Vaxart, Inc.  
IND Number  [ZIP_CODE] 
Trial Phase  Phase 2b 
Study Population  Approximately   170 healthy male and female adult volunteers  age 18 to 49 
years  inclusive with blood type O or A and who are confirmed H type-1 
antigen secretor y positive  (approximately  [ADDRESS_366135]-vaccination )   
Investigational Site  1 qualified US site (with isolation unit)  
•  
Investigational 
Product Active Vaccine:  
• Norovirus G I.1 Norwalk VP1 Vaccine (VXA -G1.1-NN), an Oral E1/E3 -
Deleted Replication -Defective Recombinant Adenovirus serotype 5 with  
double-stranded ribonucleic acid  (dsRNA) Adjuvant. The vaccine vector 
encodes for a full -length VP1 gene from Norwalk virus  (NV). The 
adjuvant is a short hairpin RNA, expressed as a 21 nucleotide  sequence 
(GAAACGA  TATGGGCTGAATAC) as a tandem sequence in forward 
and reverse orientations separated by [ADDRESS_366136] (DP) is formulated into ent eric-
coated tablet.  
• Dose: 1x1011 IU±0.5 log  
 
Placebo Control: 
• Oral tablets similar in appearance and number to active vaccine tablets  
Multiple tablets of study drug will be dispensed to allow delivery of the 
intended vaccine dose (1x1011 IU).  A matching number of placebo tablets 
will be dispensed to mainta in the study blinding.   
Viral Challenge 
Inoculum  Norovirus GI.1 (Norwalk Virus Inoculum Lot 001-09NV and Sublot 2 , IND 
[ZIP_CODE]) 
• Dose: 1x106 Genomic Copi[INVESTIGATOR_014] (GC). A dose which allows 50% - 65% 
infectivity in the healthy adult population ( per NV infection rate 
observed in the GI.1 viral titration study (Mateo, et al ; 2019) 
Study Hyp othesis Norovirus vaccine (VXA -G1.1-NN) will protect against Norovirus 
Gastroenteritis ( NVG) related to norovirus (N oV) infection in the challenge 
model 
 
  

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 11 of 114 
Date: 25 May 2023  
 Study Objectives  
 
 Primary Objective 
• Determine the clinical efficacy of VXA -G1.1-NN compared to placebo, 
to protect against  NVG caused by [CONTACT_300023] . 
  
Secondary Objectives 
• Safety and tolerability of VXA -G1.1-NN oral vaccine 
• Determine the ability of VXA -G1.1-NN to modify disease severity 
(defined in Appendices C and D ) compared to placebo  
• Determine the quantity and duration of norovirus shedding  by [CONTACT_300024] 
• Evaluate the VP1 specific IgA ASC, HBGA blocking antibody, and 
VP1 specific serum IgG responses to  VXA-G1.1-NN 
 
Exploratory Objectives  
• Determine correlation of immunogenicity parameters with clinical 
outcome 
• Further evaluate immunogenicity of VXA -G1.1-NN 
Study Definitions  NVG is a composite endpoint defined as meeting one or more of the 
following definitions  for both Acute Gastroenteritis  and NV Infection. 
 
Acute Gastroenteritis  (defined as meeting any one of the three   
  categories  listed below ): 
 
• Diarrhea:  
o ≥ 3 loose or liquid stools  produced in any 24 -hour period , or  
o > 400g of loose or liquid stools p roduced in any  
24-hour period  
• Vomiting: ≥  2 vomiting epi[INVESTIGATOR_57579] 24 -hour period, or  
• Diarrhea and vomiting:  
o One vomiting epi[INVESTIGATOR_299975] 
24-hour period, or  
o One vomiting epi[INVESTIGATOR_299976] ≥ 2 of the following  events in 
any 24-hour period:  
▪ nausea 
▪ fever (oral temperature  ≥ 37.6C) 
▪ abdominal cramps or pains  
▪ abdominal gurgling or bloating  
▪ myalgia 
See Appendix C  for grading scales for signs and symptoms of acute 
gastroenteritis.    
Norwalk Virus Infection:  
• NV infection  as detected by [CONTACT_16641]-PCR, > [ADDRESS_366137]-challenge 
Study Design  This is a Phase 2b randomized, double -blind, placebo -controlled vaccination 
and challenge study to assess the protective efficacy of the Norovirus 
vaccine (VXA -G1.1-NN). Approximately 170 healthy adults wi ll be 
randomized in a 1:1 ratio  to receive one oral dose of vaccine or placebo.  
• Arm 1: VXA-G1.1-NN oral vaccine tablets  
 [1x1011 IU±0.5 log] ; N=85 
• Arm 2: Placebo tablets similar in appearance and  
 number to active vaccine tablets ; N=85 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 12 of 114 
Date: [ADDRESS_366138] -challenge sequestration period, subjects will move 
through the study (enrollment, vaccination and challenge) sequentially in [ADDRESS_366139] twice daily  from Day 29 to discharge .  Stool and emesis  will be 
collected, and illness will be assessed using a modified Vesikari scale. 
Excretion of NV  (shedding)  will be monitored in stool and emesis. NV 
illness lasts [ADDRESS_366140] challenge (Day 33)  asymptomatic subject will be discharged 
from the isolation ward and will be followed in a series of outpatient visits  
and telephone calls.  Symptomatic subjects may be kept in the isolation ward 
for up to an additional [ADDRESS_366141] 140 subjects (approximately  70 VXA-G1.1-NN vaccine and 70 
placebo) are available to participate in the challenge phase . 
Investigational Drug Product  Approximate No. 
of Subjects  
Vaccination  170 
VXA-G1.1-NN oral vaccine tablets  
[1x1011 IU±0.5 log]  85 
Placebo tablets (identical to vaccine) 85 
Challenge (Norwalk GI.1 Virus 
Inoculum ) 140 
VXA-G1.1-NN oral vaccine tablets  
[1x1011 IU±0.5 log]  70 
Placebo tablets (identical to vaccine) 70 
An independent Safety Monitoring Committee (SMC) will convene at pre-
defined intervals during the norovirus  challenge period, and also ad hoc as 
needed during the vaccination and challenge periods, to oversee the safety of 
the study.  
Study Visits The following study visits and remote contacts will be condu cted during the 
study (also see Appendix A : Schedule of Events):  
Vaccination Phase: 
• Pre-Screening Period (Days -90 to Screening ) may be utilized for 
purposes of ascertaining subjects ’ H type-1 antigen secretor y status and 
blood type   
• Screening Period ( Days -45 to -1) 
• Day 1 Visit (Baseline assessments; day of randomization and 
vaccination ) 
• Day 8 Visit (safety and evaluation of immune response)  
• Day 28 (evaluation of immune response; 1 day prior to challenge, start 
inpatient stay)  
Challenge Phase:  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 13 of 114 
Date: 25 May 2023  
 • Day 29 (viral challenge , sequestration ) 
• Days 30 to 33 (sequestration – discharge ; +3 days and evaluation of 
immune response and safety assessment ) 
• Day 36 Visit (evaluation of immune response and safety assessment)  
• Day 57 Visit ( evaluation of immune response and safety assessment  and 
end of active period) 
Safety Follow-Up: 
• Day 120, Day 180, Day 240 and Day 300 (follow -up contact) 
• Day 365 (follow-up phone call): Study completion  
Eligibility Criteria  Inclusion Criteria : 
1. Male or female between the ages of 18 – 49 years, inclusive   
2. Able to give written informed consent  
3. Healthy1, as determined by [CONTACT_458] (PI) or PI [INVESTIGATOR_299977] 
1No clinically significant health concerns or medical illness), as 
determined by [CONTACT_9870], physical exami nation, vital signs, 
electrocardiogram (ECG), and clinical laboratories (complete blood 
count [CBC], chemistry and urinalysis)  
4. Comprehension of the study requirements with ability and 
willingness to complete all assessments and comply with 
confinement period post viral challenge, and all scheduled visits and 
contacts 
5. Confirmed blood type (A or O)  
6. Demonstrated to be H type -1 antigen secretor positive (by [CONTACT_300025]) 
7. Body mass index between 17 and 3 5 kg/m2, inclusive, at Screening  
8. Female participants must have a negative pregnancy test at pre-
vaccination and pre-challenge and fulfill one of the following2 
2Criteria: 
a. At least one year post -menopausal;  
b. Surgically sterile;  
c. Use of oral, implantable, transdermal , intravaginal  or 
injectable contraceptives for 30 days prior to immunization 
and until 60 days after challenge;  
i. A reliable form of contraception must be approved 
by [CONTACT_737] (eg, double barrier method, 
Depo-Provera, intrauterine device, Norplant, oral 
contraceptives, contr aceptive patches , vaginal ring 
contraceptive ) 
d. Not be sexually active (abstinent) or in a same sex 
relationship (must be discussed with site staff and 
documented)  
9. Male subjects must agree not to father a child or donate sperm , as 
well as to use contraception/barrier (a male condom) or be abstinent 
from heterosexual intercourse,  from vaccination through the active 
period (Day 57)  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 14 of 114 
Date: 25 May 2023  
 Exclusion Criteria :  
1. Administration /use of any investigational drug or device 30 days 
prior to vaccination  through the active period (Day 57)  
2. Administration of any licensed vaccine within 30 days prior to 
vaccination or planned use of the above stated during the active 
period (through Day 57)  
3. Presence of a significant medical condition3 which in the opi[INVESTIGATOR_299978].  
3For example, psychiatric conditions, or gastrointestinal disease, 
such as peptic ulcer, symptoms or evidence of active gastritis or 
gastroesophageal reflux disease, inflammatory bowel disease, 
alcohol or illicit drug abuse/dependency, or other laboratory 
abnormalities  
4. Laboratory  values outside the range of normal for platelet counts 
and the following coagulation tests: PT/INR, aPTT  and fibrinogen  
5. Any of the following history or conditions that may lead to higher 
risk of clotting events and/or thrombocytopenia:  
a. Family or personal history of blee ding or thrombosis  
b. History of heparin -related thrombotic events, and/or receiving 
heparin treatments  
c. History of autoimmune or inflammatory disease  
d. Presence of any of the following conditions known to increase 
risk of thrombosis within 6 months prior to scr eening: 
▪ Recent surgery other than removal/biopsy of cutaneous 
lesions  
▪ Immobility (confined to bed or wheelchair for 3 or more 
successive days)  
▪ Head trauma with loss of consciousness or documented 
brain injury  
▪ Receipt of anticoagulants for prophylaxis of thrombosis  
▪ Recent clinically significant infection  
6. Any one of the following ECG findings4 within 45 days prior to 
vaccination:  
4Exclusionary ECG findings : 
a. QTc F (interval duration > 450 msec (male) or >  470 msec 
 (female) 
b. QRS interval greater than [ADDRESS_366142] 3 years (excluding 
basal cell or squamous cell carcinoma s) 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 15 of 114 
Date: 25 May 2023  
 8. Presence of immunosuppression or medical condition possibly 
associated with impaired immune responsiveness, including d iabetes 
mellitus or angioedema  
9. Donation or use of blood or blood products within 30 days prior to 
vaccination through the  active period (Day 57)  
10. Diagnosed bleeding disorder or significant bruising or bleeding 
difficulties that could make blood draws problematic  
11. Any condition that resulted in the absence or removal of the spleen  
12. Evidence of confirmed infection with human immunodeficiency 
virus (HIV), hepatitis B surface antigen (H bsAg) or hepatitis C virus 
(HCV) with confirmatory assays  
13. Abnormal stool pattern (fewer than 3 bowel movements pe r week or 
more than 3 per day)  
14. History of irritable bowel disease or inflammatory digestive or 
gastrointestinal condition5 that could affect the distribution / safety 
evaluation of an orally administered vaccine6 
5Such conditions may include but are not limited to:  
a. Esophageal Motility Disorder  
b. Malignancy  
c. Malabsorption  (e.g. Celiac disease, gluten intolerance)  
d. Pancreaticobiliary disorders  
e. Irritable bowel syndrome  
f. Inflammatory Bowel Disease  
g. Surgical Resection with the exception of appendectomy or a 
minor resection that is deemed acceptable by [CONTACT_300026]  
h. Gastroesophageal reflux disease (GERD)  
i. Hiatal Hernia  
j. Peptic Ulcer  
(History of cholecystectomy is not exclusionary)  
6 targeting the mucosa of the small intestine  
 
15. Use of proton pump inhibitors, H2 blockers or antacids within 
7 days prior to vaccination  through the active period (Day 57 ) 
16. Use of antibiotics within 30 days prior to vaccination through the 
active period (Day 57)7  
7Note: use of a brief (≤ 10 days) course of oral or topi[INVESTIGATOR_299979], UTI, dental work, or skin infection allowed within 
the screening period, but must be completed [ADDRESS_366143] the immune function (e.g. 
systemic cortic osteroids and others) within 14 days prior to 
vaccination through the active period (Day 57)  
18. Regular use of nonsteroidal anti -inflammatory drugs within 7 days 
prior to vaccination through the active period (Day 57)  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 16 of 114 
Date: 25 May 2023  
 19. Use of over -the-counter probiotics or ant idiarrheals within 7 days 
prior to vaccination  through the active period (Day 57)  
20. Evidence of recent (within 2 months of vaccination) or of current 
nonbacterial gastroenteritis suggestive of NV infection [vom iting or 
unformed or watery stools (> 2 during a 24 -hour period)]  
21. Any gastroenteritis within the past 2 weeks prior to vaccination  
22. Acute disease within 72 hours prior to vaccination8 
8Defined as the presence of a moderate or severe illness with or 
without fever (as determined by [CONTACT_300027]). (Assessment may be repeated 
during screening period)  
23. Presence of a fever ≥ 38ºC measured orally at baseline  
24. History if hematochezia (blood in stool)  or melena (black stool)  
25. Any significant hospi[INVESTIGATOR_299980]  
26. History of serious reactions to any vaccination such as anaphylaxis, 
respi[INVESTIGATOR_66780], Guillain -Barre syndrome, hives or a bdominal 
pain 
27. History of a hypersensitivity or allergic reaction to any component 
of the investigational vaccine or placebo9. Subjects with known fish 
allergies should be excluded  
[ADDRESS_366144] for drugs of abuse or alcohol at screening, vaccination 
baseline and pre-challenge .10  
10except for previous marijuana us e; concurrent or ongoing use of 
marijuana during the active study period  
30. Consistent/habitual smoking within 2 months prior to vaccination 
(defined as smoking ≥ 1 pack of cigarettes a day). Smoking is not 
permitted during the inpatient stay  
31. Other condition s11 that would jeopardize the safety or rights of a 
subject or int erfere with the evaluation of the study 
11 in the clinical judgment of the investigator  
Social/Occupational : 
32. Living with or having daily contact [CONTACT_271956] < [ADDRESS_366145] with elderly persons  
> 70 years of age or infirmed, diapered individuals, persons with 
disabilities or incontinence13  
13This includes at work or visits to nursing homes and day -care or 
equivalent facilities  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 17 of 114 
Date: [ADDRESS_366146] received the Ad4 or Ad7 
vaccines within 2 months prior to vaccinat ion 
38. Employment as an airline flight attendant or cruise ship crew, 
scheduled to work in the 4 weeks following challenge  
39. Persons planning to live in a confined environment (eg, a cruise , 
camp, etc.) i n the [ADDRESS_366147]’s participation will last approximately [ADDRESS_366148] successful 
screening and enrollment  
• 90 days study pre -screening  
• 45 days study screening  
• 28 days vaccination phase  
• 28 days viral challenge and follow -up  
• [ADDRESS_366149] vaccination  
Randomization  Subjects will be randomized in a 1:[ADDRESS_366150]  
at the clinical site . 
Blinding Investigators , clinical staff and  study subjects will remain blinded until 
completion of the challenge  phase (through Day 57) and validation of the 
clinical data. The Sponsor’s clinical team and l aboratory personnel will also 
be blinded to subject treatment through Day 57 analyses.  
Each bottle of multi-dose DP/placebo tablets will be labeled with an open 
label. The unblinded research pharmacist will use the randomization list to 
prepare the dose of DP/placebo tablets. All DP/placebo preparation and 
administration will be performed per study specific procedures detailed in 
the Study Pharmacy Manual. 
Safety, 
Immunogenicity and 
Microbiological  
Assessments  Safety Assessments:  
General: 
• SAEs, AESIs & NOCIs will be recorded from Baseline (Day 1) through 
Day 365 
 
Vaccination Period (Day 1 to Day 28) : 
• Solicited symptoms of reactogenicity will be recorded daily from Day [ADDRESS_366151] vaccination through Day 8:  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 18 of 114 
Date: 25 May 2023  
 o Gastrointestinal reactions : nausea, vomiting, diarrhea  and 
abdominal pain  
o Systemic reactogenicity : malaise/fatigue, anorexia, fever , headache 
and myalgia (muscle pain)  
• Unsolicited A es will be recorded from Day 1  (post-vaccination)  through  
Day 28 
• 12-lead ECGs at Screening and  pre-challenge (Day 28) 
• Vital signs  and physical exams  will be collected at Screening, Day 1  
(pre-dose), Day 8, and Day 28 (pre -challenge)  
• Safety laboratory will be performed at Screening, Day 1, Day 8 and Day 
28 (pre-challenge)  as listed below:  
o CBC: Hemoglobin, Hematocrit, Platelet Count  and Complete 
White Blood Cell Count  
o Serum chemistries : ALT, AST, Total Bilirubin, BUN, 
Creatinine,  Random Glucose, Potassium  and Sodium 
o Urinalysis: Glucose, Protein and Hemoglobin   
• Female participants will have serum/urine pregnancy tests at Screening, 
Day 1 (pre-dose, if more than [ADDRESS_366152]) and  Day 28 pre-
challenge 
 
Challenge Period (Day 29 to Day 57) :  
• Unsolicited A es will continue to  be recorded from challenge (Day 29) 
through end of active phase (Day 57)  
• Vital signs  will be collected twice a day (am and pm) from  challenge  
(Day 29) through discharge  (Day 33 + 3 days ) 
• Physical exams  will be performed  daily on Days 29 through discharge  
(Day 33 + 3 days ) 
• Safety laboratory tests will be performed on Day 33. Additional time 
points may be collected if clinically indicated per the discretion of the 
Investigator  
 
Immunogenicity Assessments : 
Primary Immunoassays  
• VP1 specific IgA ASC (by [CONTACT_34536])  
• HBGA blocking antibodies (BT 50) 
• VP1 specific serum IgG (by [CONTACT_19487]) 
• VP1 specific serum IgA (by [CONTACT_19487]) 
Exploratory Immunoassays  
• VP1 specific IgG ASC  (by [CONTACT_34536])  
• VP1 specific IgG and IgA memory B cells (by [CONTACT_34536])  
• VP1 specific IgG and IgA from plasmablast cultures (by [CONTACT_6428])  
• B cell immunophenotypi[INVESTIGATOR_007] (by [CONTACT_4133] , CyTOF and/or single 
cell sequencing)  
• mucosal VP1 specific IgA (by [CONTACT_300028]), (fecal, saliva and nasal)  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 19 of 114 
Date: 25 May 2023  
 Blood Typi[INVESTIGATOR_299981] (ABO) test    
 
Assessment of Clinical  NV Illness (Acute Gastroenteritis) : 
Following challenge (Day 29 ) subjects will be monitored for the following 
signs and symptoms of acute gastroenteritis twice a day  unless greater 
frequency is clinically indicated:  
 
o diarrhea, vomiting, nausea, fever, myalgia 
o abdominal cramps  or pain and abdominal gurgling or bloating  
 
Norwalk Virus Infection:  
• NV infection  as detected by [CONTACT_16641]-PCR, > [ADDRESS_366153]-challenge.  
 
Microbiological Assessments :  
During the post-challenge phase (Day 29 – discharge [Day 33 + 3 days ]) all 
stool and emesis  specimens will be collected, weighed/measured for volume  
and tested for NV  shedding through discharge . Stool samples will also be 
graded. A stool sample will also be collected at the Day 36 and Day 57  site 
visits. 
Study Endpoints  Primary Endpoint  
• Occurrence of NVG caused by [CONTACT_300029] . 
o NVG is a composite endpoint and is defined as meeting one or 
more of the definitions for both acute gastroenteritis and NV 
infection.  
Secondary Endpoints  
• Number of subjects with acute gastroenteritis during the inpatient  
challenge  period. 
• Mean score using the Modified Vesikari Scale as a measure of 
severity of acute gastroenteritis  post-challenge at  discharge (up to  
Day 36)  
• Number of subjects with moderate or severe gastroenteritis 
(cumulative loose stools ≥ 1000 gms during the inpatient p eriod) 
• Median d uration (number of hours) of acute gastroenteritis among 
challenged subjects  
• Number of subjects with norovirus infection up to Day [ADDRESS_366154]-
challenge (quantitative reverse transcriptase polymerase chain 
reaction [qRT -PCR] positive in stool, Norwalk virus antigen in stool  
• Geometric mean genome copi[INVESTIGATOR_299982] -PCR 
• Median d uration (number of  hours) of norovirus infection among 
challenge subjects  
• Number of incidences of diarrhea or emesis among challenge 
subjects 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 20 of 114 
Date: 25 May 2023  
 SAFETY  
• Vaccine (VXA-G11-N.N) 
o Solicited symptoms of reactogenicity x [ADDRESS_366155] vaccination  
• Challenge Virus (Norwalk GI.1)  
o Unsolicited Aes x [ADDRESS_366156] challenge  
 
IMMUNOGENICITY  
Primary 
• VP1 specific IgA ASC response against Norwalk at Day 8 compared 
to placebo  
• GMT of HBGA blocking antibodies (by [CONTACT_122702] 50) against Norwalk 
virus at Day 28 compared to placebo  
• VP1 specific serum IgG response at Day 28 compared to placebo   
• VP1 specific serum IgA at Day 28 compared to placebo  
Exploratory  
• Correlations between individual immunogenicity parameters and 
clinical efficacy  
• VP1 specific IgG ASC response against Norwalk at Day 8 compared 
to placebo  
• VP1 specific fe cal IgA at Day 28 compared to placebo  
• VP1 specific saliva IgA at Day 8 and Day 28 compared to placebo  
• VP1 specific nasal IgA at Day 8 and Day 28 compared to placebo  
• Vaccine specific response s for memory IgA and/or IgG in B cells, 
IgA and IgG in plasmablasts, antibody repertoire sequencing 
analysis, flow cytometry (including homing and/or 
immunophenotypi[INVESTIGATOR_26174]), cytof and/or other assays designed to 
evaluate cell mediated immunity  
Additional assessment of serum, fecal, saliva, and mucosal immunity at 
other time points (including post -challenge) may be performed  
Halting Rules  The study will be halted (no new enrollment , vaccination or challenge will 
be allowed pending a S MC safety review) if any of the events described 
below are met during the conduct of the study.  
• Two or more subjects experience a treatment related serious adverse event 
(SAE) of any grade , or a treatment related grade 3 or 4 AE between study 
Day 1 and Day 28 (vaccination phase) .  
• Two or more subjects experience  a treatment related serious adverse event 
(SAE) of any grade , or a treatment related grade 3  or 4 unsolicited adverse 
event within 28 days after challenge.  
The SMC will provide study oversight th roughout the duration of the trial 
interventional and safety follow -up period (Day [ADDRESS_366157] -
vaccination). The IRB and CBER (Center for Biologics Evaluation and 
Research at the US FDA) will be notified if the study is halted for safety 
concerns.  
 
Statistical 
Considerations  The study hypothesis is that norovirus vaccine, VXA -G1.1-NN, will protect 
against norovirus gastroenteritis related to norovirus infection in the challenge 
model. Protective efficacy (PE) will be estimated by t he prevention of 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 21 of 114 
Date: 25 May 2023  
 norovirus gastroenteritis among vaccine recipi[INVESTIGATOR_299983].  
 
The primary endpoint of this study is a composite of occurrence of NVG 
caused by [CONTACT_300030].  
 
An Interim analysis (IA) will take place after approximately  50% of the 
planned randomized subjects have completed challenge and been discharged 
from the research unit .  This IA will reassess the appropriateness of 
assumptions used for the primary efficacy endpoint when the trial was 
designed in a blinded manner to the study team .  The IA data will be 
analyzed in an unblinded manner for the SMC.  
 
An exploratory analys es will be performed  after approximately [ADDRESS_366158] the continuation of this study as planned, but rather, inform 
program development for other trials . 
 
Please refer to Section 11 for complete statistical considerations details in 
the protocol.  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 22 of 114 
Date: 25 May 2023  
 1 INTRODUCTION : BACKGROUN D INFORMATION AND SCIENTIFIC 
RATIONALE  
 
1.1 Background  
Human noroviruses (NoV) are the leading cause of foodborne gastroenteritis and endemic diarrheal 
disease in the [LOCATION_002]  (US) and worldwide  (1, 2).  Norovirus is highly infectious and is transmitted  
very efficiently from person to person in semi -enclosed environme nts, such as nursing homes, cruise 
ships, hospi[INVESTIGATOR_600], military, school s and childcare centers  (3). The major mode of transmission is by [CONTACT_122686] -
oral spread, usually via contaminated food or water. Airborne transmission via aerosolization of the 
virus with vomiting has also been reported (4). The incubation period of norovirus is [ADDRESS_366159] of infected people (5). Infections occur year -round but peak in the colder months (November 
to April in the Northern Hemisphere). All ages are susceptible to infection; however, the elderly seem 
to be more susceptible. Viral shedding can last several weeks (6 -55 days) with a pe ak of 1 -3 days after 
onset of illness (6, 7). Viral shedding precedes the onset of illness in up to 30% of infected people (5). 
Currently no specific therapy exists for norovirus gastroenteritis  (NVG). The standard treatment is oral 
rehydration with fluids and electrolytes (8). 
 
Noroviruses (NoVs) belong to the family Caliciviridae.  Caliciviruses are divided into 4 genera: 
Norovirus, Sapo virus, Vesivirus and Lagovirus.  NoVs are genetically diverse viruses. The genus is 
divided into 6 genogroups. NoV Genogroups I, II and IV are human -transmitted. Genogroup I and II 
account for the majority of norovirus outbreaks (9). Each genogroup is further divided into genotypes 
based on the similarity of the amino acid sequence of the major viral capsid protein, VP1. Genogroup 
I contains 9 different genotypes and Genogroup II contains 22 different genotypes. Norwalk virus, the 
prototype human norovirus, is classified as a Genogroup I and Genotype 1 (GI.1) virus (2). Since the 
1990’s, GII.[ADDRESS_366160] been responsible for more than 80% of all human norovirus infections, but 
non-GII.4 (Genogroup I and other Genogroup II genotypes) are also circulating in the po pulation. Every 
2-4 years, a new GII.4 variant emerges and replaces the previously predominant variant (10, 11). In 
2012, a new GII.[ADDRESS_366161] the previou sly predominant circulating strain (12, 13). In contrast, GII.[ADDRESS_366162] of the outbreaks in China and Japan (14). Noroviruses are positive -sense, non -enveloped, 
single-stranded RNA viruses. The viral genome is 7.4 -7.7 kb in length and comprises 3 open reading 
frames (ORFs) that encode both the structural and non -structural proteins. The ORF1 (~5kb) is in the 
first two-thirds of the genome and encodes ~200 kD large poly -protein that is cleaved into 6 different 
non-structural proteins essential for viral replication such as RNA dependent RNA polymerase. ORF2 
(~1.6kb) encodes a 57kDa single major capsid protein (VP1). VP1 is comprised of a conserved internal 
shell domain (S) and protruding domain (P). The P domain is further divided into a P1 stalk sub -domain 
and a surface -exposed highly variable P2 sub -domain. P2 sub -domain is the major immunogenic and 
antigenic determinant of the NoV.  VP1 forms a dimer and 90 dimers form a T=3, icosahedral viral 
particle. ORF3 (~0.6kb) encodes a 22kDa minor structural protein (VP2), whose function might 
package the viral genome into virions and assist capsid assembly. VP1 associates with VP2 at the 
interior surface (S domain) of the capsid (15, 16). 
 
The expression of VP1 results in spontaneous self -assembly of virus -like particles (VLP) without 
packaging the viral nucleic acid or proteins. VLP is a n on-infectious particle and is morphologically 
and antigenically identical to the native NoV (17). 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 23 of 114 
Date: 25 May 2023  
 Histo-blood group antigens (HBGAs) are putative norovirus binding receptors  or attachment factors . 
HBGAs are complex glycans that are expressed on the surfaces of red blood cells, gut, and respi[INVESTIGATOR_299984]. Different norovirus species display different HBGA binding profiles. The P2 sub -domain in 
VP1 appears to be the HBGA in teraction site (18). 
 
Because norovirus cannot  easily be cultured in tissue culture, classical virus neutralization cannot be 
directly measured. Instead, the VLP -HBGA blocking assay has been used as a surrogate to measure the 
ability of antibodies from antisera from infected p eople to block VLP binding to HBGA (19).  The 
duration of protective immunity upon natural infection is complex. Human challenge studies using 
Norwalk virus as the challenge virus sugges ted that short -term immunity to homologous virus develops 
and persists for up to 6 months. However, a subsequent study showed that longer -term immunity (27 -
42 months) was not generated after homologous challenge (20, 21).  It is not completely clear what 
immune parameters are critical for protection from challenge, but one possibility is that mucosal  
Immunoglobulin A  (IgA) may be able to hinder virus infection of epi[INVESTIGATOR_1663].  Consistent with this, 
published challenge studies showed that an early induction of mucosal IgA or preexisting mucosal IgA 
response correlated with protection to Norwalk virus (7, 22).  In contrast to the results derived from  the 
challenge studies that long -term immunity can be difficult to generate, the epochal pattern of evolution 
of pandemic GII.[ADDRESS_366163] immunity in the population (12). Some 
recent mathematical models based on modeling of epi[INVESTIGATOR_299985] 4 to 8 years (23).  In summary, these results suggest that 
natural immunity can develop, with some caveats as to whether long -term sterilizing immunity is 
possible. Several animal species including humanized mice, gnotobiotic pi[INVESTIGATOR_14107], gnotobiotic calves, and 
chimpanzees have been challenged with human NoV.  However, NoV infection of non -natural hosts 
generated variable clinical outcomes from asymptomatic to mild diarrhea, and limited success has been 
achieved to reveal all aspects of human infection (24). 
 
There are currently no licensed vaccines for norovirus.  Experimental norovirus vaccines composed of 
VLPs expressing VP1 have been tested in mice and humans delivered orally and intranasally (25-29). 
[COMPANY_005] Pharmaceutical Company (previously Ligocyte) conducted two short -term efficacy studies.  
Intranasal administration of Norwalk VLP vaccine was shown to reduce Norwalk virus -associated acute 
gastroenteritis (69% vs 37%) and Norwalk virus infection (82% vs 61%) following challenge with 
homologous Norwalk virus (30).  A subsequent study was conducted with intramuscular bivalent 
vaccine (Norwalk virus VLP and a consensus VLP derived from three GII.4 NoV strains). Healthy 
participants were challenged by [CONTACT_300031].4 N oV (Cin strain 2003, Farmington Hill Strain variant). The 
vaccines were well tolerated and immunogenic. However, the incidence of GII.4 NoV -associated acute 
gastroenteritis (33% vs 26%) and GII.4 NoV infection (62.5% vs 54%) were not significantly reduced 
although severity of illness was reduced (31).  These GII.4 results seem rather unexpected since the 
intramuscular bivalent vaccine generated much higher total serum  Immunoglobulin G  (IgG) titers and 
blocking titers than the intranasal mucosal vaccine. One possible explanation is that the mucosal 
vaccine might provide better mucosal antibody responses, and thereby [CONTACT_300032] (27). 
 
Norovirus is an enteric pathogen that infects the epi[INVESTIGATOR_122662]. Importantly, 
Vaxart’s platform is based on oral delivery to the intestinal mucosa, which is analogous to the natural 
route of norovirus infection and entry. In theory, mucosal immune responses local to  the site of delivery 
should be more robust than mucosal responses generated by a more distally administered vaccine. 
Human and animal experience with Vaxart’s orally administered platform has demonstrated that 
substantial transgene specific intestinal IgA  responses can be generated in addition to systemic IgG 
responses to the expressed antigen (influenza HA and norovirus VP1). These platform attributes may 
allow for better protection against norovirus infection than an injected protein -based vaccine.  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 24 of 114 
Date: 25 May 2023  
 1.2 Norovirus vaccine: General Properties & Pharmacodynamics  
 
 VXA-G1.1-NN Product Description  
VXA-G1.1-NN product description is summarized in Table 1. 
 
Table 1:  VXA-G1.1-NN Product Description  
Generic name  [CONTACT_122728]-G1.1-NN 
Chemical name  [CONTACT_300092]-CMV-VP1(Norwalk virus) -BGH-CMV-luc dsRNA -SPA 
Genome size  33,949 bp dsRNA genome  
Viral particle size  80-100 nm 
 
VXA-G1.1-NN is E1/E3-deleted, replication -incompetent, adenovirus 5 vaccine vectors designed for 
use as a vaccine for prevention of NoV infection.  The vaccine vector encode s for a full-length VP1 
gene of Norwalk virus (VXA -G1.1-NN vaccine). In addition to the transgene  cassette, a second 
hCMVie promoter is also present in the vaccine construct which is used to express an RNA sequence 
that acts as an adjuvant. The adjuvant is a short hairpin RNA expressed off a promoter such that only 
target cells in the intestine that e xpress antigen will also express the adjuvant.  This is likely to result 
in a tight association of antigen with adjuvant in vivo. 
 
1.3 Summary of Nonclinical Studies  
Vaxart has conducted preclinical studies to determine the immunogenic potential of two NoV vac cine 
candidates, VXA-G1.1-NN (VP1 gene of Norwalk virus)  in mice and VXA -G2.4-NS (VP1 gene of 
Sydney virus)  in mice, ferrets and NHPs ( Cynomolgus  monkeys).  These studi es showed that 
vaccination with VXA-G1.1-NN and VXA -G2.4-NS reliably elicited substantial and durable systemic 
serum IgG and intestinal (fecal) IgA responses in test animals  and elicited serum -blocking antibody 
titers (blocking titer fifty assay [ BT50]). A unique immune response elicited by [CONTACT_300033] B cells. After oral vaccination or enteric infection, B 
cells residing in the lamina propria (underneath the gut epi[INVESTIGATOR_1663]) predominantly produce 
dimeric/polymeric antibodies of the IgA isotype.  After  binding to polymeric immunoglobulin receptor 
(also known as secretory component), the dimeric form of IgA antibodies  travels across the gut 
epi[INVESTIGATOR_299986] (transcytosis), leaving a secretory component 
attached to dimeric IgA.  The resulting molecule is known as secretory IgA (S igA).  SigA serves as an 
additional external barrier to  block enteric infection.  S igAs are eventually flushed out of the system  
and can be detected in fecal samples.  Given that the route of immunization is the same as the route of 
norovirus infection, it is reasonable to postulate that Vaxart’s VXA -G1.1-NN and VXA-G2.4-NS 
vaccines may enable higher degrees of localized protection against infection when compared to a 
parenteral immunization method.  This is supported by [CONTACT_300034] -G1.1-NN when compa red to mice intramuscularly injected with GI.1 
VLPs. Vaxart’s oral vaccine generated significantly higher fecal IgA when compared  to the injectable 
formulation.  
 
As described above, Vaxart’s norovirus VP1 vaccines (VXA -G1.1-NN and VXA -G2.4-NS) use the 
same replication -defective viral vector backbone and adjuvant RNA sequence as the company’s early 
oral vaccine candidates for pandemic influenza (the A/Indonesia/05/2005 (H5N1) vaccine referred to 
as ND1.1 and for seasonal influenza (the A/[LOCATION_004]/  04/2009 (H1N1) vaccine referred to as VXA -
A1.1.  Because the only difference between the vaccines is the antigen gene [NoV VP1 in VXA -G1.1-
NN and VXA -G2.4-NS versus A/[LOCATION_004]/04/2009 (H1N1) in VXA -A1.1 and A/Indonesia/05/2005 
(H5N1) in ND1.1 ], the preclinical s tudies from ND1.1 and VXA -A1.1 are relevant to and support the 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 25 of 114 
Date: 25 May 2023  
 clinical development of Vaxart’s NoV vaccines  (VXA-G1.1-NN and VXA -G2.4-NS) for prevention of 
norovirus disease.  
 
Preclinical studies with ND1.[ADDRESS_366164] of the other preclinical and clinical studies, was 
manufactured using the same process that is used to produce the  Good Manufacturing Practice  (GMP) 
material for the proposed clinical trial.  VXA -G1.1-NN and VXA -G2.4-NS vaccines is formulated as 
enteric-coated tablets for oral administration in clinical studies, similar to VXA -A1.[ADDRESS_366165] (DP) lots.  It is important to note that in several nonclinical studies reported within this section 
a liquid formulation of the ND1.[ADDRESS_366166] was studied with the seasonal vaccine 
candidate VXA -A1.1. The primary objective of the H1N1 immunogenicity study was to determine if a 
double-stranded ribonucleic acid (dsRNA) adjuvant could a ugment immune responses to the transgene 
expressed after transduction with the recombinant Ad5 -based (rAd5) vector. Study results 
demonstrated that a co -expressed dsRNA adjuvant improved the immune responses to an orally 
administered antigen and that the i mmune responses generated could elicit protective immunity to H1 
influenza.  
 
In another immunogenicity study (Study No. WCB045), mice were immunized by [CONTACT_300035] (VXA -A1.1) or on e 
expressing HA but not the dsRNA adjuvant (rAd -HA). Three weeks post immunization the group 
treated with the adjuvanted vector demonstrated a significant anti -HA titer (1.0 x 104 geometric mean 
titers [GMT]) with all animals having a detectable titer, whe reas the unadjuvanted group failed to 
generate a detectable response in any animals. The immune responses were significantly higher for the 
adjuvant compared to the non -adjuvant groups. These data indicate that the adjuvant enhances both the 
time of onset and the magnitude of the immune response.  
 
1.4 Summary of Clinical Studies  with Vaxart Oral Vaccine Platform  
Summary  information on trials completed with Vaxart’s norovirus vaccine candidates is presented 
below.  For additional information refer to the Investigator’s Brochure.  
 
 Norovirus Phase 1 Study VXA-G11-101 
This was a  single-site, randomized, double -blind, placebo -controlled clinical trial of VXA-G11-NN 
oral norovirus vaccine to determine safety and immunogenicity. The tablet vaccine is comprised o f a 
non-replicating adenovirus -based vector expressing the VP1 gene from the GI.1 norovirus strain and a 
dsRNA adjuvant.  
 
Between July and September of 2016, 152 subjects were screened, and 66 subjects were enrolled and 
dosed. Sixty five of 66 subjects co mpleted safety and immunogenicity assessments through the active 
phase (Day 29); one subject in the placebo group withdrew before Day 7. The dose groups are described 
in Table 2. 
 
 
 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 26 of 114 
Date: 25 May 2023  
 Table 2:  Subject Enrollment in Study VXA-G11-101 
Vaccine group  Dose Number of oral 
doses Number of 
subjects 
VXA-G1.1-NN low dose – 1x1010 IU 1 23 
VXA-G1.1-NN high dose – 1x1011 IU 1 23 
Placebo  1 20 
 
Safety Results 
The vaccine was well -tolerated, with no dose -limiting toxicities. Adverse events  (AEs) were mild or 
moderate. All solicited A Es reported in this trial (n=46) were grade 1 or 2 in severity with the majority 
being mild events (44 grade 1, and 2 grades 2 events). The percentage of subjects with any solicited 
symptoms was similar between test and placebo treatments  (Table 3). In the first [ADDRESS_366167] one solicited A Es reported with 25/46 (54% ) 
subjects in the VXA -G1.1-NN vaccine groups and 10/20 (50%) subjects in the placebo groups . Diarrhea 
and headache were the most common solicited symptoms following VXA -G1.1-NN administration, 
both reported by 15 (33%) subjects in the treated groups. Heada che and nausea were reported evenly 
across treatments, including placebo. The only solicited symptom demonstrating a statistically 
significant difference from placebo was diarrhea (P=0.0275), reported by 11 subjects in the high dose 
group. Nine of the 11 s ubjects reported mild severity diarrhea, while 2 subjects reported moderate 
severity epi[INVESTIGATOR_299987]. Onset of diarrhea (verbatim term “loose stools”) 
ranged from Day [ADDRESS_366168] normal activity such as work or school, 
and none required treatment with anti -diarrheal medications or rehydration therapy. There were no 
SAEs, AESIs or NOCIs reported in this stu dy through Day 365.  
 
Table 3:  Solicited Symptoms (Solicited TEAEs in Study VXA -G11-101) 
Adverse Events  Placebo Low dose  High dose  
  (n=20) (n=23) (n=23) 
Number of Subjects with Solicited Symptom 
TEAEs 10 (50%) 11 (48%) 14 (61%) 
       Diarrhea 3 (15%) 4 (17%) 11 (48%) 
       Abdominal Pain  2 (10%) 5 (22%) 0 
       Nausea 4 (20%) 4 (17%) 3 (13%) 
       Malaise 2 (10%) 1 (4%) 3 (13%) 
       Headache  8 (40%) 8 (35%) 7 (30%) 
 
Immunogenicity Results  
Antibody responses to Norovirus VP1 were assessed primarily by [CONTACT_122702] 50 assay. Titers were measured by 
[CONTACT_300036] H1 synthetic glycan as the coating antigen. Using the Leb assay, 14/23 (61%) 
subjects had a 2 -fold rise in the low dose group, and 18/23 (78%) had a [ADDRESS_366169] in the placebo group had a greater than 2 -fold rise. On day 28, the GMT by 
[CONTACT_300037] 59.0 (95% CI 33.0 -105.4), a 2.3 -fold geometric mean 
fold rise (GM FR) over the initial GMT of 26.2 (95% CI 16.6 -41.2) at baseline. The GMT for the high 
dose vaccine group was 98.5 (95% CI 64.4 -150.7), a 3.8 -fold GMFR over the initial GMT of 25.8 (95% 
CI 18.3-36.2) at baseline  (32). Similar observations were made f or titers measured with H1. The high 
dose group had significantly increased titers compared to placebo on Day 28 by [CONTACT_300038] (P=0.0003) 
or H1 (P=0.001) BT 50 assay Table 4. 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 28 of 114 
Date: [ADDRESS_366170] immunization .   In terms of fecal IgA, in the high dose group 9/19 (47%) subjects 
had a 4-fold or greater IgA responses at Day 28, and 9/21 (43%) subjects had 4 -fold or greater response 
at Day 180; the average fold increases in the specific IgA/total IgA ratio were 17.2 and 9.7, respectively. 
Fecal IgA responses in the low dose group were similar to  those of the high dose group, with 7/20 
(35%) and 5/16 (31%) showing [ADDRESS_366171] immunization. Substantial 
47hi (the intestinal mucosal) expression was observed on the activated B cells [ADDRESS_366172] 
immunization  with up to 25% of all B cells having upregulated the intestinal homing receptor .  In terms 
of increases in memory IgA, the GMFR for IgA was 15.3 for the high dose group suggesting substantial 
expansion of the anti gen specific memory cell pool.  Similarly , in the low dose group, a GMFR of 7.4 
for IgA was observed at Day 7. 
 
Summary  
The vaccine was well -tolerated, with no dose -limiting toxicities. AEs were mild or moderate. The 
primary immunological endpoint (increase in BT 50 titers) was met in the high dose  group (P=0.0003) 
with 78% showing ≥ 2 -fold rise after a single immunization. Vaccine recipi[INVESTIGATOR_299988] -primed VP1 -specific circulating ASC, IgA+ memory B cells expressing gut homing  receptor 
47) and fecal IgA, indicating robust and loc al responses clinically relevant to prevent norovirus 
infection.  
 
 Norovirus Phase 1 Dose Optimization Study  VXA-G11-102 
 
This was an open-label dose optimization trial of VXA-G1.1-NN oral norovirus vaccine to further 
determine safety and immunogenicity  with differing dosing regimens . Fifteen subjects were enrolled 
in 1 of 4 cohorts for a total enrollment of 60 subjects.  The dose and dose regimen are described in 
Table 5. 
 
Table 5:  Treatment  Groups and  Dosing Regimens  in Study VXA -G11-102 
Group Vaccine group  Dose Number of 
oral doses  Dosing 
days Number of 
subjects 
1 VXA-G1.1-NN low dose – 1x1010 IU 2 0, 7 15 
2 VXA-G1.1-NN low dose – 1x1010 IU 3 0, 2, 4 15 
3 VXA-G1.1-NN low dose – 1x1010 IU 2 0, 28 15 
4 VXA-G1.1-NN high dose – 1x1011 IU [ADDRESS_366173] frequently reported symptoms are showed in  Table 6. Diarrhea, which 
was a frequently reported symptom in the high dose group in the initial norovirus vaccine study (VXA -
G11-101), was not commonly reported in this study.  
  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 29 of 114 
Date: 25 May 2023  
 Table 6:  Solicited Adverse Events in Study VXA -G11-102 
 Solicited Treatment Emergent Adverse  
Events (TEAEs)  Group 1 Group 2 Group 3 Group 4 
(n=15) (n=15) (n=15) (n=15) 
Number of Subjects with Solicited TEAEs  5 (33%) 8 (53%) 11 (73%) 3 (20%) 
       Diarrhea 0 1 (7%) 5 (33%) 1 (7%) 
       Abdominal Pain  1 (7%) 1 (7%) 3 (20%) 1 (7%) 
       Nausea 1 (7%) 2 (13%) 2 (13%) 0 
       Malaise 2 (13%) 0 2 (13%) 1 (7%) 
       Feeling Hot  0 1 (7%) 0 0 
       Headache  4 (27%) 7 (47%) 9 (60%) 1 (7%) 
 
Immune Response 
The objective of the study was to compare schedules and dosing for the ability to elicit immune 
responses. BT [ADDRESS_366174] dose 
and 14 of 15 subjects (92%) had a 2 -fold or greater increas e in BT 50 titers after 2 doses. The GMT titer 
rose from 21.3 on day to 85.1 on day 28 for a 3.8 GMFR. The GMT at Day 56 were measured to be 
75.8, a GMFR of 3.6 over the baseline values . Table 7 compares the 101 and 102 high dose results.  
Other groups given lower doses of vaccine had lower response rates. Groups 1 and 3 had higher 
increases in the titers compared to Group 2, although this is not statistically significant. Using an 
ANCOVA model, the significance in the different groups to i ncrease the GMFR, was found to be 
P=0.0008, 0.1224, 0.0004, and <0.[ADDRESS_366175] 
increase in the tite rs. 
 
Table 7: Comparison of BT 50 Antibody Results Among Groups in the  
  VXA-G11-101 and VXA-G11-102 Trials 
Study Dose group  Dosing 
(day) D0 
GMT D28 
GMT GMFR D56 
GMT GMFR 
D56 
101 Placebo 1 24.6 28.1 1.1 N/A N/A 
101 High dose  1 25.8 97.9 3.8 N/A N/A 
[ADDRESS_366176] that didn’t respond 
the first time had a significant increase in ASC counts so all 15 subjects (100%) were able to elicit an 
ASC response following two doses. The low dose groups were compared by [CONTACT_29847] o verall 
response rate, since the dosing and the analysis were performed at different intermediate timepoints. 
Group A had the highest overall response rate where 12/14 subjects (86%) were able to induce 
meaningful ASC responses after [ADDRESS_366177] dose, but this was the result of several subjects having 
extremely high numbers of spots (3 subjects had greater than 1500 per 1 x 106), mixed with many 
subjects that didn’t respond at all.  A positive ASC was defined as higher than [ADDRESS_366178] 3 spots/well/3x105 PBMCs (IgA). 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 30 of 114 
Date: 25 May 2023  
 Figure 2: Overall IgA ASC Response Rate After Either One or Two Doses   
  (Study VXA -G11-102) 
 
 
 
 Clinical Study VXA -NVV-103 with VXA -G1.1-NN and VXA-G2.4-NS 
 
Overall Study Design and Plan  
Protocol VXA -NVV-103 Entitled “A Phase 1b, Multi -Center, Randomized, Double -Blind, Placebo -
Controlled Safety and Immunogenicity Study of Adenoviral -vector Based Oral Norovirus Vaccines 
Expressing GI.1 or GII.4 VP1  with Monovalent or Bivalent Dosing in Healthy Adult Volunteers” is a 
multi-center, randomized, double -blind, placebo -controlled study to assess the safety and 
immunogenicity of monovalent GI.1, monovalent GII.4, bivalent GI.1/GII.4 norovirus vaccines, or 
placebo at differing dose levels with varying dosing schedules.  
After a sentinel lead -in group (n=5) dosed with GII.4 vaccine, subjects were randomized in a 1:1:2:1 
manner to one of four treatment arms ( Table 8) and followed for primary safety and immunoge nicity 
for 29 days and for long -term safety though Day 365.  
A total of 80 subjects entered the study and were randomized to study treatment. A total of 77  subjects 
completed the study. Three subjects in the Bivalent GII.4/GI.1 group discontinued the study ([ADDRESS_366179] to follow up).  
 
Table 8:  Design of Study VXA -NVV-103 
Group Vaccine Dose (IU)  No. of Subjects  
1 Monovalent GII.4  5x1010 5 sentinels  
 15 randomized  
2 Monovalent GI.1  5x1010 15 randomized  
3 Bivalent GII.4 and GI.1  5x1010 x 2 30 randomized  
4 Placebo 0 15 randomized  
Total 80 
IU = International Units  

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 31 of 114 
Date: [ADDRESS_366180] discontinuations due to TEAEs in this study through 
the duration of the Active Period (Day 2 9). Overall, [ADDRESS_366181] in the placebo group (33.3%) compared with the Monovalent GI.1 group (26.7%), 
Monovalent GII.4 group (15.0%), and the Bivalent GII.4/GI.I group  (6.7%). Incidence of study vaccine 
related TEAEs was highest in the Monovalent GI.1 group (20%) compared with the placebo group 
(13.3%), Monovalent GII.4 group (5.0%), and the Bivalent GII.4/GI.I group (3.3%). One subject in the 
Monovalent GII.[ADDRESS_366182] number of possibly related TEAEs (20%) were reported in 3 subjects in the Monovalent 
GI.1 group. There was one probably related TEAE (6.7%) in the placebo group. Most subjects reported 
solicited symptoms that were mild in intensity. Five subjects reported solicited symptoms of Grade 3 
severity. Three subjects (1 each in the Monovalent GII.4 group, Monovalent GI.1 group, and Bivalent 
GII.4/GI.I group) had ≥ [ADDRESS_366183] in Bivalent GII.4/GI.I group compared to other groups. 
The incidence of malaise/fatigue was higher across the vaccine treated subjects compared to placebo. 
Myalgia and fever were reported only in the vaccine treated subjects (Table  9). 
No treatment -related trends were observed regardin g clinical laboratory evaluations. Several laboratory 
TEAEs were reported; however, the investigator considered a mild TEAE of decreased blood 
phosphorus in [ADDRESS_366184] in the Bivalent GII.4/GI.[ADDRESS_366185] safety.  
Table 9:  Summary of Solicited Symptoms of Reactogenicity (Study VXA -NVV-103) 
Grades 1 -3 Monovalent  
GII.4  
(N=20) 
n (%) Monovalent  
GI.1  
(N=15) 
n (%) Bivalent 
GII.4/GI.I  
(N=30) 
n (%) Placebo 
(N=15) 
n (%) 
Number of Subjects with at least 1 
symptom of Grades 1 -3 9 8 16 4 
Diarrhea 4 (20.0) 3 (20.0) 6 (20.0) 1 (6.7) 
Nausea 3 (15.0) 1 (6.7) 6 (20.0) 2 (13.3) 
Vomiting  1 (5.0) 0 (0.0) 2 (6.7) 0 (0.0) 
Abdominal Pain  3 (15.0) 1 (6.7) 4 (13.3) 2 (13.3) 
Malaise/Fatigue  4 (20.0) 4 (26.7) 6 (20.0) 1 (6.7) 
Myalgia (Muscle Pain)  2 (10.0) 2 (13.3) 2 (6.7) 0 (0.0) 
Anorexia 0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 
Headache  2 (10.0) 2 (13.3) 7 (23.3) 2 (13.3) 
Fever 1 (5.0) 2 (13.3) 1 (3.3) 0 (0.0) 
Temperature      
< 99 F 3 (15.0) 3 (20.0) 9 (30.0) 2 (13.3) 
99 to 99.9 F  5 (25.0) 3 (20.0) 6 (20.0) 2 (13.3) 
>= 100 F 1 (5.0) 2 (13.3) 1 (3.3) 0 (0.0) 
  The temperature summarizes the highest temperature recorded for 7 days following each vaccine.  
  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 32 of 114 
Date: 25 May 2023  
 Summary of Immunogenicity Analysis  
A summary of immunogenicity results in the Active Period (Day 2 9) is provided below:  
• Statistically significant increases in Serum GI.1 BT 50 GMT were seen in the Monovalent GI.1 group 
(p=0.0008) and Bivalent GII.4/GI.1 group (p=0.0084) compared with placebo. No significant 
differences in the GMT were seen between the Monovalent GI.1 and Bivalent GII.4/GI.1 groups 
(p=0.2772).  
• On Day 29, statistically significant increases in Serum GII.4 BT 50 GMT were seen in the Monovalent 
GII.4 group (p= 0.0017) and Bivalent GII.4/GI.1 group (p<0.0001) compared with placebo. No 
significant differences in the GMT were seen between the  Monovalent GII.4 and Bivalent 
GII.4/GI.1 groups (p=0.2320).  
• On Day 8, statistically significant increases in the average counts of GI.1 IgA were seen in the 
Monovalent GI.1 group (p<0.0001), Bivalent GII.4/GI.1 group (p<0.0001), and Monovalent GII.4 
group (p=0.0001) compared with placebo. No significant differences in the average counts of GI.1 
IgA were seen between the Monovalent GI.1 and Bivalent GII.4/GI.1 groups (p=0.6013).  
• On Day 8, statistically significant increases in the average counts of GII.4 Ig A were seen in the 
Bivalent GII.4/GI.1 group (p<0.0001), Monovalent GII.4 group (p<0.0001) and Monovalent GI.1 
group (p=0.0080) compared with placebo. No significant differences in the average counts of GI.1 
IgA were seen between the Monovalent GII.4 and B ivalent GII.4/GI.1 groups (p=0.6079).  
• On Day 29, statistically significant increases in the GMT of VP1 specific serum GI.1 IgG were seen 
in the Monovalent GI.1 group (p=0.0010) and the Bivalent GII.4/GI.1 group (p=0.0092) compared 
with placebo. No signific ant differences in the GMT were seen between the Monovalent GI.1 and 
Bivalent GII.4/GI.1 groups (p=0.1293).  
• On Day 29, statistically significant increases in the GMT of VP1 specific serum GII.4 IgG were 
seen in the Bivalent GII.4/GI.1 group (p<0.0001) and the Monovalent GII.4 group (p=0.0001) 
compared with placebo. No significant differences in the GMT were seen between the Monovalent 
GII.4 and Bivalent GII.4/GI.1 groups (p=0.3932).  
• On Day 8, statistically significant increases in the average counts of ASC GI.1 IgG were seen in the 
Monovalent GII.4 group (p=0.0002), Monovalent GI.1 group (p=0.0019), and the Bivalent 
GII.4/GI.1 group (p<0.0001) compared with placebo. No significant differences in the average 
counts of ASC GI.1 IgG were seen between the Monova lent GI.1 and Bivalent GII.4/GI.1 groups 
(p=0.4172).  
• On Day 8, statistically significant increases in the average counts of ASC GII.4 IgG were seen in 
the Bivalent GII.4/GI.1 group (p<0.0001) and Monovalent GII.4 group (p<0.0001) compared with 
placebo. No significant differences in the average counts of ASC GII.4 IgG were seen between the 
Monovalent GII.4 and Bivalent GII.4/GI.1 groups (p=0.2694).  
• On Day 29, statistically significant increases in the GMT of VP1 specific serum GI.1 IgA were seen 
in the Monov alent GI.1 group (p=0.0391) compared with placebo. No significant differences in the 
GMT of VP1 specific serum GI.1 IgA were seen between the Monovalent GI.1 and Bivalent 
GII.4/GI.1 groups (p=0.6184).  
• On Day 29, statistically significant increases in the G MT of VP1 specific serum GII.4 IgA were 
seen in the Bivalent GII.4/GI.1 group (p=0.0002) and the Monovalent GII.4 group (p=0.0018) 
compared with placebo. No significant differences in the GMT of VP1 specific serum GII.4 IgA 
were seen between the Monovalent  GII.4 and Bivalent GII.4/GI.1 groups (p=0.6295).  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 38 of 114 
Date: [ADDRESS_366186] been enrolled in 13 clinical trials completed with Vaxart’s oral Ad5 
vaccine platform. Three phase 1 studies using the Norwalk GI.1 norovirus candidate (VXA -G1.1-NN) 
have been conducted in 206 subjects. A total of 640 subjects participated including 497 subjects who 
received Vaxart’s oral vaccines at varying dose levels and dosing schedules, acros s four clinical 
programs (seasonal and pandemic influenza, norovirus, RSV and coronavirus) and 143 subjects 
received placebo. To date, the vaccines were well tolerated, and in the placebo -controlled studies, the 
vaccine groups, at all dose levels, did not differ significantly in the frequency of adverse events ( aEs) 
recorded from the placebo groups.  A summary of the clinical studies conducted using Vaxart’s vaccine 
platform is presented i n Table 17. 
 
Table 17:  Clinical Studies Completed  Using Vaxart Oral Ad5 Vaccine P latform  
Target 
Pathogen  Vaccine 
Candidate(s)  
 Protocol 
Number and 
(Oral Vaccine 
Formulation)  Year 
Study 
Completed  
(Active 
Phase) Subjects 
with ≥ 1 
Vaccine 
Exposure  Subjects 
Receiving 
Placebo 
Influenza H5  ND1.1 
 VXA01-001  
(H5 Capsule)  2011 42 12 
VXA01-001A 
(H5 RCC)  2012 12 - 
Influenza H1  
 
 
   
 
VXA-A1.1  
 VXA02-001  
(H1 Tablet) 2012 25 12 
VXA02-002  
(H1 RCC) 2013 37 - 
VXA02-003  
(H1 Tablet) 2014 12 12 
VXA-CHAL-201  
(H1 Tablet)  
[BARDA 
Funded] 2017 71 36 
VXA-RLT-1  
(H1 Fast/Fed ) 2018 8 - 
Influenza B  VXA-BYW.10 
 VXA03-001  
(Flu B Tablet) 2016 38 16 
Norovirus GI.1   VXA-G1.1-NN 
 VXA-G11-101 
(NV Tablet) 2016 46 20 
VXA-G11-102 
(NV Tablet)  2017 60 - 
Norovirus GI.1  
and GII.4  VXA-G1.1-NN 
and  
VXA-G2.4-NS 
 VXA-NVV-103 
(NV Tablet)  2019 65 15 
RSV VXA-RSV-f 
 VXA-RSV-101 
(RSV Tablet)  2016 46 20 
Coronavirus  VXA-CoV2-1 VXA-COV2-101  
(SARS-CoV-2  
S & N Tablet)  2021 35 0 
Total Subjects Dosed  497 143 
Ad5 = serotype 5 adenovirus ; BARDA = Biomedical Advanced Research and Development Authority ; BB-IND = biologic -
based investigational new drug; NV = norovirus; RCC = Radio -Controlled Capsule; RSV = respi[INVESTIGATOR_299989] v irus 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 39 of 114 
Date: 25 May 2023  
 Safety in Vaxart’s oral vaccine programs has been assessed by [CONTACT_300039], aEs and serious aEs (SAEs) in the intent -to-treat (ITT) population of each 
study. Solicited local and systemic aEs were collected for [ADDRESS_366187] (AESIs) and new onset of chronic illness (NOCIs) were 
monitored throughout the one -year safety follow -up period.  No related SAEs,  AESIs or NOCIs have 
been reported for any subject receiving single  or multiple doses of Vaxart’s VAASTTM oral vaccines to 
date.   
 
1.8 Rationale for GI.1 Human Challenge Study (VXA -NVV-201) 
The human challenge model has been used successfully to determine the efficacy of both GI.11 and 
GII.4 norovirus vaccines (30, 31). The challenge with GI.1 was more successful because the GI.1 
challenge induced illness in more control subjects. The challenge model has been called into question 
as an overly stringent model because the in oculum used in these studies induce s illness in over half of 
the unvaccinated control subjects. In nature the dose may be much lower. For example, in the Atmar 
study using the GI.1 challenge the protective efficacy  of a parenteral GI.1 NV vaccine  was 47%. The 
hope is that the efficacy will be considerably higher in field studies.   The challenge study may also 
provide immunological data that may aid in determining an immunologic correlate of protection. A 
correlate of protection could greatly aid in predicti ng vaccine efficacy in different age groups.  An 
effective Norovirus vaccine must prevent the two most common norovirus genotypes, GI.1 and GII.4.  
Vaxart is developi[INVESTIGATOR_007] a bivalent  vaccine for use in the field.  
 
 
1.9 Potential Risks and Benefits  
 Vaccine Risks 
Vaxart’s Ad5 vector is a replication incompetent  vaccine, lacking the E1 and E3 gene regions, which 
have been removed recombinantly.  Replication incompetent Ad5 has been used in over 200 gene 
therapy and vaccine studies in humans (36-39). VXA-G1.1-NN is an investigational new drug. Similar 
doses of the related investigational drugs (vaccines) ND1.[ADDRESS_366188] been tested in prior 
phase 1 and phase 2  studies; the numbers were rel atively small (n = ~500 subjects ). Based on the results 
from 3 studies completed with the  VXA G1.1 -NN norovirus vaccine , doses of 2 x 1011 ±0.5 logs, 
delivered by [CONTACT_300040]. 
 
The safety monitoring practices employed by [CONTACT_3181] (ie, physical examination, vital 
signsgastrointestinal  and systemic reactogenicity (solicited symptoms), 12 -lead electrocardiogram  
(ECG), hematology, serum chemistry, urinalysis, immunogenicity assessments, and AE questioning) 
are adequate to protect the subjects’ safety and should detect all expected treatment -emergent AEs 
(TEAEs).  
 
Since the initiation of the current protocol, multiple i njected adenovirus vectored vaccines approved 
for use via Emergency Use Authorization (EUA) for the prevention of COVID -[ADDRESS_366189] reported severe 
events of thrombosis in combination with thrombocytopenia (thrombosis with thrombocytopenia 
syndrome, TTS), in s ome cases accompanied by [CONTACT_79602]. Though the TTS events were reported with 
adenovirus  vectored vaccines for COVID -19, the FDA has asked Sponsors of adenovirus  vectored 
vaccines for other indications to broadly monitor for these risks.  
 
Investigators shoul d be alert to the signs and symptoms of thromboembolism and/or thrombocytopenia. 
Study participants should be instructed to seek immediate medical attention if they develop symptoms 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 40 of 114 
Date: [ADDRESS_366190] pain, leg pain a nd/or swelling, persistent 
abdominal pain, severe or persistent headaches, blurred vision or other vision changes, mental status 
changes or seizures, petechia, purpura beyond the site of vaccination, and/or easy bruising/bleeding. 
The medical management of  thrombosis with thrombocytopenia is different from the management of 
isolated thromboembolic diseases. Investigators should  follow available guidelines for the assessment 
and treatment of thrombotic thrombocytopenia (e.g., American Society of Hematology 2 021British 
Society for Haematology 2021; CDC 2021). The use of heparin may be harmful and alternative 
treatments may be needed. Consultation with hematologists is strongly recommended . 
 Norovirus Challenge  Risks 
The intended challenge NV dose of  1x106 GC is expected to elicit acute watery diarrhea within 12-[ADDRESS_366191], cold clammy skin, hypotension, lethargy, stupor, and muscle crampi[INVESTIGATOR_007]. 
The complications of severe fluid loss  include hypoglycemia (low blood sugar), acidosis, kidney 
failure, pulmonary edema  (fluid in lungs), arrhythmia (heart rhythm abnormalities), coma, and death. 
Dehydration will be managed with aggressive fluid rehydration (oral and/or intravenous  [IV]) with 
potassium repletion. It is expected that NoV shedding will occur in the stool; ho wever, transmission 
from person to person is mitigated by [CONTACT_300041]. Subjects that maintain the standard hygiene (ie, hand washing with 
soap and water after defecatio n) are unlikely to transmit the strain person to person.  
 Risk of Blood Draw 
The approximate volume of blood planned for collection from each subject over the course of the study 
presents no undue risk to the subjects nor does the possibility of collection (for wasting to ensure clean 
sample) of additional blood in the event an indwelling cannula is utilized and the possibility of 
additional blood for recheck of safety labs if deemed necessary by [CONTACT_079] (PI).  
 
 Known Potential Benefits  
Since these are experimental vaccines against norovirus, t here are no benefits to the subjects for their 
participation in this research study.  
2 HYPOTHESIS, OBJECTIVES AND PURPOSE  
2.1 Study Hypothesis  
Norovirus vaccine (VXA -G1.1-NN) will protect against Norovirus Gastroenteritis ( NVG) in the 
challenge model . 
2.2 Study Objectives  
 Primary Objective  
• Determine the clinical efficacy of VXA -G1.1-NN compared to placebo,  to protect against NVG 
caused by [CONTACT_300042] . 
 Secondary Objective s 
• Safety and tolerability of VXA -G1.1-NN oral vaccine  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 41 of 114 
Date: 25 May 2023  
 • Determine the ability of VXA -G1.1-NN to modify disease severity (defined in Appendices C 
and D) compared to placebo  
• Determine the quantity and duration of norovirus shedding  by [CONTACT_300043]  
• Evaluate the VP1 specific IgA ASC, HBGA blocking antibody, and VP1 specific serum IgG 
responses  to VXA-G1.1-NN 
 Exploratory Objectives  
• Determine correlation of immunogenicity parameters with clinical outcome  
• Further evaluate immunogenicity of VXA -G1.1-NN 
3 STUDY DESIGN AND ENDPOINTS  
 
3.1 Description of Study Design  
This is a Phase 2 b randomized, double -blind, placebo -controlled vaccination and challenge study to 
assess the protective efficacy of the Norovirus vaccine (VXA -G1.1-NN). To ensure at least 140 subjects 
(approximately 85 NV vaccine and 85 placebo) are available to participat e in the challenge phase , 
approximately 170 healthy young adults will be randomized in a 1:[ADDRESS_366192] will receive an oral dose o f 1x1011 IU±0.[ADDRESS_366193] -
challenge isolation period, subjects will move through the study (enrollment, vaccination and challenge) 
sequentially in a total of approximately 14 to 16 cohorts. Subjects will be ran domized in cohorts of  
approximately 10 to 12 each. Approximately 28 days (+30 days) post-vaccination , each cohort will be 
admitted to the isolation ward and challenged with the NV GI.1 Norwalk challenge strain. After 
challenge, subjects will be monitored for signs and symptoms of AGE from Day 29 to discharge. S tool 
and emesis  will be collected. Excretion of NV (shedding) will be monitored in stool  and emesis . Illness 
will be assessed using a mod ified Vesikari scale . NV illness last s 2-[ADDRESS_366194]-challenge (Day 33 ) subjects will be evaluated for signs and symptoms of acute 
gastroenteritis.  If there is no clinical illness present, asymptomatic subjects will be discharged from the 
isolation ward and will be followed up in a series of outpatient visits and telephone calls.  Symptomatic 
subjects will remain in the unit up to an additional 3 days ( Day 36), per the judgement of the 
investigator.  
An independent Safety Monitoring Committee (SMC) will convene at pre -defined intervals during the 
norovirus challenge period, and also ad hoc as needed during the vaccination and challenge periods, 
to oversee the safety of the study.  
 
Each subject’s participation will last approximately [ADDRESS_366195] successful screening and enrollment  
• 90 day pre-screening  period 
• 45 day screening  period 
• 28 day vaccination phase  
• 28 day viral challenge and follow -up  
• [ADDRESS_366196] vaccination  
 
 
 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 42 of 114 
Date: 25 May 2023  
 Table 18:  Study Design and Vaccine Groups  (Study VXA -NVV-201) 
Product/Test Agent  No. of 
subjects 
VXA-G1.1-NN oral vaccine tablets [1x1011 IU±0.5 log]  85 
Placebo identical to NVV  85 
Challenge Norwalk Virus Strain [Lot 001-09NV and Sublot 2  
(1x106 GC)] 140* 
*All subjects suitable to undergo challenge at Day 29 will participate in the challenge phase.  
 
3.2 Study Endpoints  
 Primary Endpoint  
• Occurrence of NVG caused by [CONTACT_300044] . 
o NVG is a composite endpoint and is defined as meeting one or more of the definitions 
for both acute gastroenteritis and NV infection.  
 Secondary Endpoint s 
• Number of subjects with acute gastroenteritis during the inpatient challenge period  
• Mean score using the Modified Vesikari Scale as a measure of severity of acute gastroenteritis  
post-challenge at discharge (up to Day 36) 
• Number of subjects with moderate or severe gastroenteritis (cumulative loose stools ≥ 1000gms 
during the inpatient period)   
• Median d uration (number of hours) of acute gastroenteritis among challenged subjects  
• Number of subjects with norovirus infection up to Day [ADDRESS_366197]-challenge ( quantitative reverse 
transcriptase polymerase chain reaction [qRT-PCR] positive in stool, Norwalk virus antigen in stool  
• Geometric mean genome copi[INVESTIGATOR_299982] -PCR 
• Median d uration (number of hours) of norovirus infection among challenge subjects  
• Number of incidences of diarrhea or emesis among challenge su bjects 
 
 Safety Endpoints  
• Vaccine (VXA-G11-N.N) 
o Solicited symptoms of reactogenicity x [ADDRESS_366198] vaccination ;  
o Unsolicited AEs x [ADDRESS_366199] vaccination;  
o SAEs, AESIs and NOCIs x [ADDRESS_366200] vaccination  
 
• Challenge Virus (Norwalk GI.1)  
o Unsolicited AEs x [ADDRESS_366201] challenge  
 Immunogenicity  Endpoints  
Primary 
• VP1 specific IgA ASC response against Norwalk at Day 8 compared to placebo  
• GMT of HBGA blocking antibodies (by [CONTACT_122702] 50) against Norwalk virus at Day 28 compared to 
placebo 
• VP1 specific serum IgG response at Day 28 compared to placebo  
• VP1 specific serum IgA at Day 28 compared to placebo  
 
Exploratory  
• Correlations between individual immunogenicity parameters and clinical efficacy  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 43 of 114 
Date: 25 May 2023  
 • VP1 specific IgG ASC response against Norwalk at Day 8 compared to placebo  
• VP1 specific fecal IgA at Day 28 compared to placebo  
• VP1 specific saliva IgA at Day 8 and Day 28 compared to placebo  
• VP1 specific nasal IgA at Day 8  and Day 28 compared to placebo  
• Vaccine specific response for memory IgA and/or IgG in B cells, IgA and IgG in plasmablasts, 
antibody repertoire sequencing analysis, flow cytometry (including homing and/or 
immunophenotypi[INVESTIGATOR_26174]), and other assays designed to evaluate cell mediated immunity  
Additional assessment of serum, fecal, saliva, and mucosal immunity at other time points (including 
post-challenge) may be performed  
[ADDRESS_366202] Inclusion Criteria  
1. Male or female between the ages of 18 – 49 years, inclusive   
2. Able to give written informed consent 
3. Healthy1, as determined by [CONTACT_458] (PI) or PI [INVESTIGATOR_299990]  
1No clinically significant health concerns or medical illness), as determined by [CONTACT_9870], 
physical examination, vital sign s, electrocardiogram (ECG), and clinical laboratories 
(complete blood count [CBC], chemistry and urinalysis)  
4. Comprehension of the study requirements with ability and willingness to complete all 
assessments and comply with confinement period post viral cha llenge, and all scheduled visits 
and contacts  
5. Confirmed blood type (A or O)  
6. Demonstrated to be H type -1 antigen secretor positive (by [CONTACT_300045])  
7. Body mass index between 17 and 3 5 kg/m2, inclusive, at Screening  
8. Female participants must have a negative pregnancy test at pre-vaccination and pre-challenge 
and fulfill one of the following2 
 
2Criteria: 
a. At least one year post -menopausal;  
b. Surgically sterile;  
c. Use of oral, implantable, transdermal , intravaginal  or injectable 
contraceptives for 30 days prior to immunization and until 60 days after 
challenge;  
i. A reliable form of contraception must be approved by [CONTACT_3786] (eg, double barrier method, Depo -Provera, 
intrauterine device, Norplant, or al contraceptives, 
contraceptive patches , vaginal ring contraceptive ) 
d. Not be sexually active (abstinent) or in a same sex relationship (must be 
discussed with site staff and documented)  
9. Male subjects must agree not to father a child or donate sperm , as well as to use 
contraception/barrier (a male condom) or be abstinent from heterosexual intercourse,  from 
vaccination through the active/interventional period of the study (Day 57)  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 44 of 114 
Date: [ADDRESS_366203] Exclusion Criteria  
1. Administration /use of any investigational drug or device 30 days prior to vaccination  through 
the active period (Day 57)  
2. Administration of any licensed vaccine within 30 days prior to vaccination or planned use of 
the above stated during the active  period (through Day 57)  
3. Presence of a significant medical condition3 which in the opi[INVESTIGATOR_299991]3 
3 For example, psychiatric conditions, or gastrointestinal disease, such as peptic ulcer, 
symptoms or evidence of active gastritis or gastroesophageal reflux disease, 
inflammatory bowel disease, alcohol or illicit drug abuse/dependency, or other 
laboratory abnormalities  
4. Laboratory  values outside the range of normal for platelet counts and the following coagulation 
tests: PT/INR, aPTT  and fibrinogen  
5. Any of the following history or conditions that may lead to higher risk of clotting events and/or 
thrombocytopenia:  
e. Family or personal history of bleeding or thrombosis  
f. History of heparin -related thrombotic events, and/or receiving heparin treatments  
g. History of autoimmune or inflammatory disease  
h. Presence of any of the following conditions known to increase risk of thrombosis within 
6 months prior to screening : 
▪ Recent surgery other than removal/biopsy of cutaneous lesions  
▪ Immobility (confined to bed or wheelchair for 3 or more successive days)  
▪ Head trauma with loss of consciousness or documented brain injury  
▪ Receipt of anticoagulants for prophylaxis of thrombosis  
▪ Recent clinically significant infection  
6. Any one of the following ECG findings4 within 45 days prior to vaccination:  
4Exclusionary ECG findings:  
a. QTc F (interval duration > 450 msec (male) or >  470 msec (female)  
b. QRS interval greater than [ADDRESS_366204] 3 years (excluding basal cell or squamous 
cell carcinoma s) 
8. Presence of immunosuppression or medical condition possibly associated with impaired 
immune responsiveness, including d iabetes mellitus or angioedema  
9. Donation or use of blood or blood products within 30 days prior to vaccination through the 
active period (Day 57)  
10. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make 
blood draws problematic  
11. Any condition that resulted in the absence or removal of the spleen  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 45 of 114 
Date: 25 May 2023  
 12. Evidence of confirmed infection with human immunodeficiency virus (HIV), hepatitis B 
surface ant igen (HBsAg) or hepatitis C virus (HCV)  with confirmatory assays  
13. Abnormal stool pattern (fewer than 3 bowel movements pe r week or more than 3 per day)  
14. History of irritable bowel disease or inflammatory digestive or gastrointestinal condition5 that 
could affect the distribution / safety evaluati on of an orally administered vaccine6 
5Such conditions may include but are not limited to:  
a. Esophageal Motility Disorder  
b. Malignancy  
c. Malabsorption (eg. Celiac disease, gluten intolerance)  
d. Pancreaticobiliary disorders  
e. Irritable bowel syndrome  
f. Inflammatory Bow el Disease  
g. Surgical Resection with the exception of appendectomy or a minor resection that is 
deemed acceptable by [CONTACT_147100]  
h. Gastroesophageal reflux disease (GERD)  
i. Hiatal Hernia  
j. Peptic Ulcer  
(History of cholecystectomy is not exclusionary ) 
6 targeting the mucosa of the small intestine  
 
15. Use of proton pump inhibitors, H2 blockers or antacids within 7  days prior to vaccination 
through the active period (Day 57)  
16. Use of antibiotics within 30 days prior to vaccination  through the active period (Day 57 )7  
7Note: use of a brief  (≤ 10 days) course of oral or topi[INVESTIGATOR_299992], UTI, dental 
work, or skin infection allowed within the screening period, but must be completed [ADDRESS_366205] the immune function (e.g. systemic corticosteroids and 
others) within 14 days prior to vaccination through the active period  (Day 57) 
18. Regular use of nonsteroidal anti -inflammatory drugs within 7 days prior to vaccination  through 
the active period (Day 57)  
19. Use of over -the-counter probiotics or antidiarrheals within 7 days prior to vaccination  through 
the active period (Day 57)  
20. Evidence of  recent (within 2 months of vaccination) or of current nonbacterial gastroenteritis 
suggestive of NV infection [vom iting or unformed or watery stools (> 2 during a 24 -hour 
period)] 
21. Any gastroenteritis within the past 2 weeks prior to vaccination  
22. Acute dise ase within 72 hours prior to vaccination8 
8Defined as the presence of a moderate or severe illness with or without fever (as determined 
by [CONTACT_300046]). (Assessment may be 
repeated during screening peri od) 
23. Presence of a fever ≥ 38ºC measured orally at baseline  
24. History if hematochezia (blood in stool) or melena (black stool)  
25. Any significant hospi[INVESTIGATOR_299993].1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 46 of 114 
Date: [ADDRESS_366206] for drugs of abuse or alcohol  at Screening, vaccination baseline and pre-
challenge .10  
10except for previous marijuana use; concurrent or ongoing use of marijuana during the active 
study period  
30. Consistent/habitual smoking within 2 months prior to vaccination (defined as smoking ≥ 1 
pack of cigarettes a day). Smoking is not permitted during the inpatient stay  
31. Other condition s11 that would jeopardize the safety or rights of a subject or interfere w ith the 
evaluation of the study 
11 in the clinical judgment of the investigator  
Social/Occupational : 
32. Living with or having daily contact [CONTACT_300047] < [ADDRESS_366207] with elderly persons > [ADDRESS_366208] received the Ad4 or Ad7 vaccines within 2 months 
prior to vaccinat ion 
38. Employment as an airline flight attendant or c ruise ship crew, scheduled to work in the 4 weeks 
following challenge.  
39. Persons planning to live in a confined environment (eg, a cruise , camp, etc.) i n the [ADDRESS_366209] the right to withdraw from the study at 
any time and for any reason, without penalty.  The Principal Investigator [INVESTIGATOR_1238]/or designee may, at her/his 
discretion, withdraw a subject from continuin g in the study if it is in the subject’s best interest, or if the 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 47 of 114 
Date: [ADDRESS_366210],  to capture  protocol specified 
assessment s and AEs, SAEs , AESIs and NOCIs (refer to  Section 7.11 ).  
  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 48 of 114 
Date: 25 May 2023  
 5 STUDY DRUG   
 
5.1  Study Drug(s) and Control Description  
 
VXA-G1.1-NN final DP is produced as small white enteric -coated tablets Table 19. The DP is 
formulated as compressed powdered solid material containing  lyophilized drug substance (VXA -G1.1-
NN), tromethamine (TRIS), sucrose, arginine, hydrolyzed fish gelatin (type A), polyvinylpyrrolidone 
(PVP-grade K90), microcrystalline cellulose, pre -gelatinized starch, magnesium stearate, hydrophobic 
colloidal silica,  and hydrochloric acid for pH adjustment.  With the exception of the active ingredient 
all excipi[INVESTIGATOR_299994] -licensed oral DPs currently listed in the FDA Inactive Ingredients 
Database and are GRAS categorized.  
 
Table 19:  Active Product Description  (VXA-G1.1-NN) 
Generic name  [CONTACT_122728]-G1.1-NN 
Chemical name  [CONTACT_300092]-CMV-VP1(Norwalk virus) -BGH-CMV-luc dsRNA -SPA 
Genome size  33,[ADDRESS_366211] will be matched to the active treatment groups.  
The placebo will be dispensed by [CONTACT_779]’s in -house pharmacy in a manner indistinguishable from the 
active treatment groups.  
 
 Drug Product Packaging and Labeling  
 
DP tablets will be packaged into foil -sealed, HDPE screw -cap containers with [ADDRESS_366212] 
Operating Procedures (SOP).  
 
Secondary packaging of the DP upon dispensing from the pharmacy to the clinical staff for su bject 
dosing will be determined with consideration of the sites’ pharmacy SOPs and outlined in the study 
pharmacy manual.  The final subject use material (cup or secondary bottle) wil l be appropriately labeled 
with the subject’s unique identifier, the time/date of dose preparation within the pharmacy, an 
expi[INVESTIGATOR_299995], and additional information as deemed necessary.  
 
 Drug Product Storage and Stability  
VXA-G1.1-NN vaccine and placebo tablets will be stored at 2 to 8°C at the clinical site until ready for 
use.  Test data on representative DP lots support the stability of the DP tablets stored at 2 to 8°C for at 
least [ADDRESS_366213]. Additionally, data from accelerated stability studies 
indicate that handling at controlled room temperature or brief exposure to temperatures above room 
temperature (below 37 °C) is acceptable for this product.  
DP tablets should not be frozen.  Do not use and contact [CONTACT_300048].  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 49 of 114 
Date: [ADDRESS_366214] Dose  
DP doses will be prepared at the site by [CONTACT_300049] a blinded manner.  The observed concentration of VXA -G1.1-NN active ingredient per tablet has 
been within the range of 2x109 IU – 5x1010 IU. The actual concentration of active vaccine per tablet is 
determined during release testing and provided to clinical sites within the Certificate of Analyses 
(CoAs).  Mu ltiple tablets of the DP will be dispensed per dose to deliver the complete investigation al 
dose of 1x1011 IU ± 0.[ADDRESS_366215] 15 minutes prior to administration, the dose container(s) will be removed from the refrigerator 
and allowed to equilibrate with room temperature.  Multiple subject doses m ay be withdrawn from the 
container with proper drug accountability.  If tablets remain in the primary bottle container upon 
preparation of subject doses, the desiccant pack should be replaced, and the container tightly capped 
before being returned to the r efrigerator.  The DP containers may be held at ambient room temperature 
for no more than [ADDRESS_366216] 4 hours prior to 
initiation of oral dosing.  Following randomization subjects will be dispensed their assigned DP dose  
(VXA-G1.1-NN or placebo tablets)  on Day 1.  They will swallow the tablets with 360 to 480 mL of 
water followed by  a light snack (e.g., crackers) to aid in tablet transit out of the stomach. Normal food 
consumption may resume 90 minutes after dosing.  
 
Dose Adjustments /Modifications/Delays  
Dose adjustments and or modifications are not planned or allowed under this clinical protocol.  All 
subjects should receive the full 1x1011 IU ± 0.5 logs  dose or matching placebo at Day 1. Any 
modification from this planned dose should be recorded as a protocol deviation and reported to the 
Sponsor (or designee).  
 
 Study Drug Accountability  
The Investigator and study site must ensure that an accurate record  of DP disposition is maintained, 
and that study drug is dispensed only by [CONTACT_113640], unblinded personnel as documented on the 
delegation of authority log.  Records of product disposition and dispensing must consist at a minimum 
of the date received, date  administered, quantity administered, and the subject to w hom the drug was 
administered.  
The unblinded pharmacy staff will be responsible for maintaining accurate records of the shipment and 
dispensing of the study drug.  The investigational product records must be available for inspection by 
[CONTACT_1034]’s unblinded representative and is subje ct to inspection by a regulatory agency at any time.  
Copi[INVESTIGATOR_299996].  An unblinded study 
monitor will review the investigational product records . 
Clinical Trials Materials Returns form and the  drug accountability forms must be maintained in a 
blinded secure area throughout the duration of the study.  At the completion of the study, all unused 
product must be returned to the Sponsor or designee, per instruction by [CONTACT_1034].  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 50 of 114 
Date: 25 May 2023  
 6 NV CHALLENGE INOCU LUM 
The Norovirus GI.1 (Norwalk Virus Inoculum Lot 001 -09NV, IND [ZIP_CODE]) inoculum was prepared 
from a 20% suspension of a liquid stool from a NV -infected subject in a previous human challenge 
study. This inoculum was prepared by [CONTACT_300050], sterilely filtering the virus e xtract into vials, and determining the titer of the extract. These 
procedures were performed under Good Manufacturing Practices conditions at  
 From there, the inoculum was sent to an outside contractor for safety 
testing. The preparation, qualification, and quantification of this inoculum were submitted to the FDA 
under IND [ZIP_CODE]. 
 
To accommodate the increased sample size of the trial, additional  GI.[ADDRESS_366217] 
(PBH), to challenge the additional Subjects .  The dilution process is attached as Appendix F and an 
updated IND [ADDRESS_366218] uring 
team following the dilution procedure described in the Preparation of NV  Challenge Inoculum Work 
Instruction, Appendix F. During the aliquoting of 001 -09NV sublot 2,  additional vials from the 
beginning, middle and end of the run were prepared for qua lity control testing and  shipped on dry ice 
to either  or  for testing.  
 
6.2 Storage and Stability  of NV Challenge Virus  
The filled, purified material is stored long term in a controlled -80°C freezer. The final subject use 
material can be stored  short term in either a 4°C refrigerator or can be held short term on wet ice. The 
final subject material is not held or stored for more than [ADDRESS_366219] use material has been pre -set at 8 hours . 
 
The final titer for 001 -09NV PBH was 2.4 x 10e6 genome copi[INVESTIGATOR_014] (GC)/mL. The titer in 2009 was 5 x 
10e6 GC/mL. Titer of 001 -09NV Final Fill sublot  1, a 1/10 dilution of 001 -09NV PBH was 5 x 10e5 
GC/mL in [ADDRESS_366220] curve that passed 

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 51 of 114 
Date: 25 May 2023  
 QC, for all nine vials across three independent assays was 5.36 10e5 GC/ml. The titer was consistent 
across the  aliquoting run. Notably, the titer of 001 -09NV sublot  1 ranged from 6 x 10e5 GC/mL to 3 x 
10e5 GC/mL  between 2009 and 2022, indicating that 001 -09NV Final Fill sublot 2 is performing 
consistently with 001 -09NV Final Fill sublot 1. The reported titer is slightly higher than expected from 
the 1/8 dilution of  master stock but falls within the established range of titer based on historic results 
of 001-09NV Final Fill  sublot 1 (5 x 10e5 GC/mL +/ - 2 x 10e5 GC/mL).  
 
 
6.3 Preparation and Administration of NV Challenge Virus 
Subjects will receive a single oral dose of safety-tested inocul um approximately 28 days (+30  day 
window) post vaccination . The oral route was chosen because of ease of administration and successful 
precedent with this route from all other NoV challenge studies .  
 
Subjects will be challenged with a single oral dose of 1.1x106 GC of NV based on information from 
the NV GI.[ADDRESS_366221] challenge studies and the NV dose -response 
model (see Section 1.6).  The dose -response model and experience with this dose indicates that this 
dose is sufficient to result in an infection rate between 50% to 65% among susceptible, secretor -positive 
status individuals.  The dose is a single -subject dose (three 1 -mL vials for a total of 3 mL of NV 
inoculum Lot 001 -09NV, or one 3 mL vial for Sublot 2 , IND [ZIP_CODE])  
Three (3) or one (1) vial(s) per subject will be thawed under sterile conditions and swabbed with 
disinfectant.  The inoculum vial(s) will be added to [ADDRESS_366222] with the inocula w ith 10% bleach solution.  Cups used for administration 
and any leftover inocula should also be cleaned with bleach and discarded.  If the subject, person 
administering dose, or person preparing inocul um spi[INVESTIGATOR_299997], the affected area must be 
immediately cleaned with a 10% bleach solution.  Hands should be washed thoroughly with soap and 
water. 
Partially used vials may not be used for human administration or for in vitro experimental studies. At 
the end of the study, the site will receive instruction  from the Sponsor regarding the final disposition of 
any remaining NV inoculum.   
 
7 STUDY PROCEDURES AND SCHEDULE  
Refer to the APPENDIX A:        SCHEDULE OF EVENT S 
7.1 Pre-Screening Period (Day -90 to Screening)  
Subjects will be pre-screened for purposes of ascertaining H type -1 antigen secretory status and blood 
type. Subjects who are eligible for screening  based on the results of the pre -screening  assessments  or 
known secretory status and blood type  will be contact[CONTACT_300051] s tudy specific screening period.  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 52 of 114 
Date: 25 May 2023  
 7.2 Visit 00: Screening Visit (Stud y Day -45 to -1) 
If the subject is secretor positive (genetically susceptible) and blood type A or O, he or she will be 
invited to a full screening visit at the outpatient visit site.  
At this screening visit, the Study Investigator  will perform a clinical assessment and blood will be 
collected for laboratory tests. At the time of screening, blood cell counts, blood chemistry, liver 
function, HIV, HB sAg, and HCV status will be tested : a pregnancy test will also be conducted for 
female participants . Vital signs will also be collected (temperature, blood pressure, heart rate, breathing 
rate) as well as height and weight for BMI calculation. A medical history and review of concomitant 
medications will also be performed.  
The Study Investigator will provide counseling as needed to subjects on the results of these tests, 
especially on HIV, HBV, and HCV status. Medical history, physical exam, vital signs and lab results 
must be within normal limits , or abnormalities deemed not clinically sig nificant, at the time of screening 
for the subjects to participate in the study.  Subjects who are eligible to participate in the study will be 
contact[CONTACT_197860] .    
The followin g procedures will be performed  to determine eligibility : 
• Informed conse nt 
• Demographics  
• Medical history 
• Eligibility criteria 
• Physical examination  
• Review of concomitant medications  
• Vital signs (including h eight and weight)  
• ECG 
• Blood screen (HIV, HBsAg, HCV)  
• Safety labs 
o CBC: Hemoglobin, Hematocrit, Platelet Count and Complete White Blood Cell Count  
o Serum Chemistry : ALT, AST, Total Bilirubin , BUN, Creatinine,  Random Glucose, 
Potassium  and Sodium   
o Urinalysis : Glucose, Protein and  Hemoglobin  
• Blood Sample : coagulation tests, lab panel (PT /INR, aPTT and fibrinogen)  
• Female pregnancy t est (serum) 
• Drug screen  (urine and alcohol breath test)  
 
Subjects will be reminded to fast and refrain from ingesting solid food for at least 4 hours prior to the 
Day 1 study drug administration.   
 
7.3 Visit 01: Study Day 1 , Study Drug Administration  
Subjects will undergo the following assessments and procedures prior to randomization and study drug 
administration:  
• Assess inclusion/exclusion criteria  
• Physical examination (targeted)  
• Vital signs  
• Safety Labs   
o CBC 
o Serum Chemistry  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 53 of 114 
Date: 25 May 2023  
 o Urinalysis  
(Note: Safety labs do not need to be performed if screening safety lab tests were completed 
within 2 days prior to study drug administration  on Day 1)   
• Female pregnancy test (u rine) 
• Drug screen  (urine and alcohol breath test)  
• Blood samples for immunogenicity  (PBMCs, serum and fixed whole blood)  
• Fecal sample for immunogenicity  
• Saliva sample for immunogenicity  
• SAM (Synthetic Absorptive Matrix) for nasal mucosal lining fluid  (MLF) evaluation  
• Review of concomitant medications  
• Medical history  
 
Refer to the Laboratory Manuals for details regarding sample collection and handling.  
 
Study eligibility will be reviewed and re -confirmed at this study visit. Those subjects who satisfy all 
inclusion crit eria and none of the exclusion criteria will qualify and be eligible to be randomized  into 
the study. 
The following procedures will be performed  following randomization : 
• Study drug administration (vaccine or placebo) – administer study drug tablets , after subject 
has been fasting for at least 4 hours prior to start of dosing  
(please refer to  Pharmacy Manual for detailed study drug administration instructions)  
• Solicited symptoms of reactogenicity e-Diary (electronic Diary) – dispense e-Diary to subject  
and provide instruction s for use 
• Assess for solicited and unsolicited adverse events after initiation of study drug administration  
7.4 Visit 02: Study Day [ADDRESS_366223] 
vaccination, to allow optimal evaluation of immune response. Subjects will undergo the following 
assessments and procedures : 
• Physical examination (targeted)  
• Vital signs  
• Safety Labs  
o CBC 
o Serum Chemistry  
o Urinalysis  
• Review and collect solicited symptoms of reactogenicity  e-Diary  
• Review of concomitant medications  
• Query for AEs 
• Blood samples  for immunogenicity  (PBMC and fixed whole blood)  
• Saliva sample for immunogenicity  
• SAM (nasal MLF evaluation ) 
 
7.5 Visit 03: Study Day 2 8, 1 day prior to challenge  [+3 days for visit window and 
+30 days window for repeat Visit 03] 
All subjects will return to the site at Day 28 for safety assessments and collection of samples to complete 
the vaccination phase of the study.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 54 of 114 
Date: 25 May 2023  
 Study subjects will begin their in patient stay 1 day before challenge. Subjects will be assigned to a 
single room and instructed about the protocol -required procedures (e .g., stool handling), hygiene 
practices, and the “Rules and Procedures” to be follo wed while in  the inpatient unit. Subj ects will also 
be monitored for evidence  of behaviors which might pose a safety risk to themselves, other subjects, or 
staff and could be cause for ineligibility for challenge and the remainder of the inpatient stay.  Refusal 
to comply with protocol -required procedures, adherence to hygiene practices could constitute 
ineligibility  
Any subject who is deemed ineligible will be discharged  from unit  prior to challenge. Subjects may 
return for re -evaluation of challenge eligibility within [ADDRESS_366224] (defined by [CONTACT_300052]), starting from the midni ght prior to the challenge day.  
Subjects will undergo the following assessments and procedures . Subjects will also be screened for 
eligibility for enrollment into the challenge phase : 
• Physical examination (targeted)  
• Vital signs  
• ECG 
• Safety Labs  
o CBC 
o Serum Chemistry  
o Urinalysis  
• Female pregnancy test (urine)  
• Stool sample  for enteric pathogens  (BioFire) 
• Influenza A & B antigen test  
• Drug screen  (urine, alcohol breath test)  
• Blood samples for immunogenicity  (PBMC, serum and fixed whole blood)   
• Fecal sample for shedding  (pre-challenge baseline)  
• Fecal sample for immunogenicity  
• Saliva sample for immunogenicity  
• SAM (nasal MLF evaluation ) 
• Review of concomitant medications  
• Query for AEs 
 
This visit is required fo r all subjects regardless of challenge status, since there are blood draws 
impacting immune endpoints from vaccination stage. It is a deviation if Visit 03 does not occur.  Visit 
3 has a +3 day window, followed by a +[ADDRESS_366225]’s original Day [ADDRESS_366226]’s challenge visit is delayed (+ 
30 days).  However, a stool sample is needed at the repeat Day 28 Visit, if challenge is postponed within 
window, for enteric pathogens (BioFire), if needed, and  for shedding pre -challenge  baseline. The stool 
sample for fecal immunogenicity may be collected 1 day or within 24 hours of Day 28 through pre-
challenge on Day 29.  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 55 of 114 
Date: 25 May 2023  
 BioFire GI Testing Guidance:  
• Subjects without symptoms of AGE in the [ADDRESS_366227] BioFire 
GI pathogen assay  
• For subjects with symptoms of AGE in the [ADDRESS_366228] positive on 
BioFire for an enteric pathogen  OTHER THAN NOROVIRUS, they may be re -evaluated for 
a future challenge as allowed by [CONTACT_990].   
• If no AGE sym ptoms in the preceding [ADDRESS_366229]  
• Any subject in this situation should be discussed with Vaxart M M (including which pathogen 
was positive on BioFire at initial challenge screening) for approval to re -evaluate for 
challenge.   
• A subject that tests positive for Norovirus at Day 28 will be excluded from future norovirus 
challenge.  
 
 
 
7.6 Visit 04: Study Day 29 (Challenge Day)  
 
 Pre-challenge Assessments  
On the morning of challenge, fasting subjects will have baseline vitals (temperature, blood pressure, 
heart rate, breathing rate) recorded and a final eligibility confirmation  (medical history and targeted 
physical examination)  will be completed prior to oral ingestion of the challenge inoculum.   
 
 Viral Challenge Eligibility  
Results of Day 28 assessments (except  the immunological  tests) as well as the pre -challenge 
assessments on Day 29,  must be available and reviewed prior to virus administration .  Subjects 
who have any of the following conditions are not eligible for participation in the challenge phase:  
• clinically significant symptoms or signs of norovirus acute gastroenteritis (per the judgment 
of the investigator) as assessed by:  
o Investigator -assessed signs of norovirus illness  
o Targeted physical examination   
(exception: mild headache,  with no signs or symptoms  of infection and no fever, may 
be allowed);  
• positive for enteric pathogens (Bio Fire); 
• positive Influenza A or B antigen test result;  
• an oral temperature  of >37.5°C; 
• any finding (clinical or laboratory value), that in the opi[INVESTIGATOR_871], should exclude 
the subject from viral challenge due to safety concern;  
• any conditions, that in the opi[INVESTIGATOR_871],  might interfere with the subject’s ability 
to complete participation in the challenge (sequestration) phase, per protocol;  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 56 of 114 
Date: 25 May 2023  
 • any finding (clinical or laboratory v alue), that in the opi[INVESTIGATOR_871],  might interfere 
with ability to assess the primary study objectives.  
 
Should a subject be deemed inappropriate for continued participation into the challenge phase, the 
reason for ineligibility will be docume nted and the subject will be rolled into the safety follow -up 
period. The subject will enter the safety follow -up period continue to be contact[CONTACT_300053]  365, 
as described in Section  7.[ADDRESS_366230] nothing by 
[CONTACT_1966], except water, for 90 minutes before and after ingestion of the challenge inoculum.  Subjects 
will drink 1 00 mL of sodium bicarbonate solution (~1.3% NaHCO 3) prior to viral challenge ; 
approximately [ADDRESS_366231] the NV inoculum ( Lot 001-09NV and Sublot 2 , IND 
[ZIP_CODE]) suspended in 100 mL of distilled water . 
 
 Visits 04 – 08: Post-Challenge Observation Period  
(Day 29 – Day 33 [+ 3 Days]) 
Following ingestion of the challenge inoculum, the following procedures will be performed:  
 
• Study subjects  have daily targeted physical exams and  will be monitored for symptoms  of 
NV illness  and vital signs twice daily while in the clinical research unit post -challenge .   
• All fecal samples  will be graded for consistency (grade 1 to 5) and weigh ed.  
• All emesis will be collected and weighed  when available .  
• Following challenge, anticipating signs and symptoms will be assessed . The maximum 
symptom severity for the  day will be determined using a standard rating scale.  
• Anticipated  signs and symptoms of norovirus acute gastroenteritis include:  diarrhea, vomiting , 
nausea, fever, abdominal cramps  or pain, abdominal gurgling or bloating  and myalgia.  These 
symptoms will be  solicited and  graded. 
• The maximum temperature, total diarrheal stool volume, number of diarrh eal stools, total 
emesis volume, and number of emesis  epi[INVESTIGATOR_299998] 24 h  period during 
the inpatient stay.  
• On Day 33  (either prior to disch arge or if subject remains sequestered)  
o Blood sample  for Immunogenicity (PBMC and fixed whole blood ) 
o Safety Labs  
▪ CBC  
▪ Serum Chemistry  
▪ Urinalysis  
o Discharge criteria must be assessed and met (per checklist)  
o NV signs and  symptoms e-Diary will be dispensed prior to discharge with  instruction 
for use, unless subject remains an inpatient through Day 36 (Day 33 + 3days)  
The nursing staff  as well as the trained study staff  will monitor the subject’s vital signs and assess for 
signs and symptoms of ac ute NoV illness twice daily from Day [ADDRESS_366232] NV Signs and Symptoms assessment of the day but before 12:00pm, the site will record 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 57 of 114 
Date: [ADDRESS_366233] assessment of the next day. Grading scales (Appendices C and D) will be used to classify 
diarrhea, nausea, and vomiting. Subjects will also be asked to rate symptoms of myalgia and fatigue 
as mild, moderate or sev ere.  AEs and concomit ant medication usage  will also be collected during the 
inpatient stay. During the first 4 days after challenge , subjects will receive daily weight, fluid intake, 
and fluid output measurements.  The Study Investigator , or his/her designated representative, will 
monitor subjects daily. The subjects will remain in the inpatient unit at least [ADDRESS_366234] disposable gloves, gowns, and masks.  
A portion of stool and emesis samples passed by [CONTACT_300054] 4°C .  These specimens will be tested for the presence of the NoV challenge strain by [CONTACT_16641] -
PCR. Fecal and sa liva samples collected before challenge and 28 days after challenge will be tested for 
NoV viral protein 1 (VP1) antibody .  
On the day of discharge from the inpatient unit, approximately 60 mL of whole blood will be collected 
for PBMC isolation , and a sample for safety labs.  
[IP_ADDRESS] Discharge Criteria 
Study subjects will be evaluated for discharge 4  days after challenge  (Day 33). If subject is still 
symptomatic with NV illness and it is clinically indicated, they will remain in the isolation u nit for 
additional day s up to Day 36 . At the time of discharge, subjects will be instructed on the importance of 
hand washing and careful personal hygien e and given antimicrobial soap. Subjects will be asked to  
follow appropriate sanitation and hygiene for 1 month following virus ingestion.  At the time of 
discharge, subjects will be given stool collection kits to take home so that they can bring a stool sample 
within 24 hours of their return on Day 36 (first follow-up visit).  Subjects will also be dispensed an  
e-Diary that they will use to record signs and symptoms of NV illness daily through their Day 36 visit.  
[IP_ADDRESS] Early Termination/Early Discharge  
Subjects that desire to withdraw from the study or are withdrawn by [CONTACT_737]  (eg, due to 
continuing non -compliance or safety concerns) during the inpatient period will be given instructions 
on appropriate follow up. If a subject desires to leave the inpatient containment unit early, the study 
staff will ensure  the subject is no longer having symptoms, diarrhea, or emesis. A document of early 
termination/withdrawal will be completed by [CONTACT_300055] -signed by [CONTACT_423].  The subject 
will not be compensated for any inpatient days that are not completed , including the day of early 
termination.  
7.7 Visit 09: Study Day 36 ([ADDRESS_366235] challenge)  
A targeted physical exam and vital signs will be performed.  Subjects will bring in a stool collected 
within 24  hours of Day 36 visit. Subjects will be given stool col lection kits to take home, so they can 
bring a stool specimen collected within 24  hours of their next follow-up visit (Day 57).  Subjects will 
be contact[CONTACT_300056] -up appointment and to bring a stool specimen with them 
to their next appointment.  Subjects who do not bring in a stool specimen will be asked to drop off a 
specimen the next day.  At the clinic al site, stool samples will be processed per Lab Manual  
Subjects who underwent challenge will undergo the follow ing assessments and  procedures : 
• Vital signs  
• Review of concomitant medications  
• Query for AEs 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 58 of 114 
Date: 25 May 2023  
 • Blood samples for immunogenicity  (PBMC and fixed whole blood)  
• Saliva sample for immunogenicity  
• SAM (nasal mucosal lining fluid)  
• Symptom grading  (signs of NoV infection)  
• Review and collect NV signs and symptoms e-Diary  
 
7.8 Visit 10: Study Day 57 ( [ADDRESS_366236] challenge ± 3 days) 
Subjects who underwent challenge will undergo the follow ing assessments and procedures:  
• Physical examination (targeted)  
• Vital signs  
• Female pregnancy test (urine)  
• Blood samples for immunogenicity  (serum, PBMC and fixed whole blood ) 
• Fecal sample for shedding  
• Fecal sample for immunogenicity  
• Saliva sample for immunogenicity  
• SAM (nasal mucosal lining fluid)  
• Review of concomitant medications  
• Query for AEs 
 
Any subjects that did not undergo viral challenge should be contact[CONTACT_218907] 57 for safety follow -up 
and queried for SAEs, AESIs and NOCIs . 
 
For subjects who are ineligible for challenge phase, Section 7.8 of the protocol should be followed 
instead of Section 7.11; that is, subjects who are not challenged should begin the safety follow up at 
Visit 10 (Day 57). This visit may be a phone contact. No separate “early termination” visit needs to 
occur. Only subjects who truly terminate  participation in the study should have an early termination 
visit.  
 
7.9 Visit 11 (Day 120) – Visit 14 (Day 300)  Safety Follow -up Contacts  
 
• Visit 11: Study Day 120 ( [ADDRESS_366237] challenge + 1 week) 
• Visit 12: Study Day 180 ( [ADDRESS_366238] challenge + 1 week) 
• Visit 13: Study Day 240 ( [ADDRESS_366239] challenge + 1 week) 
• Visit 14: Study Day 300 ( [ADDRESS_366240] challenge + 1 week) 
Subjects will be contact[INVESTIGATOR_530] (text/email/phone) every 2 months during the safety follow -up period and 
queried for  the following:  
• Query for SAEs 
• Query for AESIs and NOCIs  
 
 
7.10 Visit 15: Study Day 365  ([ADDRESS_366241] challenge + 1 week) End of Study 
Contact 
[CONTACT_300057] 365 phone call :  End of study contact  
• Query for SAEs 
• Query for AESIs and NOCIs  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 59 of 114 
Date: 25 May 2023  
  
7.11 Early Termination  
 
 Early Termination ( Day 1 – Day 28; Vaccine Phase ) 
Subjects will undergo the following assessments and procedures:  
• Physical examination  
• Safety labs  
o CBC  
o Serum Chemistry  
o Urinalysis  
• Vital signs  
• Urine pregnancy test (females)  
• Fecal sample for immunogenicity  
• Saliva sample for immunogenicity  
• Blood sample for Immunogenicity (see Appendix A  for details of samples and testing to 
be performed )  
• Review and collect e-Diary if still in use prior to withdrawal  
• Review of concomitant medications  
• Query for AEs  
• Update contact [CONTACT_300058] ( –ay 29 - Day 57;  Challenge Phase ) 
Subjects who underwent challenge and terminate during the challenge period will undergo the 
following assessments and procedures : 
• Physical examination  
• Vital signs  
• Urine pregnancy test (females)  
• Fecal sample for immunogenicity  
• Saliva sample for immunogenicity  
• Blood sample for Immunogenicity (see Appendix A  for details of samples and testing to 
be performed)  
• SAM (nasal mucosal lining fluid)  
• Review and collect e-Diary if still in use prior to withdrawal  
• Review of concomitant medications  
• Query for AEs 
• Update contact [CONTACT_300059] (Day 58 to Day 365  – Safety Follow -Up Period ) 
Subjects who terminate early during the safety follow up period  will undergo the following 
assessments :  
• Query for SAEs, AESIs and NOCIs  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 60 of 114 
Date: 25 May 2023  
 7.12 Unscheduled Visit(s)  
Subjects who experience any serious or severe adverse effects or experience an event of concern can 
be scheduled for a n additional  visit for further evaluation. If an unscheduled visit occurs, a member of 
the clinical study team (PI, sub -investigator, nurse coordinator, or clinical nurse) will evaluate the 
subject to determine the cause of the visit and pro vide care as needed.  All procedures and/or sample 
collections should be documented within in unscheduled visit CRF . 
 
7.13 Immunogenicity Assessments  
Primary Immunoassays  
• VP1 specific IgA ASC (by [CONTACT_19487]) 
• HBGA blocking antibodies (BT 50) 
• VP1 specific serum IgG (by [CONTACT_19487]) 
• VP1 specific serum IgA (by [CONTACT_19487]) 
Exploratory Immunoassays  
• VP1 specific IgG ASC  
• VP1 specific IgG and IgA memory B cells (by [CONTACT_34536])  
• VP1 specific IgG and IgA from plasmablast cultures (by [CONTACT_6428])  
• B cell immunophenotypi[INVESTIGATOR_007] (by [CONTACT_300060]/or single cell sequencing)  
• Fecal VP1 specific IgA (by [CONTACT_300061]) 
• Saliva VP1 specific IgA (by [CONTACT_300061]) 
• Mucosal VP1 specific IgA (by [CONTACT_300061]) 
• Fixed whol e blood (by [CONTACT_300062] )  
 
Additional exploratory immunogenicity assays may also be performed to further evaluate the activity 
of the VXA -G1.1-NN vaccine candidate on samples stored for future use (with subjects’ consent).  Note 
that not all sample timepoints may be relevant for the  some of the analysis, so not all assays will be 
performed at all timepoints . 
7.14 Assessment of Clinical Illness  
Following challenge , study subjects will be monitored twice a day unless greater frequency is 
clinically indicated  through discharge (Day 33 + 3 days)  for the following gastrointestinal signs and 
symptoms of norovirus illness : 
o diarrhea, vomiting, nausea, fever, myalgia  
o abdominal cramps, pain, gurgling or bloating  
7.15 Norwalk Virus Infection  
NV infection as detected by [CONTACT_16641] -PCR, > [ADDRESS_366242]-challenge.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 61 of 114 
Date: 25 May 2023  
 7.16 Microbiological Assessments  
During the challenge phase  sequestration period  all fecal and emesis specimens will be 
weighed/measured for v olume. All fecal and emesis will be collected daily and tested for NV. Stool 
will be graded.  A stool sample will also be collected at Day [ADDRESS_366243]  4 days. Vital signs (temperature, blood 
pressure, heart rate, respi[INVESTIGATOR_697]) will be measured twice a day (am and pm) throughout the 
confinement period until discharge . Subjects will be interviewed daily by a study investigator to 
determine the occurrence of illness  signs and symptoms . This data will be recorded on a standardized 
form and graded in severity according to a standardized scale.  A focused physical examination may be 
performed at the discretion of the Investigator according to the nature of a subject’s complaint.  
8.2 Study Definitions  
Norovirus  Gastroenteritis  (NVG): 
NVG is a composite endpoint defined as meeting one or more of the following definitions for both 
Acute Gastroenteritis and NV Infection  during the inpatient period . 
 
Acute Gastroenteritis  (clinical NV illness) : 
Acute Gastroenteritis (AGE) is defined as meeting any one of the three categories  listed below:  
 
• Diarrhea:  
o ≥ 3 loose or liquid stools produced in any 24 -hour period, or  
o > 400g of loose or liquid stools produced in any 24 -hour period;  
• Vomiting: ≥  2 vomiting epi[INVESTIGATOR_57579] 24 -hour period, or  
• Diarrhea and vomiting:  
o One vomiting epi[INVESTIGATOR_299999] 24 -hour period, or  
o One vomiting epi[INVESTIGATOR_299976] ≥  2 of the following events in any 24 -hour period:  
▪ nausea 
▪ fever (oral temperature ≥ 37.6 C) 
▪ abdominal cramps or pains  
▪ abdominal gurgling or bloating  
▪ myalgia 
See Appendix C  for grading scales for signs and symptoms of acute gastroenteritis.    
Norwalk Virus Infection:  
• NV infection as detected by [CONTACT_16641] -PCR, > [ADDRESS_366244] every 
stool that is passed, from the time of challenge until discharge.  Subjects will be instructed to use a 
plastic stool collection basin (hat). Subjects will be instructed on how not to collect urine in the same 
container. All stools will be weighed and graded by [CONTACT_5984].  The grading of stool is based on 
consistency and the definition of diarrhea is a grade 3 or higher  in stool, as follows:  
• Grade 1 – well formed (does not take the shape of the container)  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 62 of 114 
Date: 25 May 2023  
 • Grade 2 – soft (does not take the shape of the container)  
• Grade 3 – thick liquid (diarrhea, takes the shape of the container readily)  
• Grade 4 – opaque watery diarrhea  
• Grade 5 – rice water dia rrhea (clear watery)  
Any grade 3 or higher stool weigh t, will be used to estimate the volume of fluid loss (assume 
approximately 1 -gram diarrheal stool = [ADDRESS_366245]).  
Similarly, any epi[INVESTIGATOR_19749] a stool “hat” or a plastic “kidney” 
basin, provided. If a vomiting or diarrhea epi[INVESTIGATOR_300000] a basin (e.g., the subject 
has an “accident” while sleepi[INVESTIGATOR_19751] a toilet), then the volume of the output 
will be estimated.  
8.4 Management of Fluid Loss  
Subjects who develop diarrheal stools (grade 3 or higher) will begin oral fluid replacement at 1.5 times 
the stool volume. Vomitus will be replaced with oral fluids in equal amounts, 1:[ADDRESS_366246] 
develops severe watery  diarrhea or persistent vomiting and cannot maintain full hydration by [CONTACT_300063], IV fluid replacement will be administered.   
Assessment of dehydration may include u rine specific gravity and serum electrolytes (Sodium, 
Potassium, Chloride, Bicarbonate) a nd renal function ( blood urea nitrogen [ BUN] and creatinine)  and 
physical assessment . 
An Investigator  is available by [CONTACT_19792]. Nurses will notify the on -call 
Investigator  if any of the following occurs in a subject who is experienc ing diarrhea and/or vomiting:  
• Syncope 
• Complaint of dizziness or lightheadedness or established orthostatic hypotension  
• Urine specific gravity > 1.025  
• > 500 mL behind in ORS replacement  
• Vomiting of ≥ [ADDRESS_366247] 4 hours  
• High fever ≥ 39 C (102.1F) 
• Severe headache, severe malaise, or severe abdominal pain  
• Subject has a complaint for which he/she requests treatment  
• Any other clinical situation that concerns the nurse  
 
8.5 Indications for Concomitant Medications  
Any concomitant medication, prescription or over -the-counter, will be evaluated for continuation 
during the inpatient setting (eg, long -standing single -agent anti -hypertensive medication or cholesterol 
medication).  Any such medication will need to be disc ussed with and approved by [CONTACT_19794].  The supply of medication will be the responsibility of the subject and will be handed 
over to the research staff upon admission; daily administration will be recorded.  Any un -declared 
prescription or over -the-counter medications that are discovered during the inpatient stay will constitute 
a violation of the ward “Rules and Procedures.”  
Other medications may be administered during the study period as follows:  
• Smoking is not allowed on the wa rd, but subjects will be able to request a nicotine patch.  
• Anti-pyretics and analgesics (ie, ibuprofen, acetaminophen, aspi[INVESTIGATOR_248], or similar non -steroidal 
agents) may be prescribed for severe headaches, other pains, or fevers (eg, sustained 
temperatures of ≥ 39C). 
• At the investigator’s discretion (eg, upon review of serum electrolyte results during severe 
diarrhea), oral potassium and/or IV fluids may be administered for repletion of electrolyte 
losses. 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 63 of 114 
Date: 25 May 2023  
 • Other medications, which are deemed necessary for the safety and welfare of the subject .  
The prescription of any medication must be ordered and signed by [CONTACT_300064].  
8.6 Prohibited and Controlled Medications/Treatments  
All concomitant medications will be recorded from 3 0 days prior to  start of screening through 
completion of the challenge active  study period ( Day 57). 
Subjects may not initiate new medications  (or change the dose of an allowed concurrent medication)  
within [ADDRESS_366248] vaccination , with exceptio ns, as outlined in the study exclusion criteria 
Section 4.2. Subjects will be questioned regarding any changes in concomitant medication usage 
through th e end of the challenge active study period (Day 57) .  Any changes from Baseline will be 
recorded within the corresponding Case Report Form (CRF).  
9 ASSESSMENT OF SAFETY  
The safety assessment of the study vaccine  and challenge virus will be through the detection and 
documentati on of AEs, both solicited AEs and unsolicited AEs, and/or clinically significant laboratory 
abnormalities, from baseline (time of vaccination) through [ADDRESS_366249] vaccination  –Day 1 - Day 365). 
9.[ADDRESS_366250] a causal relat ionship with the investigational vaccine.  An 
AE can therefore be any unfavorable and unintended sign (including abnormal laboratory findings), 
symptoms, physical examinations, or disease temporally associated with the use of the investigational 
vaccine, w hether related to the investigational vaccine.  This definition includes exacerbations of pre -
existing conditions.  Stable pre -existing conditions which do not change in nature or severity during 
the study are not considered AEs; however, these should be r eported as part of the medical history.  
Solicited AEs are pre -specified reactogenicity symptoms including :  
• fever 
• nausea 
• vomiting 
• diarrhea 
• headache 
• malaise/fatigue  
• myalgia (muscle pain)  
• abdominal pain  
• anorexia 
 
9.[ADDRESS_366251] 7 days following vaccination. These solicited symptoms will be graded as follows  
in Table 20: 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 64 of 114 
Date: 25 May 2023  
 Table 20 SOLICITED SYMPTOM REACTOGENICITY TABLE  
 
Symptom  Grading 
Normal Mild Moderate  Severe Life 
Threatening  0 Grade 1 Grade 2 Grade 3 Grade 4 
Fever 
(oral temp)  < 
100.4°F 
(< 
38.0°C) 100.4 – 101.1°F 
(38.0 – 38.4°C) 101.2 – 102.0°F 
(38.5 – 38.9°C) 102.1 – 104°F 
(39.0 – 40°C) > 104.0°F  
(>40°C) 
Headache  None Event easily 
tolerated, causing 
minimal 
discomfort and no 
interference with 
activity Repeated use of 
non-narcotic pain 
reliever for >24 
hours or some 
interference with 
activity Any use of narcotic 
pain reliever or 
prevents daily 
activity ER visit or 
hospi[INVESTIGATOR_221260] 
(muscle 
pain) None Event easily 
tolerated, causing 
minimal 
discomfort and no 
interference  with 
activity Event sufficiently 
discomforting to 
interfere with 
daily activity  Significant; 
Prevents daily 
activity ER visit or 
hospi[INVESTIGATOR_300001], causing 
minimal 
discomfort and no 
interference with 
activity Some interference 
with activity but 
no medical 
intervention  Prevents daily 
activity and 
requires medical  
intervention  ER visit or 
hospi[INVESTIGATOR_300002], causing 
minimal 
discomfort and no 
interference with 
activity Some interference 
with activity but 
no medical 
intervention  Prevents daily 
activity and 
requires medical  
intervention  ER visit or 
hospi[INVESTIGATOR_300003] 1 or 2 epi[INVESTIGATOR_11630] 
24 hours >2 epi[INVESTIGATOR_11630] 24 
hours Requires outpatient 
IV hydration  ER visit or 
hospi[INVESTIGATOR_300004] 2 to 3 loose stools 
in 24 hours 4–5 loose stools in 
24 hours 6 or more loose 
stools in 24 hours  ER visit or 
hospi[INVESTIGATOR_122675]/ 
Fatigue None Event easily 
tolerated, causing 
minimal 
discomfort and no 
interference with 
activity Some interference 
with activity  Significant; 
Prevents daily 
activity ER visit or 
hospi[INVESTIGATOR_059]  
a Everyday activity include s attendance at work, school, and usual habits of th e subjects.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 65 of 114 
Date: [ADDRESS_366252], observed by [CONTACT_300065]. 
Unsolicited AEs (all AEs not collected in the solicited symptom e-Diary during the first 7 days 
following vaccination) will be monitored and collected from the time of vaccination through Day [ADDRESS_366253] challenge  (Day 29) through end of active 
phase (Day 57) as AEs relevant to challenge virus .  
9.1.2      Grading of Severity of an Adverse Event  
Severity of AEs  will be graded as:   
Mild:  events require minimal or no treatment and do not interfere with the subject’s daily 
activities.  
Moderate :  events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning  and daily 
activities. 
Severe:  events interrupt a subject’s usual daily activity and may require systemic drug therapy 
or other treatment. Severe events are usually incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration of the 
event at each level of intensity to be performed. AEs characterized as intermittent require 
documentation of onset and duration of each epi[INVESTIGATOR_1865].  
 Relationship to Challenge Virus  
Relationship (causality or attribution) of all AEs to NV infection, or to an alternate etiology (unrelated 
to the study) is part of the documentation process, but it is not a factor in determining what is (or is not) 
reported in the s tudy.  If there is any doubt as to whether a clinical observation is an AE, the event 
should be reported.  All AEs must have their relationship assessed using 1 of 2  terms:  related to NV 
infection, or not related (an alternate etiology can be identified a nd is likely or feasible).  To help assess, 
the following guidelines are used.  
 
Related to norovirus challenge :  There is a reasonable possibility that the NV infection caused the AE. 
Reasonable possibility means that there is evidence to suggest a causal relationship between the NV 
illness and the AE, and there is no reasonable alternate etiology.  
 
Not Related :  There is not a reasonable possibility that the event is related to NV and there is a 
reasonable alternate etiology  
 Relationship to Study Vaccination  
For all solicited and unsolicited AEs, including NOCIs, the Investigator will make a judgment regarding 
the relationship of the AE to the investigational product in a blinded manner . All AEs must be recorded 
in the source documents as well as  the case report form  (CRF). 
The degree of certainty with which an AE is attributable to study vaccine or an alternative cause will 
be determined by [CONTACT_1004]:  
• Temporal relation to administration o f study vaccine administration  
• The existence of other plausible explanations for the AE 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 66 of 114 
Date: 25 May 2023  
 The relationship of the AE to study drug administration will be specified as follows:  
Not related: In the Investigator’s opi[INVESTIGATOR_1649], there is no causal relationship betwee n study drug 
administration and the AE;  
Related: The AE follows a known temporal sequence from the time of study drug administration, 
cannot be explained by [CONTACT_300066] a recognized pharmacological phenomenon.  
 
9.2 Definition of Serious Adverse Event   
A SAE is any AE that results in any of the following outcomes:  
1. Death 
2. A life-threatening event. Life -threatening events mean that the study subject was, in the 
opi[INVESTIGATOR_19755], at risk of death at the time of the event; it does not refer 
to an even t which hypothetically might have caused death if it were more severe.  
3. Requires inpatient hospi[INVESTIGATOR_1081]  
4. Results in persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions  
5. Congenital abnormality or birth defect  
6. Important medical event that may not result in one of the above outcomes but may 
jeopardize the health of the study subject and/or requires medical or surgical intervention 
to prevent on e of the outcomes listed in the above definition of SAE. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospi[INVESTIGATOR_1838], or the development of drug dependency or drug abuse.  
All SAEs will be:  
• recorded in the research record  
• reported to the local IRB, per local IRB guidelines  
• reviewed and evaluated by a study clinician and the PI  
• followed through resolution b y a study clinician  
• All SAEs, life -threatening events and deaths, whether related or unrelated, will be reported 
to the study sponsor within 24 hours of site awareness.  
• Other SAEs regardless of relationship, will be reported to the study sponsor within [ADDRESS_366254] (AESI)  
An AESI should not necessarily be classified to be a serious adverse event, even though the event may 
be clinically significant.  If an AESI is reported, Vaxart should be promptly informed and information 
relevant to the event should be promptly collected using the same process as that used for reporting 
serious adverse events (see  Section 8.2) Please see list of AESIs on APPENDIX E : Lists of Adverse 
Events of Special Interest.  
 
9.4 Definition of New Onset of Chronic Illness (NOCI) 
A NOCI is defined as diagnosis post study drug adminis tration of a new medical condition, which is 
chronic in nature, including those potentially controllable by [CONTACT_12617] (eg,  diabetes, asthma).  The 
occurrence of NOCIs will be queried for from Day [ADDRESS_366255] -vaccination through the safety follow -up 
period (Day  365). 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 67 of 114 
Date: 25 May 2023  
 9.5 Study Halting Rule s 
 
The study will be halted (no new enrollment , vaccination s, or challenge  will be allowed pending a SMC 
safety review) if any of the events described below are met during the  overall conduct of the study 
(vaccine and challenge phase) .  
• Two or more subjects experience a treatment related serious adverse event (SAE) of any 
grade, or a treatment related grade 3 or 4 AE between Day 1 and Day 28 (vaccination phase) . 
• Two or more subjects experience a treatment related serious adverse event (SAE) of any 
grade, or a treatment related grade 3  or 4 unsolicited AE within 28 days after challenge.  
The SMC will provide study oversight throughout the duration of the trial interventional and safety 
follow-up period (Day [ADDRESS_366256] -vaccination). The IRB and CBER will be notified  if the 
study is halted for safety concerns . 
 
9.6 Safety Oversight  
A Medical Monitor ( MM) will perform the oversight of safety for this study. The MM is a physician 
experienced in the conduct of research clinical studies. The primary responsibility of the MM is to 
monitor subject safety. The MM will be responsible for reviewing the cumulative safety data, including 
a review of safety laboratory test results and AE reporting. The MM considers st udy-specific data as 
well as relevant background information about the disease, test agent, and target population under 
study. The MM is empowered to request a Safety Monitoring Committee (SMC) safety review which 
can suspend the study, recommend amendment s to the protocol, and/or to request further information.  
9.7 Safety Monitoring Committee (SMC)  
A SMC will be created for oversight and adjudication of AEs.  The committee will consist of 
independent physicians with vaccine clinical trials experience, and the MM, who does not enroll 
patients into the study.  The sponsor will have a member as a non -voting observer of the SMC. The 
Sponsor’s Chief Medical Officer (CMO) and the study’s PI [INVESTIGATOR_152428] a non -voting members of the 
SMC. The CMO’s main role will be to  provide background information on the study protocol as well 
as past safety experience with the Vaxart oral vaccine platform. The PI [INVESTIGATOR_300005]. The responsibilities of the SMC will be to:  
1) Review and be familiar with key clinical documentation concerning subject safety including but 
not limited to: study protocol, informed consent form, Investigator’s Brochure and the SMC 
Charter. 
2) Provide ongoing oversight of the study. Periodic safety reviews of the ongoing study will be 
conducted at pre -defined time points . Additionally, ad hoc meetings will be convened if any serious 
vaccine or study treatment related events or trends are observed.  
3) The SMC will also have formal meetings if any of the pre -specified Halting Rules are met t o review 
safety data and make recommendations on how to proceed. The IRB will be notified if the study is 
halted for safety concerns.  
4) Review the symptomatic data collected for early cohorts in the challenge phase , blinded to 
treatment, to confirm the chall enge virus is performing as anticipated  may be undertaken .  If fewer 
subjects are showing symptoms, additional interim analyses may be recommended by [CONTACT_4484].  
Any unblinded analyses will be restricted to the SMC.  
5) The SMC will function in accordance with t he following provisions: (1) [LOCATION_002] (US) Code 
of Federal Regulations (CFR) applicable to clinical studies (21 CFR Part 50, 21 CFR Part 54, 21 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 68 of 114 
Date: 25 May 2023  
 CFR Part 312.55 and 312.56. (2) ICH E6 and 62 Federal Register [ZIP_CODE] (1997): Good Clinical 
Practice (GCP): Consolidated Guideline.  
Further details of the composition, pre -specified meetings and objectives of the SMC will be outlined 
in the SMC Charter.   
[ADDRESS_366257] of the trial follows 
the currently approved protocol/amendment(s), with  Good Clinical Practice  (GCP), and with applicable 
regulatory requireme nt(s). Monitoring refers to the methods used by [CONTACT_300067], 
or Contract Research Organizations (CROs) delegated site monitoring responsibilities, to oversee the 
conduct of, and reporting of data from, clinical investigations. Site monitoring includes ensuring 
appropriate clinical investigator supervision of study site staff and third -party contractors.   
Details of clinical site monitoring are documented in a Clinical Monitoring Plan (CMP). The CMP 
describes in detail who will condu ct the monitoring, at what frequency monitoring will be done, at what 
level of detail monitoring will be performed, and the distribution of monitoring reports.  
[ADDRESS_366258] norovirus 
gastroenteritis related to norovirus infection in the challenge model. Protective efficacy (PE) will be 
estimated by [CONTACT_300068][INVESTIGATOR_300006] t hose who were challenged.  
 
The null hypothesis is that the absolute protective efficacy is zero. The two-sided alternative hypothesis 
is that the absolute protective efficacy is not equal to  zero. 
 
H0: PE = 0 
HA: PE ≠ 0 
The estimated protective efficacy is defined as: 𝐴𝑅0−𝐴𝑅1
𝐴𝑅0 
Where AR 1 is the observed norovirus gastroenteritis rate among vaccinated subjects and AR 0 is the 
norovirus gastroenteritis rate among subjects receiving placebo.  
 
A Fisher’s Exact Test with  a 5% two -sided significance level will be used to evaluate the primary 
endpoint of clinical efficacy of VXA -G1.1-NN compared to placebo, to protect against NVG caused 
by [CONTACT_300042].  The sample size will be determined in order to evaluate 
the primary endpoint using a Fisher’s Exact test with a 5% significance level (Section 11.2)  
 
The study hypothesis will also be evaluated using the Chi -Squared test as a sensitivity analysis for the 
primary endpoint as the Fisher’s Exact test can be overly conservative in some circumstances.  
 
An additional study hypothesis will also be evaluated as a sensitivity analysis. The null hypothesis 
will be that the absolute protective efficacy is zero, and the one -sided alternative hypothesis wi ll be 
that the absolute protective efficacy is greater than zero.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 70 of 114 
Date: 25 May 2023  
  
 Blinding Procedures  
Investigators and subjects will remain blinded to treatment assignment until completion of the challenge  
phase (through Day 57) and validation of  the clinical data. The Sponsor’s clinical team and laboratory 
personnel will also be blinded to subject treatment through Day 57 analyses. Investigators may be 
unblinded prior to the final Day 365 end-of-study follow-up phone call.  
 
Each bottle of multi-dose DP/placebo tablets will be labeled with an open label. The unblinded research 
pharmacist will use the randomization list to prepare the dose of DP /placebo tablets. All DP/placebo 
preparation and ad ministration will be performed per stu dy specific procedures detailed in the Study 
Pharmacy Manual.  
  
Only in a medical emergency, when knowledge of the study treatment is essential for further 
management of the subject, will the randomization code be broken. In the event that this is necessar y, 
the PI [INVESTIGATOR_300007], who will 
provide the PI [INVESTIGATOR_300008]. The PI [INVESTIGATOR_300009] y documents.  If time allows, the 
investigator will notify the Sponsor Medical Monitor (MM) prior to unblinding the treatment received 
by [CONTACT_31031].  
11.4 Final Analysis Plan  
Clinical, safety, reactogenicity, and challenge data through approximately Day 57 ([ADDRESS_366259] 
challenge) will represent the primary clinical database for this trial. Once the last subject completes the 
Day 57 visit, the primary clinical database will be cleaned, monitored and locked. Unblinded analyses 
of primary and secondary endpoints, including available safety data, are planned. As it is anticipated 
that subjects will remain in long -term safety follow -up at the time of these analyses, blinded site 
clinicians and Medical Monitors not involved in the analysis, publication or c linical study report (CSR) 
preparation will be responsible for assessing SAEs and AESIs, and NOCIs, until all subjects have 
completed the final follow -up visit. All analyses of data included in the preliminary report for early 
release will be considered th e final analysis of these data, and also included in the final CSR.  
Analysis of exploratory endpoints may be performed and released as the data are available from the 
research laboratories. Any such analyses would be considered the final analysis for the endpoint and  
included in the CSR.  
The final CSR will be completed after the last subject’s last visit is completed, and the final clinical 
database, including all long -term safety follow -up data, is cleaned, monitored and locked. Additional 
exploratory endp oint data not available at the time of CSR preparation may be included in an addendum 
to the CSR.  
A formal statistical analysis plan (SAP) will be developed and finalized prior to unblinding for any 
interim analysis and prior the primary clinical database lock, which defines the analyses to be included 
in the preliminary report and final CSR . 
11.[ADDRESS_366260] of including or 
excluding the outliers. Any substantive differences in these analyses will be reported.  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 71 of 114 
Date: 25 May 2023  
 11.6 Interim Analysis  
 
Interim analysis (IA) will take place after about 50% of all randomized subjects have completed 
challenge and been discharged from the research unit .  This interim analysis will reassess the 
appropriateness of assumptions used for the primary efficacy endp oint when the trial was designed  in 
a blinded manner to the study team .  The interim analysis data will be analyzed in an unblinded 
manner for the SMC to support the following recommendation  rules shown in the section below.  
 
Conditional Power assessment  and Sample size re -estimation rules at IA  
 
The sample size re -estimation rule will be set up using conditional power.  Conditional power will be 
used to assess the futility of continuing further investigation and / or for sample size re -estimation. If 
the conditional power is observed to be sufficiently small at the interim analysis, we would conclude 
that it is futile to continue the investigation.   
The sample size re -estimation rule (if necessary) will be defined using three thresholds for conditional 
power, denoted by 𝑐1, 𝑐2,  and 𝑐3.  The thresholds are given by:  
𝑐1=0.25, 𝑐2=0.5, 𝑐3=0.872 
 
These thresholds define the “underpowered interval” where it is most sensible to increase the 
trial’s sample size.  The total sample size in the trial may be mod ified at this interim analysis as 
follows: 
• If CP≤𝑐1, retain the original sample size and stop the trial for futility.  
• If CP>𝑐1 and CP≤𝑐2 (unfavorable interval), premature to stop the study for futility . 
• If CP>𝑐2 and CP≤𝑐3 (underpowered interval), increase the sample size in all remaining 
trial arms to achieve the maximum conditional power of 87.2%.  
• If CP>𝑐3, retain the original sample size and continue the trial.  
 
The sample size re -estimation rule is non -binding and could be overridden by [CONTACT_300069].  
Although the interim analysis results nor SMC recommendation to continue the study required a 
sample size re-estimation, the sponsor decided to add [ADDRESS_366261] the continuation of this study as planned, but rather, inform 
program development for other trials . 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 72 of 114 
Date: 25 May 2023  
 12 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
12.1 Source Documentation  
Source data are all information, original records of clinical findings, observations, or other activities in 
a clinical trial ne cessary for validation of the clinical data.  Examples of these original documents and 
data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, 
memoranda, subjects’ e-Diaries, evaluation checklists, phar macy dispensing records, recorded data 
from automated instruments, copi[INVESTIGATOR_16213], microfiches, photographic negatives, microfilm or magnetic media, x -rays, and subject files 
and records  kept at the pharmacy, at the laboratories, and medico -technical departments involved in the 
clinical trial.  All information on the CR F will be traceable to these source documents, which are 
generally maintained in the subject’s study file.  The source do cuments will also include a copy of the 
signed Informed Consent/  Health Insurance Portability and Accountability Act  (HIPAA) authorization.  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of 
the data repo rted. Source documents are maintained for recording data for each subject enrolled in this 
clinical study. Study subjects’ data collected on the CRF during the trial will only be identified by 
[CONTACT_18022].  If, as an exception, it is necessary for safet y or regulatory reasons to identify the 
patient, both the Sponsor and the Investigator are bound to keep this information confidential.  
All the information required by [CONTACT_19827]; any omissions require explanation.  
Each source documen t and corresponding CRF should be completed and available for monitoring 
and/or collection within a timely manner so that the monitor may check the entries for completeness, 
accuracy and legibility, ensure the CRF is signed by [CONTACT_737], and transmi t the data to the 
Sponsor. 
All source documents and CRF should be completed in a neat, legible manner to ensure accurate 
interpretation of data. Black or blue ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making 
a change or correction, cross  out the original entry with a single line and initial and date the change. 
DO NOT ERASE, OVERWRITE OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
The Investigator or designee must enter the information required by [CONTACT_300070].  T he Sponsor’s clinical site monitor will review the CRF for completeness and accuracy and 
instruct site personnel to make any required corrections or additions.  
12.2 Data Management  
Quality control audits of all key safety, laboratory, and clinical data in the database will be made after 
data entry has been completed.  Coexistent medical conditions, AEs and other medical events will be 
coded using MedDRA dictionary. Concomitant medications will be coded using  the World Health 
Organization Drug Dictionary  (WHO-DD). When the database has been declared to be complete and 
accurate, the database will be locked.  Any changes to the database after that time can only be made by 
[CONTACT_19831].  
13 QUALITY ASSURANCE AND QUALITY CONTROL  
This clinical trial is internally monitored for quality assurance.  A Protocol -Specific Quality Assurance 
Plan will be developed for this study. This plan, composed of  Quality Control  (QC) and Quality 
Assurance  (QA), will be developed in collaboration with the PI, clinical study coordinator, Regulatory 
Affairs Specialist, and the QM Coordinator. The QC process will describe the day -to-day logic and 
edits checks of source documents, CRFs, and laboratory documents.  Th e QA process involves periodic 
retrospective audits of study records and prospective reviews of clinical operations and assurance that 
all research required training has been completed as applicable.  These audits also involve the review 
of the regulatory file, consent forms/process, eligibility, vaccine accountability and storage, specimen 
collection, processing, storage, and shippi[INVESTIGATOR_007].  All observations are reviewed with the PI, Study 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 73 of 114 
Date: 25 May 2023  
 Coordinator, and Clinical Research Manager; Corrective Action Plans are formulated in response to 
any issue.  
14 ETHICAL CONSIDERATIONS (AND INFORMED CONSENT)  
14.[ADDRESS_366262]  
The Investigator will ensure that this study is conducted in full conformity with the principles set forth  
in The Belmont Report:  Ethical Principles and G uidelines for the Protection of Human Subjects of 
Research of the US National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal 
Regulations 25 691 (1997).   
14.[ADDRESS_366263] of the subjects’ safety to implement changes prior to approval. In both the US and in 
other countries, only institutions holding a current U. S. Federal -Wide Assurance issued by [CONTACT_300071] (OHRP) may participate.  
Prior to enrollment of subjects into this clinical study, the protocol and the informed consent form(s)  
(ICF) will be reviewed and approved by [CONTACT_19821]. An y amendments to the protocol or 
consent materials will also be reviewed and approved by [CONTACT_19821]. The responsible official 
for the IRB will sign the IRB letter of approval of the protocol prior to the start of this clinical study. If 
amendments to the protocol are required, the amendments will be submitted to the IRB; an IRB letter 
of approval of the amendment must be obtained prior to implementing the  amendment.  
14.[ADDRESS_366264] for secretor status and ABO blood type . Eligible subjects will be required to sign a study specific  
ICF before any assessments or evaluations required by  [CONTACT_300072] .  Informed consent will 
be initiated prior to the individual’s agreeing to participate in the study and continues throughout the 
individual’s study participation.  The Informed Consent Form explains the storage and future use of 
specimens , and subjects will be asked t o consent for future testing of samples .  Extensive discussion of 
risks and possible benefits of this therapy will be provided to the subject.  Consent forms describing in 
detail the study, study procedures and risks are given to the potential subject and written documentation 
of informed consent is required prior to starting any study procedure.  Consent forms will be IRB -
approved, and the subject will be asked to read and review the document. Upon reviewing the 
document, the investigator will explain the research study to the subject and answer any questions that 
may arise.  The subjects will sign the informed consent document prior to any procedures being done 
specifically for the study.  The subject should have the opportunity to discuss the study with t heir 
surrogates or think about it prior  to agreeing to participate.  The subject may withdraw consent at any 
time throughout the course of the trial.  A copy of the informed consent document will be given to the 
subject for their records.  The rights and w elfare of the subject will be protected by [CONTACT_300073].  
14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
This clini cal study will include women and men who are 1 8 years of age and older, and all minorities 
who meet the inclusion/exclusion criteria, regardless of religion, sex, or ethnic background.   
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 74 of 114 
Date: [ADDRESS_366265] all documents and 
records required to be maintained by [CONTACT_093], including but not limited to, medical records 
(office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subjects in this study.  The clinical s tudy site 
will permit access to such records.  
Subject identity data will be contained in paper study records which will be kept in a locked file cabinet 
and in a secure electronic database, accessible only to authorized users at the clinical site. The stud y 
database will be user -restricted and password -protected. The study database will identify subjects by a 
coded study Volunteer ID number assigned by [CONTACT_19826];  thus subjects will not be 
identified by [CONTACT_2300].  
 
15 REFERENCES  
1. Bresee JS, Widdowson MA, Monroe SS, Glass RI. Foodborne viral gastroenteritis: challenges 
and opportunities. Clin Infect Dis. 2002;35(6):[ADDRESS_366266] Dis. 
2014;58(12):1746 -52. 
3. Teunis PF, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, et al. Norwalk virus: how 
infectious is it? J Med Virol. 2008;80(8):1468 -76. 
4. Marks PJ, Vipond IB, Carlisle D, Deakin D, Fey RE, Caul EO. Evidence for airborne 
transmission of Norwalk -like virus (NLV) in a hotel restaurant. Epi[INVESTIGATOR_19277]. 
2000;124(3):481 -7. 
5. Graham DY, Jiang X, Tanaka T, Opekun AR, Madore HP, Estes MK. Norwalk virus  infection of 
volunteers: new insights based on improved assays. J Infect Dis. 1994;170(1):[ADDRESS_366267] Dis. 2008;1 4(10):[ADDRESS_366268] Dis. 2015;212(3):397 -405. 
8. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med. 2 009;361(18):1776 -
85. 
9. Vega E, Barclay L, Gregoricus N, Shirley SH, Lee D, Vinje J. Genotypic and epi[INVESTIGATOR_300010], 2009 to 2013. J Clin Microbiol. 
2014;52(1):[ADDRESS_366269] Dis. 2011;17(8):1389 -95. 
11. Zheng DP, Widdowson MA, Glass RI, Vinje J. Molecular epi[INVESTIGATOR_300011] -
genotype 4 noroviruses i n the [LOCATION_002] between 1994 and 2006. J Clin Microbiol. 
2010;48(1):168 -77. 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 75 of 114 
Date: [ADDRESS_366270] Dis. 2013;208(11):[ADDRESS_366271] Dis. 
2013;19(8):1231 -8. 
14. de Graaf M, van Beek J, Vennema H, Podkolzin AT, Hewitt J, Bucardo F, et al. Emergence of a 
novel GII.17 norovirus - End of the GII.4 era? Euro Surveill. 2015;20(26).  
15. Karst SM, Wobus CE, Goodfellow IG, Green KY, Virgin HW. Advances in norovirus biology. 
Cell Host Microbe. 2014;15(6):668 -80. 
16. Vongpunsawad S, Venkataram Prasad BV, Estes MK. Norwalk Virus Minor Capsid Protein VP2 
Associates within the VP1 Shell Domain. J Virol. 2013;87(9):4818 -25. 
17. Jiang X, Wang M, Graham DY, Estes MK. Expression, self -assembly, and antigenicity of the 
Norwalk virus capsid protein. J Virol. 1992;66(11):6527 -32. 
18. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Viral shape -shifting: norovirus evasion of 
the human immune system. Nat Rev Microbiol. 2010;8(3):231 -41. 
19. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. Binding of Norwalk virus -like 
particles to ABH histo -blood group antigens is blocked by [CONTACT_300074]. J Virol. 2002;76(23):[ADDRESS_366272] Dis. 1990;161(1):18 -21. 
21. Parrino TA, Schreiber DS, Trier JS, Kapi[INVESTIGATOR_300012], Blacklow NR. Clinical immunity in acut e 
gastroenteritis caused by [CONTACT_300075]. N Engl J Med. 1977;297(2):86 -9. 
22. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, et al. Human susceptibility 
and resistance to Norwalk virus infection. Nat Med. 2003;9(5):[ADDRESS_366273] Dis. 2013;19(8):1260 -7. 
24. Tan M, Jiang X. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS 
Pathog. 2010;6(8):e1000983.  
25. Ball JM, G raham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk 
virus-like particles given orally to volunteers: phase I study. Gastroenterology. 1999;117(1):40 -8. 
26. Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with reco mbinant 
Norwalk virus -like particles induces a systemic and mucosal immune response in mice. J Virol. 
1998;72(2):[ADDRESS_366274] Dis. 
2010;202(11):1649 -58. 
28. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes M K. Recombinant Norwalk 
virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and 
vaginal) immune responses. J Virol. 2001;75(20):9713 -22. 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 76 of 114 
Date: 25 May 2023  
 29. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, a nd 
cellular immune responses to oral Norwalk virus -like particles in volunteers. Clin Immunol. 
2003;108(3):[ADDRESS_366275] experimental human Norwalk Virus illness. N Engl J Med. 2011;365(23):[ADDRESS_366276] Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults. J Infect 
Dis. 2014;211(1):87 0. 
32. Kim L, Liebowitz D, Lin K, Kasparek K, Pasetti MF, Garg SJ, et al. Safety and immunogenicity 
of an oral tablet norovirus vaccine, a phase I randomized, placebo -controlled trial. JCI Insight. 
2018;3(13).  
33. Liu P, Hsiao HM, Jaykus LA, Moe C. Quantif ication of Norwalk virus inocula: Comparison of 
endpoint titration and real -time reverse transcription -PCR methods. J Med Virol. 
2010;82(9):[ADDRESS_366277] Environ Microbiol. 2011;77(15):[ADDRESS_366278] Environ Microbiol. 2011;77(19):6884 -8. 
36. Dudding BA, Bartelloni PJ, Scott RM, Top FH, Jr., Russell PK, Buescher EL. Enteric 
immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, 
immunogenicity, and po tency in volunteers. Infection and immunity. 1972;5(3):295 -9. 
37. Emini EA, editor Ongoing Development and Evaluation of a Potential HIV -1 vaccine Using a 
Replication -Defective Adenoviral Vector. Keystone Conference on HIV Vaccines; 2003; Banff, 
Canada: Ab stract 012.  
38. Schwartz AR, Togo Y, Hornick RB. Clinical evaluation of live, oral types 1, 2, and 5 adenovirus 
vaccines. Am Rev Respir Dis. 1974;109(2):233 -9. 
39. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science t o 
clinical application. J Pathol. 2006;208(2):299 -318. 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 78 of 114 
Date: 25 May 2023  
 APPENDIX B:   CHALLENGE VIRUS  PREPARATION  
The Norovirus GI.1 (Norwalk Virus Inoculum Lot 001 -09NV, IND [ZIP_CODE])  inoculum was prepared by 
 [CONTACT_300076] A for use in clinical trials 
under IND [ZIP_CODE].    The viral inoculum was prepared under Good Manufacturing Practices  (GMP) 
conditions as described in this section.   Vaxart has received authorization to cross -reference ’s 
IND, as well as obtained GI.[ADDRESS_366279] was produced at a time and the production room(s ), and their associated equipment were 
broken down and sanitized between products. The Processing facility does not have HEPA filtered 
air. However, the facility generally has between Class [ADDRESS_366280] Operating  Procedures  (SOPs) that cover all operations .  A list of the 
SOPs that are used in the facility is shown in the tables below. Manufacturing data is recorded in 
production batch records that are prepared for each lot of material produced. Quality control da ta is 
recorded in logbooks assigned to each quality control program. Original versions of production and 
quality control records are maintained in the facility and copi[INVESTIGATOR_300013].  
Table A:  SOPs for Facilities and Operations  
SOP No. SOP Description  
1000.[ADDRESS_366281] Operating Procedures and Forms  
Employee Training  
Data Entry and Error Correction  
Signature [CONTACT_300093][INVESTIGATOR_300014] & Manufacturing 
Norovirus  
Control of Raw Materials  
Clinical Core Production Room Usage  

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 79 of 114 
Date: [ADDRESS_366282] Release  
 
Quality Control/Quality Assurance  
Compliance with  current Good Manufacturing Practice  (cGMP) is maintained through a quality 
systems approach. This approach involves developi[INVESTIGATOR_300015]. The specific quality control and quality assurance 
programs that are used to maint ain cGMP are listed below. Details on the facilities and operations 
control programs have been compi[INVESTIGATOR_40177] a Type V Facilities Drug Master File that will be maintained 
at the FDA. The investigator and other regulatory entities can access this file through letters of 
reference as necessary.  
Table B:   Facilities and Operations Controls  
Controls Description  
Controls over Facility and Equipment  
Controls over Organization and Personnel  
Sterilization and Cleaning Controls  
Raw Materials Controls  
Environmental Monitoring  
Packaging and labeling Controls  
Holding and Distribution Controls  
Laboratory Testing Controls  
Records, Documents and Change Controls  
Corrective and Preventative Action Programs  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 81 of 114 
Date: 25 May 2023  
 Sterility 
including 
Bacteriostasis 
+Fungistasis  Immersion USP/21 CFR 610.12  
 Protocol #[ZIP_CODE], [ZIP_CODE] 
and [ZIP_CODE]  Negative Negative 
Mycoplasma  Points to consider for Viral Stocks, GLP  
 Protocol # [ZIP_CODE]  Negative Negative 
Endotoxin  BET/LAL Gel Clot I/A Assay, GMP  
 Protocol # [ZIP_CODE]  < 5000 
EU/mL 235 EU/mL  
  

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 84 of 114 
Date: 25 May 2023  
 APPENDIX E:      LIST OF ADVERSE EVENTS OF SPECIAL INTEREST  (AESIs) 
Gastrointestinal Disorders 
• Celiac disease  
• Crohn’s disease  
• Ulcerative colitis 
• Ulcerative proctitis  
 
Liver Disorders 
• Autoimmune cholangitis  
• Autoimmune Hepatitis  
• Primary biliary cirrhosis  
• Primary sclerosing cholangitis  
 
Metabolic Diseases 
• Addison’s disease  
• Autoimmune thyroiditis (including Hashimoto thyroiditis)  
• Diabetes mellitus type 1  
• Grave’s or Basedow’s disease  
 
Coagulopathy  
• Acquired amegakaryocytic thrombocytopenia   
• Axillary vein thrombosis   
• Cerebral venous thrombosis  
• Disseminated intravascular coagulation  
• Hepatic vein thrombosis  
• Intracranial venous sinus thr ombosis 
• Portal vein thrombosis  
• Pulmonary thrombosis  
• Severe fever with thrombocytopenia syndrome  
• Thrombocytopenia  
• Thrombotic thrombocytopenia purpura  
• Transverse sinus thrombosis  
• Vena cava thrombosis  
• Amegakaryocytic thrombocytopenia  
• Cavernous sinus thrombosis  
• Deep vein thrombosis  
• Embolism venous  
• Immune thrombocytopenia  
• Mesenteric vein thrombosis  
• Pulmonary embolism  
• Pulmonary venous thrombosis  
• Subclavian vein thrombosis  
• Thrombocytopenia purpura  
• Thrombosis  
• Vena cava embolism  
• Venous thrombosis  
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 85 of 114 
Date: 25 May 2023  
 Musculosk eletal Disorders 
• Antisynthetase syndrome  
• Dermatomyos itis 
• Juvenile chronic arthritis (including Still’s disease)  
• Mixed connective tissue disorder  
• Polymyalgia rheumatic  
• Polymyositis  
• Psoriatic arthropathy  
• Relapsing polychondritis  
• Rheumatoid Arthritis  
• Scleroderma, including diffuse systemic form and CREST Syndrome  
• Spondyloarthritis, including ankylosing spondylitis, reactive arthritis (Reiter’s Syndrome) 
and undifferentiated spondyloarthritis.  
• Systemic lupus erythematous  
• Systemic sclerosis  
 
Neuroinflammatory Disorders 
• Acute disseminated encephalomyelitis, including site specific variants (e.g., non -infections 
encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis)  
• Cranial nerve disorders, including paralysis/paresis (e .g., Bell’s palsy) 
• Guillain-Barre syndrome, including Miller Fisher syndrome and other variants  
• Immune related peripheral neuropathies and plexopathies, including chronic inflammatory 
demyelinating polyneuropathy, multifocal motor neuropathy and polyneuropathies associ ated 
with monoclonal gammopathy  
• Multiple sclerosis  
• Narcolepsy  
• Optic neuritis  
• Transverse Myelitis  
 
Skin Disorders  
• Alopecia areata 
• Autoimmune bullous skin diseases (including pemphigus, pemphigoid and dermatitis 
herpetiformis  
• Cutaneous lupus erythematosus  
• Erythema nodosum  
• Morphea 
• Lichen planus  
• Psoriasis 
• Sweet’s syndrome  
• Vitiligo 
 
Vasculitis  
• Large vessels vasculitis including: giant cell arteritis such as Takayasu’s arteritis and 
temporal arteritis  
• Medium sized/and or small vessels vasculitis including: polyarthritis nodosa, Kawasaki’s 
disease, microscopic polyangiitis, Wegener’s granulomatosis, Churg -Strauss syndrome 
(allergic granulomatous angi itis), Buerger’s disease thromboangi itis obliterans), ne crotizing 
vasculitis and anti -neutrophil cyt oplasmic antibody (ANCA) positive vasculitis (type 
unspecified), Henoch -Schönlein purpura, Behcet’s syndrome, leu kocytoclas tic vasculitis.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 86 of 114 
Date: 25 May 2023  
  
Others 
• Antiphospholipid syndrome  
• Autoimmune hemolytic anemia  
• Autoimmune glomerulonephritis (including IgA nephropathy, glomerulonephritis rapi[INVESTIGATOR_90974], membranous glomerulonephritis, membranoprolif erative glomerulonephritis, 
and mesangioproliferative glomerulonephritis)  
• Autoimmune myocarditis/cardiomyopathy  
• Autoimmune thrombocytopenia  
• Goodpasture syndro me 
• Idiopathic pulmonary fibrosis  
• Pernicious anemia  
• Raynaud’ s phenomenon  
• Sarcoidosis  
• Sjogren’s syndrome  
• Stevens-Johnson Syndrome  
• Uveitis 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 87 of 114 
Date: 25 May 2023  
 APPENDIX  F: Preparation of NV Challenge Inoculum  
IND [ZIP_CODE], Amendment 31, 001 -09NV Sublot 2, Manufacture  and Stability and Sterility 
Testing Results : Preparation  of NV Challenge lnoculum Work Instruction  
 
1. PURPOSE  
 
The purpose of this Work Instruction (WI) is to document the activities related to the dilution 
and preparation of an administration dose of Norwalk Virus lnoculum Lot [ADDRESS_366283] wear appropriate personal protective 
equipment (PPE), including at minimum face masks, sterile glo ves, gowns, and eye 
protection. Additionally, hair and shoe covers, will be also required. This WI will apply to 
the Dilution of the Stock material provided by  [CONTACT_300077]/sterility testing and preparation of individual dosing vials 
for the current study (VXA -NVV-201). 
 
3. ABBREVIATIONS  
 
BSC - Biological Safety Cabinet NTF - Note to File  
NV - Norwalk virus  
  SWFI - Sterile Water For Injection  
TMF - Trial Master File  
 
4. MATERIALS  
 
o PPE (  SOP# COES -105-.01) 
o Sterile Glass Beaker (SO ml MFR: Pyrex)  
o Sterile Glass Beaker (1000 ml MFR: Pyrex)  
o Cryovials/Cryotubes (3 ml Cryovial MFR: Simport; 5 ml Cryovial MFG: 
VWR) 
o Sciences Pi[INVESTIGATOR_6343] (1 ml Pi[INVESTIGATOR_300016]: Eppendorf, 5 ml Pi[INVESTIGATOR_300016]: 
PhysioCare)  
o Sterile Water for Injection (SO ml vials MFR: Fresenius Kabi)  
o 20 ml Syringe for Diluent (MFR: McKesson)  
o 3ml Syringe Luer -Lok™Tip MFR : B -D 
o Mini-Spi[INVESTIGATOR_300017] (MFR : B 
Braun) 
 

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 88 of 114 
Date: 25 May 2023  
 5. EQUIPMENT  
 
o Vortex (Vortex - VWR Analog Vortex Mixer MFR: VWR)  
o Freezer (Ultra -Low Temperature Freezer MFR: New Brunswick Model: Ul0l -
86) 
o BSC (Labgard, Class II, Type A2 BSC MFR: Nuaire Model: NU -425-200) 
 
6. WORK INSTRUCTIONS  
 
6.[ADDRESS_366284] or designee will swab the outside of the tube with disinfectant 
and allow the frozen stock material provided by  (25 -35 ml Norwalk Virus 
lnoculum -5.0 X 10e6 genome copi[INVESTIGATOR_014] (GC)/ml, Lot 001 -09NV, IND [ZIP_CODE]) to thaw 
on ice in the Class II microbiological safety cabinet.  
 
6.[ADDRESS_366285] or designee will gently Vortex the  
liquid material for several minutes (minimum, 5 mins.}, then:  
 
6.2.1 Remove 6 x 1ml aliquots for virus titering. Aliquots wi ll be shipped on dry ice 
for priority overnight delivery to  The remainder of the stock NV will be stored 
at 4 degrees Celsius (Refrigerated) until  reports titer results and commencing 
6.3. 
 
Stock titer will be quantified by [CONTACT_16641] -PCR of three aliquo ts according to SOP 4007.02 
(  Three additional aliquots will be reserved as back up samples.  
 
The determined titer of 0019 -09NV PBH master stock was 2.4 GC/ml, outside the 
established range of 5 x 10e6 gc/ml +/ - 2 X 10e6 gc/ml. Therefore, the stock di lution 
was calculated for a final titer of 3 x 10e5 GC/ml, the current reported titer of the  
doses in use. Calculation of the dilution is reported in the Work Sheet for 
Determining the Dilution of 001 -09NV PBH. A dilution of 1:8 was determined to be 
needed to yield 3 x 10e5 GC/ml.  
 
 
Lot release testing plan (  will ship test samples directly to each Test  
Operator)  
 

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 89 of 114 
Date: [ADDRESS_366286] or designee will transfer 25 ml of the stock NV to a sterile 50 ml 
beaker and begin the 1:8 dilution of the stock material.  
 
6.4 Transfer 12.5 ml of the stock material into a sterile 1000 -ml glass beaker containing  
62.5 ml SWFI and gently swirl/mix for several minutes (minimum, 5 mins), then  
 
6.5 Transfer the remainder of the stock material to the 75 ml from 6.3  and add an 
additional 62.5 ml SWFI and gently swirl/mix for several minutes (minimum, 5 mins.}, then  
 
6.6 Rinse the stock material container thoroughly into the bottle with an additional 50 ml 
SWFI and gently swirl/mix for several minutes (minimum, 5 mins .), finally 
 
6.7 The total volume {200 ml, 3x10e5 GC / ml} is ready for individual pi[INVESTIGATOR_300018] (3 ml) and of various retained samples (1 ml} to be  harvested at 
commencement, middle and completion of aliquoting vials for the  challenge dosing. All 
dosing and retained samples will be stored at -60C. 
• Commencement - 21, 1 ml vials for sterility, endotoxin and V. titer  
• Middle - 6, 1 ml vials for V. titer  
• End - 21, [ADDRESS_366287]/designee will then begin aliquoting the 1:8 dilution NV into the 
designated retained (1 ml) and "dosing" sample vials (3 ml) as described in 6.[ADDRESS_366288]/designee will prepare the vials in the fol lowing order:  
 
 
6.9.1 Twenty-one (21) 1 ml samples (in 3 ml sterile cryotubes)  
 
6.9.2 Twenty-five (25) 3 ml dosing vials (in 5 ml sterile cryotubes)  
 
6.9.3 Six (6) 1 ml samples (in 3 ml sterile cryotubes)  

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 90 of 114 
Date: 25 May 2023  
  
6.9.4 Twenty-four (24) 3 ml dosing vials (in 5 ml sterile cryotubes}  
 
6.9.5 Twenty-one (21) 1 ml samples (in 3 ml sterile cryotubes)  
 
All of the 3 mL dosing vials will be held (5 -60 degrees C.) until finalization of lot 
release testing and FDA approval of IND update.  
 
Preparation and Administration of the Individual NV Challenge  
 
6.[ADDRESS_366289] from 6.9.2 or 6.9.4 above will be thawed (following frozen 
storage). The vial should be swabbed with disinfectant. Each [ADDRESS_366290] with the inocula with 
10 % bleach solution. Cups u sed for administration and any leftover inocula should 
also be cleaned with bleach and discarded.  
 
If the subject, person administering the dose, or the person preparing inoculum spi[INVESTIGATOR_300019], the affected area must be immediately cleaned with 10% b leach 
solution. Hands must be washed thoroughly with disinfectant soap and water.  
 
Partially used vials will be disinfected and discarded and may not be used for human 
administration or for any in vitro experimental studies.  
 
 
 
 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 91 of 114 
Date: 25 May 2023  
 APPENDIX G:      SUMMARY O F CHANGES TO PROTOCOL  
PROTOCOL VXA -NVV-201 HISTORY  : 
Document   Date  
Protocol Amendment 5.0, Version 6.0  25 May 2023  
Protocol Amendment 4, Version 5.0  07 February  2023 
Protocol Amendment 3, Version 4.0  23 June 2022  
Protocol Amendment 2; Version 3.0  07 January 2022  
Protocol Amendment 1; Version 2.0   01 December 2021 
Original Protocol; Version 1.0   28 October 2018  
 
VXA-NVV-201 Protocol Amendment 5, Version 6.0, 25 May 2023  
 
Protocol Amendment 5 (Version 6.0) of this phase 2 Norovirus GI.1 challenge protocol (VXA -NVV-201) 
was finalized in June [ADDRESS_366291] other minor typographical 
errors. A description of the changes along with a brief rationale for each change is presented in the table 
below. 
 
Section No.  
& Title Description of Change  Brief Rationale  
Cover page -Product Original text:  
 
Challenge strain: Norovirus GI.1 (Norwalk 
Virus Inoculum Lot 001 -09NV) 
 
Updated text: 
 
(Norwalk Virus Inoculum Lot 001 -09NV 
and Sublot 2)  Update Inoculum Lot  
Administrative 
changes to Protocol 
Cover Page and 
footers Updated Pr otocol Version  Updated sponsor new protocol version 
number and date.  
List of Abbreviations 
and Acronyms  Original text: international units  
Updated text: infectious units  Provided intended meaning of IU  
   
Clinical Synopsis 
Study Population  Original Text:  
140 healthy male and female adult 
volunteers age 18 to 49 years inclusive with 
blood type O or A and who are confirmed H Updated for actual intended sample size  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 92 of 114 
Date: 25 May 2023  
 type-1 antigen secretory positive 
(approximately [ADDRESS_366292] -
vaccination)  
Updated t ext: 
Approximately 170 healthy male and female 
adult volunteers age 18 to 49 years  
inclusive with blood type O or A and who 
are confirmed H type -1 antigen secretory 
positive (approximately [ADDRESS_366293]-vaccination)   
Clinical Protocol 
Synopsis Viral Challenge Inoculum  
Original text:  
Norovirus GI.1 (Norwalk Virus Inoculum 
Lot 001-09NV, IND [ZIP_CODE])  
Updated text:  
Norovirus GI.1 (Norwalk Virus Inoculum 
Lot 001-09NV and Sublot 2, IND [ZIP_CODE])  
 Update Challenge Inoculum  
Clinical Protocol 
Synopsis 
Study design  Original text:  
This is a Phase 2b randomized, double -
blind, placebo -controlled vaccination and 
challenge study to assess the protective 
efficacy of the Norovirus vaccine (VXA -
G1.1-NN). Approximately 140 healthy 
adults will be randomized in a 1:1 ratio to 
receive one oral dose of vaccine or placebo.  
• Arm 1: VXA -G1.1-NN oral vaccine tablets 
[1x1011 IU±0.5 log]; N=70  
• Arm 2: Placebo tablets similar in 
appearance and  number to active vaccine 
tablets; N=70  Update Arm size, sample size  and 
cohort increase  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 93 of 114 
Date: [ADDRESS_366294] -challenge sequestration 
period, subjects will move through the study 
(enrollment, vaccination and challenge) 
sequentially in 10 to 12 cohorts.  
Updated text:  
This is a Ph ase 2b randomized, double -
blind, placebo -controlled vaccination and 
challenge study to assess the protective 
efficacy of the Norovirus vaccine (VXA -
G1.1-NN). Approximately 1 70 healthy 
adults will be randomized in a 1:1 ratio to 
receive one oral dose of vac cine or placebo.  
• Arm 1: VXA -G1.1-NN oral vaccine 
tablets  
 [1x1011 IU±0.5 log]; N=8 5 
• Arm 2: Placebo tablets similar in 
appearance and  
 number to active vaccine tablets; 
N=[ADDRESS_366295] -challenge sequestration 
period, subjects will move through the study 
(enrollment, vaccination and challenge) 
sequentially in 14 to 16  
Original t ext: 
Approximately [ADDRESS_366296] 120 
subjects (~ 60 VXA -G1.1-NN vaccine and 
60 placebo) are available to participate in 
the challenge phase.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 94 of 114 
Date: 25 May 2023  
  
Updated text:  
Approximately [ADDRESS_366297] 140 
subjects (approximately 70 VXA-G1.1-NN 
vaccine and 70 placebo)  are available to 
participate in the challenge phase.  
Updated table:
 
 
3.1 Study Design and 
Endpoints  Original text:  
This is a Phase 2b randomized, double -
blind, placebo -controlled vaccination and 
challenge study to assess the protective 
efficacy of the Norovirus vaccine (VXA -
G1.1-NN). To ensure at least 120 subjects 
(approximately 70 NV vaccine and 70 
placebo) are available to participate  in the 
challenge phase, approximately 140 healthy 
young adults will be randomized in a 1:[ADDRESS_366298] will receive 
an oral dose of 1x1011 IU±0.5 log VXA -
GI.1-NN or placebo comprised of multi ple 
tablets per dose.  
Updated text:  
This is a Phase 2b randomized, double -
blind, placebo -controlled vaccination and Update sample size  

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 95 of 114 
Date: 25 May 2023  
 challenge study to assess the protective 
efficacy of the Norovirus vaccine (VXA -
G1.1-NN). To ensure at least 140 subjects 
(approximately 85 NV vaccine and 85 
placebo) are available to participate in the 
challenge phase, approximately 17 0 healthy 
young adults will be randomized in a 1:[ADDRESS_366299] will receive 
an oral dose of 1x10 11 IU±0.5 log VXA -
GI.1-NN or placebo comprised of multiple 
tablets per dose.  
Table 10: Study 
Design and Vaccine 
Groups Original text:  
VXA-G1.1-NN oral vaccine tablets [1x1011 
IU±0.5 log] =70 
Placebo identical to NVV =70 
Challenge Norwalk Virus Strain [Lot 001 -
09NV (1x106 GC)] =120* 
Updated text:  
VXA-G1.1-NN oral vaccine tablets [1x1011 
IU±0.5 log] =85 
Placebo identical to NVV =85 
Challenge Norwalk Virus Strain [Lot 001 -
09NV and Sublot 2 (1x106 GC)] =140 
 
 Update sample size  
6.0  NV 
CHALLENGE 
INOCULUM  Added following text  
Updated text:  
To accommodate the increased sample size 
of the trial, additional GI.[ADDRESS_366300] (PBH),  to 
challenge the additional Subjects.  The 
dilution process is attached as Appendix F 
and an updated IND [ZIP_CODE] subsequently Clarification on dilution of original 
master inoculum stock 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 96 of 114 
Date: 25 May 2023  
 submitted to the FDA with sterility, 
endotoxin, and titer testing results.   
6.1 Formulation, 
Packaging, and 
Labeling of NV 
Challenge Virus  Added following text  
Updated text:  
The Sublot 2 inoculum material diluted and 
prepared for single use to complete this 
challenge study was packaged in one 3mL 
cryovials.  The dilution and aliquoting of 
virus were performed at  in 
 with oversight by a 
representative from the original 
manufacturing team following the dilution 
procedure described in the Preparation of 
NV Challenge Inoculum Work Instruction, 
Appendix F. During the aliquoting of 001 -
09NV sublot 2, additional vials from the 
beginning, middle and end of the run were 
prepared for quality control testing, and 
shipped on dry ice to either  or 
 for testing.  
 Clarification on workflow of diluting of 
the original master inoculum stock  
6.2 Storage and 
Stability of NV 
Challenge Virus  Added following text  
Updated text:  
The final titer for 001 -09NV PBH was 2.4 
x10e6 genome copi[INVESTIGATOR_014] (GC)/mL. The titer in 
2009 was 5 x 10e6 GC/mL. Titer of 001 -
09NV Final Fill sublot 1, a 1/10 dilution of 
001-09NV PBH was 5 x 10e5 GC/mL in 
[ADDRESS_366301] curve that passed  
QC, for all nine vials across three 
independent assays was 5.36 10e5 GC/ml. 
The titer was consistent across the 
aliquoting run. Notably, the titer of 001 -
09NV sublot 1 ranged from 6 x 10e5 Updated Stability and titer information 
for new inoculum  stock (sublot 2)  

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 97 of 114 
Date: 25 May 2023  
 GC/mL to 3 x 10e5 GC/mL between 2009 
and 2022, indicating that 001 -09NV Final 
Fill sublot 2 is performing consistently with 
001-09NV Final Fill sublot 1. The reported 
titer is slightly higher than expected from 
the 1/8 dilution of master stock but falls 
within the established range of ti ter based on 
historic results of 001 -09NV Final Fill 
sublot 1 (5 x 10e5 GC/mL +/ - 2 x 10e5 
GC/mL). 
7.5 Visit 03: 
Study Day 28, 1 day 
prior to challenge [+3 
days for visit window 
and +30 days window 
for repeat Visit 03]  Added following text:  
The stool sample for fecal immunogenicity 
may be collected 1 day or within 24 hours of 
Day 28 through pre -challenge on Day 29.  Clarification of Visit 3 procedures  
7.6.3 Viral 
Challenge 
Administration  Original text:  
Subjects will have fasted overnight prior to 
viral challenge. Additionally, they should 
have nothing by [CONTACT_1966], except water, for 90 
minutes before and after ingestion of the 
challenge inoculum.  Subjects will drink 100 
mL of sodium bicarbonate solution (~1.3% 
NaHCO3) prior to viral challenge; 
approximately [ADDRESS_366302] the NV inoculum (Lot 001 -09NV, 
IND [ZIP_CODE]) suspended in 100 mL of 
distilled water.  
Updated text:  
Subjects will have fasted overnight prior to 
viral challenge. Additionally, they should 
have nothing by [CONTACT_1966], except water, for 90 
minutes before and after ingestion of the 
challenge inoculum.  Subjects will drink 100 
mL of sodium bicarbonate solution (~1.3% 
NaHCO3) prior to viral  challenge; 
approximately [ADDRESS_366303] the NV inoculum (Lot 001 -09NV and 
Sublot 2, IND [ZIP_CODE]) suspended in 100 mL 
of distilled water.  Updated inoculum  lots 
Definition of Adverse 
Event Original text:  
Subjects will utilize a solicite d symptom e -
Diary issued on the day of vaccination to Added language mappi[INVESTIGATOR_300020].1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 98 of 114 
Date: [ADDRESS_366304] 7 
days following vaccination.  
Updated text:  
Subjects will utilize a solicited symptom e -
Diary issued on the day of vaccination to 
daily record the events during  the first 7 
days following vaccination. These solicited 
symptoms will be graded as follows:  
Added Grading table  
 
11.1 Study 
Hypothesis  Original text:  
 
The study hypothesis is that norovirus 
vaccine, VXA -G1.1-NN, will protect against 
norovirus gastroenteritis related to norovirus 
infection in the challenge model. Protective 
efficacy (PE) will be estimated by [CONTACT_300078][INVESTIGATOR_300021] t hose who were 
challenged.  
 
The null hypothesis is that the absolute 
protective efficacy is zero. The two-sided 
alternative hypothesis is that the absolute 
protective efficacy is not equal to  zero. 
 
H0: PE = 0 
HA: PE ≠ 0 
The estimated protective efficacy i s defined 
as: 𝐴𝑅0−𝐴𝑅1
𝐴𝑅0 
Where AR 1 is the observed norovirus 
gastroenteritis rate among vaccinated 
subjects and AR 0 is the norovirus 
gastroenteritis rate among subjects receiving 
placebo. 
 
 
Updated text:  
 
The study hypothesis is that norovirus 
vaccine, VXA-G1.1-NN, will protect against Updated to clarify that the two -sided 
Fisher’s Exact Test will be used to 
evaluate the primary endpoint for the 
trial and to add sensitivity analyses for 
the primary endpoint  to aid in 
interpretation of the primary analysis 
results. 

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 99 of 114 
Date: 25 May 2023  
 norovirus gastroenteritis related to norovirus 
infection in the challenge model. Protective 
efficacy (PE) will be estimated by [CONTACT_300078][INVESTIGATOR_300022].  
 
The null hypothesis is that the absolute 
protective efficacy is zero. The two-sided 
alternative hypothesis is that the absolute 
protective efficacy is not equal to  zero. 
 
H0: PE = 0 
HA: PE ≠ 0 
The estimated protectiv e efficacy is defined 
as: 𝐴𝑅0−𝐴𝑅1
𝐴𝑅0 
Where AR 1 is the observed norovirus 
gastroenteritis rate among vaccinated 
subjects and AR 0 is the norovirus 
gastroenteritis rate among subjects receiving 
placebo. 
 
A Fisher’s Exact Test with a 5% two -sided 
significance level will be used to evaluate 
the primary endpoint of clinical efficacy of 
VXA-G1.1-NN compared to placebo, to 
protect against NVG caused by [CONTACT_300079].  The sample size 
will be determined in order to evaluate the 
primary endpoint using a Fisher’s Exact test 
with a 5% significance level (Section 11.2)  
 
The study hypothesis will also be evaluated 
using the Chi -Squared test as a sensitivity 
analysis for the primary endpoint as t he 
Fisher’s Exact test can be overly 
conservative in some circumstances.  
 
An additional study hypothesis will also be 
evaluated as a sensitivity analysis. The null 
hypothesis will be that the absolute 
protective efficacy is zero, and the one -sided 
alternative hypothesis will be that the 
absolute protective efficacy is greater than 
zero.  
 
H0: PE = 0 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 100 of 114 
Date: 25 May 2023  
 HA: PE > 0 
 
This hypothesis will be evaluated using a 
one-sided Fisher’s Exact test. The two 
sensitivity analyses described above will not 
be used for decision making for this trial; 
rather, these are sponsor -requested 
corroborative analyses to aid in the 
interpretati on of the primary analysis results 
and facilitate planning for potential future 
studies. The formal statistical analysis plan 
(SAP) will provide additional guidance for 
interpreting results among the sensitivity 
analyses. 
 
11.2 Sample Size 
Determination  Original text:  
Considering the first [ADDRESS_366305] -
vaccination.  
Updated text:  
Considering the first [ADDRESS_366306] -vaccination.  The 
increased sample size may also facilitate 
determining an immunologic correlate of 
protection.  Updated stati stical methodology, power 
calculations and sample size  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 101 of 114 
Date: 25 May 2023  
 Appendix F: 
Preparation of NV 
Challenge Inoculum  See updated text in Appendix F  Added Work instruction for preparation 
of NV Challenge Inoculum  
SUMMARY OF 
CHANGES TO 
PROTOCOL  Renamed the Table of Amendments to 
Appendix G  Clarification  
 
VXA-NVV-201 Protocol Amendment 4, Version 5.0, 07 February  2023 
 
Protocol Amendment 4 (Version 5.0) of this phase 2 Norovirus GI.1 challenge protocol (VXA -NVV-201) 
was finalized in June 2022 and approved by [CONTACT_1201] .  It is being amended to incorporate sample size increase, 
addition of an exploratory analysis after appro ximately 50 Subjects complete the challenge period and being 
vaccinated under the same lot, adding a blinded interim immunogenicity analysis for the same subjects 
included in the planned interim analysis, as well as other administrative changes for clarity . A description of 
the changes along with a brief rationale for each change is presented in the table below.  
 
Section No.  
& Title Description of 
Change  Brief Rationale  
Administrative 
changes to Protocol 
Cover Page  Updated Protocol 
Version Updated sponsor new protocol version number and date.  
Clinical Protocol 
Synopsis; Study 
Design Updated Study 
Population by 
[CONTACT_300080] [ADDRESS_366307] -vaccination  
Clinical Pr otocol 
Synopsis; Study 
Design. Updated the study 
Design and number 
of subjects in the 
table. Approximately [ADDRESS_366308] 120 subjects (~ 60 VXA-G1.1-NN 
vaccine and 60 placebo) are available to participate in the 
challenge phase.  
Investigational Drug Product  No. of Subjects  
Vaccination  140 
VXA-G1.1-NN oral vaccine 
tablets  
[1x1011 IU±0.5 log]  70 
Placebo tablets (identical to 
vaccine) 70 
Challenge ( Norwalk GI.1 
Virus Inoculum)  120 
VXA-G1.1-NN oral vaccine 
tablets  
[1x1011 IU±0.5 log]  60 
Placebo tablets (identical to 
vaccine) 60 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 102 of 114 
Date: 25 May 2023  
 Clinical Protocol 
Synopsis; Statistical 
Considerations  Updated the 
statistical 
considerations for 
Exploratory Analysis 
and added an 
additional blinded 
interim 
immunogenicity 
Analysis. An exploratory analyses to be performed after approximately 
[ADDRESS_366309] the continuation of this 
study as planned, but rather, inform program development for 
other trials.  
 
Section 7 STUDY 
PROCEDURE AND 
SCHEDULE. 7.5  Updated the section 
Name 7.5 ‘ Visit 03: 
Study Day 28 , 1 
day prior to 
challenge  [+3 days 
for visit window 
and +30 days 
window for repeat 
Visit 03. Also 
Removed Note.  Updated the Section Name [CONTACT_18904] “ Visit 03: Study Day 28 
[+30 days], 1 day prior to challenge” to  
“Visit 03: Study Day 28 , 1 day prior to challenge  [+3 days 
for visit window and + 30 days window for repeat Visit 03]  
 
* Removed - Note: Day [ADDRESS_366310]’s original Day [ADDRESS_366311]’s challenge 
visit is delayed (+ 30 days).  
 
Section [ADDRESS_366312]’s original Day [ADDRESS_366313] ’s challenge visit is delayed (+ 
30 days).  
Visit 3 has a +3 day window, followed by a + 30 days 
window for repeat Visit 03, if needed, to rescreen subjects 
for challenge.  
 
BioFire GI Testing Guidance:  
• Subjects without symptoms of AGE in the [ADDRESS_366314] BioF ire GI pathogen 
assay 
• For subjects with symptoms of AGE in the [ADDRESS_366315] positive on BioFire for an 
enteric pathogen  OTHER THAN NOROVIRUS, they 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 103 of 114 
Date: 25 May 2023  
 may be re -evaluated for a future challenge as allowed 
by [CONTACT_990].   
• If no AGE symptoms in the preceding [ADDRESS_366316]  
• Any subject in this situation should  be discussed with 
Vaxart MM (including which pathogen was positive 
on BioFire at initial challenge screening) for approval 
to re-evaluate for challenge.   
• A subject that tests positive for Norovirus at Day 28 
will be excluded from future norovirus challeng e. 
 
Section 7.6.4: Visits 
04 – 08: Post-
Challenge 
Observation Period  
(Day 29 – Day 33 [+ 
3 Days]) 
 Added additional 
instructions related 
to Emesis or 
Diarrhea occurred 
after the Last NV 
signs and symptoms 
and first NV 
symptoms  of the day 
but before 12 :00Pm. . If a subject experiences emesis or diarrhea after the first NV 
Signs and Symptoms assessment of the day but before 
12:00pm, the site will record the occur rence on the first 
Norovirus Signs and Symptoms for the corresponding 
calendar day on which it occurred. If a subject experience any 
of the other symptoms on the Norovirus Signs and Symptoms 
form after the last assessment of the calendar day, those 
symptoms will be recorded on the first assessment of the next 
day 
Section 7. 8: Visit 10: 
Study Day 57 ( [ADDRESS_366317] challenge 
± 3 days)  Added additional 
guidance for the 
subjects who are 
ineligible for 
challenge phase.  For subjects who are ineligible for challenge phase, Section 7.8 
of the protocol should be followed instead of Section 7.11; that 
is, subjects who are not challenged should begin the safety 
follow up at Visit 10 (Day 57). This visit may be a phone 
contact. No separate “early termination” visit needs to occur. 
Only subjects who truly terminate participation in the study 
should have an early termination visit.  
 
Section 7.9: Visit 11 
(Day 120) – Visit 14 
(Day 300) Safety 
Follow-up Contacts  
 
 Added the number of 
days expected  for 
each visit  • Visit 11: Study Day 120 ( [ADDRESS_366318] challenge + 1 
week) 
• Visit 12: Study Day 180 ( [ADDRESS_366319] challenge + 1 
week) 
• Visit 13: Study Day 240 ( [ADDRESS_366320] challenge + 1 
week) 
• Visit 14: Study Day 300 ( [ADDRESS_366321] challenge + 1 
week) 
 
Section 7.10: Visit 15: 
Study Day 365 ([ADDRESS_366322] challenge + 
1 week) End of Study 
Contact 
 [CONTACT_300081] “ Visit 15: Study Day [ADDRESS_366323] ” to “Visit 15: Study Day 365 ([ADDRESS_366324] 
challenge + 1 week) End of Study Contact  
 
 
[CONTACT_300082].1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 104 of 114 
Date: 25 May 2023  
 Section 7.11: Early 
Termination  Removed wordings 
in section 7.11.2 
Early Termination 
(Day 29 - Day 57;  
Challenge Phase ) 
 ***REMOVED ***  Subjects who did not undergo 
challenge  and discontinue between Days 29 and Day 
57 do not need the above listed ET assessments, but 
rather should be managed as  early terminations during 
the Safety Follow -up Period (see Section 7.11.3 ). 
 
Section 11: 
STATISTICAL 
CONSIDERATIONS;  Updated the 
considerations for  
table [ADDRESS_366325]-vaccination . 
 
Section 11.6: Interim 
Analysis. Updated the section 
related to interim 
analysis. Although the interim analysis results nor SMC recommendation 
to continue the study required a sample size re -estimation, 
Vaxart decided to add [ADDRESS_366326] two  
cohorts and all others.  
Section 11.7: 
Exploratory Analysis Updated the details 
related to 
exploratory Analysis 
and an additional 
blinded interim 
immunogenicity 
Analysis. An exploratory analysis will take place after approximately [ADDRESS_366327] the continuation of this study as planned, but rather, 
inform program development for other trials . 
 
 
 
VXA-NVV-201 Protocol Amendment 3, Version 4.0, 23 June 2022  
 
Protocol Amendment 2 (Version 3.0) of this phase 2 Norovirus GI.1 challenge protocol (VXA -NVV-201) 
was finalized in January [ADDRESS_366328] lots that allow administration via a 
single dose of tablets (rather than three sub -doses).  Additionally, information to support an interim analysis 
following co mpletion of challenge in ~50 subjects (50%) has been incorporated into the protocol. Minor 
changes to the sample collection schedule , as well as the Sponsor and Clinical Site study teams have been 
incorporated within Protocol Amendment 3 (Version 4.0) . A description of the changes along with a brief 
rationale for each change is presented  in the table  below. 
 
 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 105 of 114 
Date: 25 May 2023  
 Section No.  
& Title Description of Change  Brief Rationale  
 Administrative 
changes to Protocol 
Cover Page  Updated Contact [CONTACT_300083].  
Synopsis: Study 
Design  
Section 7.[ADDRESS_366329] 48 hours to twice a day (am and pm)  for the 
duration of the post challenge sequestration period .  
Synopsis: Study 
Visits: Challenge 
Phase  
Section 8 Clinical 
Evaluation:  Updated immunogenicity and 
safety assessments  Evaluation of immune response and safety 
assessment were added on Day 33 and 57 of 
challenge phase  to allow for a more complete 
immune response dataset .  
Synopsis: Safety, 
Immunogenicity and 
Microbiological 
Assessments   Updated frequency of collection 
of vital signs collection  The frequency of  collection of vital signs  has been 
modified from every [ADDRESS_366330] 48 hours to 
twice a day (am and pm) during the post -vaccination 
phase until discharge. This approach allows for 
adequate data collection while balancing the burden 
on study subjects and site staff.  
Synopsis: Study 
Endpoint; Section 
3.2.4. Immunogenicity 
Endpoints :  Updated exploratory endpoints  Saliva and nasal samples collection  was added on 
Day 8 to allow for a more complete immune response 
dataset.  
Synopsis: Statistical 
Considerations  
Section 11: Statistical 
Considerations  Study hypothesis updated and 
details added regarding planned 
interim analysis  Information added in support of the Interim Analysis.  
Section 5.1.[ADDRESS_366331] Dose 
Preparation and 
Administration  Updated Study drug 
administration information and 
added reference to pharmacy 
manual Section was updated to remove language on sub -
doses as new lot of DP to be utilized to dose 
remaining cohorts will utilize a single dose approach;  
reference to pharmacy manual was  added.  
 
Section 7.4 Visit 02: 
Study Day 8  
 Added saliva and nasal 
samples collection  To evaluate presence of NoV viral protein (VP1) 
antibody on Day 8,  saliva and nasal samples 
collections were added.  
Section 7.6.   
Visits 04 – 08: Post 
Challenge  
Observation Period  
(Day 29 – Day 33 [+ 
3 Days]) 
 Updated frequency of 
collection of vital signs and 
NVV signs and symptoms  
collection of immunogenicity 
blood samples  To allow for more accurate and timely collection 
of NVV signs and symptoms for analysis, 
frequency of collection of signs and symptoms 
was changed from every 2 hours to twice a day 
(am and pm).  
 
Fixed whole blood sample collection was added 
to be collected on Day 33 to evaluate further 
immunogenicity during the challenge phase.   
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 106 of 114 
Date: 25 May 2023  
 Section 7.13 
Immunogenicity 
Assessment  
 Updated Immunogenicity 
Assessment  Removed Ad5 neutralizing antibody and  
Nab responses by [CONTACT_300084] (optional)  
 
 
 
 
VXA-NVV-201 Protocol Amendment  2 (Version. 3.0), 07 January 2022 
 
Overall Rationale for the Amendment:   
 
Protocol Amendment 1 (Version 2.0) of this phase 2 Norovirus GI.1 challenge protocol (VXA -NVV-201) was 
finalized in December 2021 , was approved by [CONTACT_300085].  However, during study set-
up areas for modification were identified. These included the need to add testing for influenza A & B prior to 
viral challen ge and to clarify that subjects must be negative for enteric pathogens ( via BioFire) as well as 
influenza prior to challenge.  Additionally, to ensure more accurate and timely collection of solicited symptoms 
of reactogenicity post vaccination and signs  and symptoms of norovirus illness post viral challenge the use of 
an e-Diary (rather than paper diary card) is being implemented in Amendment 2. Lastly, the initial drug product 
lot of VXA -G1.1-NN vaccine tablets to be utilized for dosing in this study ha s a concentration of 2. 2x109 IU 
per tablet.  Therefore, to deliver the full clinical dose of 1x1011 IU±0.5 log  ~[ADDRESS_366332] also been 
incorporated into Amendment 2 (Version 3.0).  
 
The table below summarizes the changes incorporated into Amendment 2 and provides  a brief rationale for 
each modificatio n. 
 
Section No.  
& Title Description of Change  Brief Rationale  
List of 
Abbreviations 
and Acronyms  Additions of e-Diary Updated with new terms utilized in 
Amendment 2 for sake of completeness.  
Globally 
throughout  
Protocol Reference to diary cards has been modified to e -
Dairy (electronic diary)  To allow for more accurate and timely 
collection of solicited symptoms of 
reactogenicity post vaccination and signs 
& symptoms of norovirus illness post viral 
challenge, e -Diary will be used instead of 
paper diar y cards. 
Synopsis 
4.[ADDRESS_366333] 
Inclusion 
Criteria  Inclusion Criteria # 9: Italicized text added  
 
Male subjects must agree not to father a child or 
donate sperm , as well as to use 
contraception/barrier (a male condom) or be 
abstinent from heterosexual intercourse,  from 
vaccination through the active period (Day 57)  The inclusion criteria regarding male birth 
control and contraception was expanded 
for added clarification.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 107 of 114 
Date: 25 May 2023  
 Section 1.6: 
Table 14 Table 14:   Description of illness after challenge 
with two different doses of Norwalk virus (Study 
VXA-G11-201.1) The forma tting for table 14 for corrected.  
No changes were incorporated to the data 
presented.  
Section 5.1.3 : 
Drug Product 
Dosage 
Preparation and 
Administration  
Section 7.3: 
Visit 01: Study 
Day 1, Study 
Drug 
Administration   Preparation of Drug Product: the following 
paragraph was added:  
The initial lot of VXA -G1.1-NN DP [Lot: DP -
05.[ZIP_CODE]] that will be utilized for clinical dosing 
in this protocol has a concentration of 2.2x109 
IU per tablet. Therefore, multiple tablets (n=45) 
of the DP will be dispensed per dose to deliver 
the complete investigational dose of 1x1011 IU ± 
0.5 logs in the active treatment group. To 
maintain the study blind, the same number of 
placebo tablets (n=45) will be dispensed to 
subjects in the control group.  
 
Study Drug Administration  – additional 
information was added as shown below:  
Study subjects should be fasting and refrain from 
ingesting solid food for at least  4 hours prior to 
initiation of oral dosing.  Following 
randomization subjects will be dispensed their 
assigned DP dose  (VXA-G1.1-NN or placebo 
tablets) on Day 1.  Dosing will be divided into 
three sub-dosing periods: Time = 0 (dose 1/3), 
Time = 2 hours (dose 2/3) and Time = 4 hours 
(dose 3/3). At each of the 3 sub -dosing periods 
15 tablets will be dispensed, which subjects w ill 
swallow with 360 to 480 mL of water. After each 
sub-dose subjects will be dispensed a light snack 
(e.g., crackers) to aid in tablet transit out of the 
stomach. A total of 45 tablets will be dispensed 
to deliver a full vaccine dose of 1x1011 IU ± 0.5 
logs or a matching placebo dose.   Normal food 
consumption may resume 90 minutes after 
dosing. 
 The VXA-G1.1-NN vaccine DP [Lot# 
DP-05-[ZIP_CODE]] that will supply  dosing in 
this study has a per tablet concentration of 
2.2x109 IU.  Therefore, to deliver the full  
clinical dose of 1x1011 IU±0.5 log ~45 
tablets will need to be administered.  To 
accommodate delivery of the high number 
of tablets and to ensure adequate 
absorption in the small intestines,  dosing 
at Day 1 has been divided into 3 sub -
doses of 15 tablets per sub-dose, 
administered 2 hours apart over a 4 -hour 
period 
 
Information on study drug administration 
procedures with sub -dosing over 4 hours 
was added.  
Section 7.2 Visit 
00: Screening 
Visit (Study Day 
-45 to -1  
Appendix A  : 
Schedule of 
Events The Blood sample for BT [ADDRESS_366334] was within this section in error.  
No immunogenicity samples are being 
collected prior to Day 1.  
Section 7.3  
Visit 01: Study 
Day 1, Study A note was added indicating the following:  
(Note: Safety labs do not need to be performed if 
screening safety lab tests were completed within Modification was incorporated stating that 
if the safety labs for the screening visit 
were collected within 2 days of the 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 108 of 114 
Date: 25 May 2023  
 Drug 
Administration  
Appendix A: 
Schedule of 
Events 2 days prior to study drug administration  on 
Day 1)  baseline visit at Day 1, then the screening 
values can be utilized for Day 1 safety 
assessments and do not need to be 
repeated. 
Section 7.5: 
Visit 03: Study 
Day 28 [+30 
days], 1 day 
prior to 
challenge  The following note has been added:  
Note: Day [ADDRESS_366335]’s original Day [ADDRESS_366336]’s challenge visit is 
delayed (+ 30 days).  
 Note added to clarify that Day 28 
immunogenicit y samples should be 
collected at the scheduled visit (4 weeks 
posts vaccination), even  if the subject’s 
challenge visit is delayed (+ 30 days) , to 
allow consistency across all subject data 
for this timepoint.   
Section 7.5: 
Visit 03: Study 
Day 28 [+30 
days], 1 day 
prior to 
challenge  
Appendix A: 
Schedule of 
Events Influenza A & B antigen test has been added to 
the pre-challenge assessments at Day 28 (+ 30 
days) Screening for influenza A & B has been 
added pre -challenge to ensure that 
subjects infected wi th flu are not 
participating in the viral challenge. 
Screening out these subjects will ensure 
that infectious subjects are not being 
admitted to the clinical isolation unit, 
and to help ensure that signs & 
symptoms associated with flu are not 
being interpr eted as associated with NV 
illness.  
Section 7.6.2  : 
Viral Challenge 
Eligibility  The following to criteria added to the list for viral 
challenge eligibility:  
• positive for enteric pathogens (Bio Fire) 
• positive Influenza A or B antigen test result  
 Screening out subjects positive for 
enteric pathogens and influenza will 
ensure that infectious subjects are not 
being admitted to the clinical isolation 
unit, and to help ensure that assessments 
of signs & symptoms of  NV illness are 
not confounded due to  preexisting 
infection.  
Section 15: 
References  Section was moved to be presented directly 
following Section 14.  Moved to remain with the body of the 
protocol rather than following the 
Appendices. No change to content was 
incorporated.  
Additional minor wording, spelling and/or formatting modifications have been incorporated 
for added clarity and consistency.  
  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 109 of 114 
Date: 25 May 2023  
 VXA-NVV-201 Protocol Amendment  1 (Version. 2.0), 01 December 2021  
 
Overall Rationale for the Amendment:   
 
The original version of this phase 2 Norovirus GI.1 challenge protocol (VXA-NVV-201) was 
finalized in October [ADDRESS_366337] (VXA -G1.1-NN vaccine)  at the time .  The study is being reinitiated at this time utilizing the 
same sample size and study design as the original protocol.  Updates to the background and clinical 
experience sections, as well as t he Sponsor and Clinical Site location and study teams have been 
incorporated within Protocol Amendment 1. Additionally, safety and risk information has been 
updated to incorporate clinical experience with the Vaxart oral vaccine platform as well as 
regulatory input obtained over the past few years.  
 
The table below summarizes the changes incorporated into Amendment 1 as well as a brief rationale 
for each modification.  
 
Section No.  
& Title Description of Change  Brief Rationale  
Title Page  Vaxart’s address and study team contact [CONTACT_300086].  
The Clinical site ’s address and contact [CONTACT_300087].  The title page has been updated to 
reflect current information on the 
Sponsor and clinical site.  
List of 
Abbreviations 
and Acronyms  Additions of CyTOF, Nab, PF4 and TTS  Updated with new terms utilized in 
Amendment 1 for sake of 
completeness . 
Synopsis  
6.3 Preparation 
and 
Administration  
of NV Challenge 
Virus Information on the  Viral inoculum illness/infection rate 
has been updated based on the G1.1 titration study 
completed in 2019 (Mateo, et al).  
Original 60% - 70%- changed to 50% -65% Updated to reflect most current 
information.  
Synopsis Cohort sizes have been updated based on  
new isolation ward capacity  The size of the subject cohorts ha s 
been reduced to accommodate the 
size of the clinical isolation unit 
which has [ADDRESS_366338] 
Exclusion 
Criteria  Exclusion Criteria:  
An exclusion criteri on has been  added to exclude 
subjects at risk for clotting events and 
thrombocytopenia #4 and #5  
4. Laboratory values outside the range of normal for 
platelet counts and the following coagulation 
tests: PT/INR, aPTT an d fibrinogen  
5. Any of the following history or conditions that 
may lead to higher risk of clotting events and/or 
thrombocytopenia:  Per guidance received from FDA, 
subjects will be screened for risk 
factors of clotting disorders prior to 
dosing and excluded if they have 
laboratory values or family history 
that places them at higher risk of 
thrombocytopenia and thrombosis 
syndrome (TTS) , that has been 
reported  with some injected Ad5 
vectored vaccines for COVID -19. 

Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 110 of 114 
Date: 25 May 2023  
 i. Family or personal history of bleeding or 
thrombosis  
j. History of heparin -related thrombotic events, 
and/or receiving heparin tre atments 
k. History of autoimmune or inflammatory 
disease 
l. Presence of any of the following conditions 
known to increase risk of thrombosis within 6 
months prior to screening:  
▪ Recent surgery other than removal/biopsy 
of cutaneous lesions  
▪ Immobility (confined to bed or wheelchair 
for 3 or more successive days)  
▪ Head trauma with loss of consciousness or 
documented brain injury  
▪ Receipt of anticoagulants for prophylaxis 
of thrombo sis 
▪ Recent clinically significant infection   (See Section 2.1: Potential Risks and 
Benefits).  
4.[ADDRESS_366339] 
Exclusion 
Criteria Exclusion Criteri on #6: ECG findings within [ADDRESS_366340] 
Exclusion 
Criteria Exclusion Criteri on #14: Added in clarification for 
Malabsorption to include e.g. Celiac disease, gluten 
intolerance  Additional information added for 
sake of clarification.  
4.[ADDRESS_366341] 
Exclusion 
Criteria Exclusion Criteri on #24: Removed stool sample with 
occult blood during  screening and added in its place, 
History if hematochezia (blood in stool) or melena 
(black stool).  Vaxart has dosed ~600 adult subjects 
up to age 80 years with its oral Ad5 
vaccines.  A safety signal (solicited 
and/or unsolicited AEs) related to GI  
bleeding has not been observed.  
Hence to facilitate the screening 
process, the test for occult blood at 
screening has been removed.  
However, a new exclusion criterion 
which specifically excludes 
individuals with any history of GI 
bleed has been added.  
4.[ADDRESS_366342] 
Exclusion 
Criteria Exclusion Criter ion #29: Added clarification for the 
drug test positive for marijuana; concurrent or ongoing 
use of marijuana during the active study period.  Additional information added for 
sake of clarification.  
Synopsis  Within Safety, Immunogenicity and Microbiological  
Safety Assessments: Solicited symptoms of 
reactogenicity. Myalgia (Muscle pain) was added  Inadvertently left out of the original 
protocol 
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 111 of 114 
Date: 25 May 2023  
 Synopsis 
3.2.4 
Immunogenicity 
Endpoints  
7.13 
Immunogenicity 
Assessments  Within Safety, Immunogenicity and Microbiological  
Assessments and Study Endpoints:  
VP1 specific serum IgA (by [CONTACT_19487]) was added into the 
Primary Immunoassays and removed from Exploratory 
Immunoassays.  
Both the VP1 Specific serum IgA and IgG will be run 
by [CONTACT_300088] E LISA Updates incorporated based on 
advancements in assay development 
achieved by [CONTACT_300089]. The VP1 specific serum IgA 
(by [CONTACT_19487]) will be qualified, hence 
elevated to a primary assay in the 
protocol. 
Synopsis 
3.2.4 
Immunogenicity 
Endpoint 
7.2 Visit 00: 
Screening Visit  Additional information added for safety laboratory 
panels Additional information added for 
sake of clarification.  
1.[ADDRESS_366343] several years.  Modified to include updated 
information.  
1.4.3 Clinical 
Study VXA -
NVV-103 with 
VXA-G1.1-NN 
and VXA -G2.4-
NS Additional information on the VXA -NVV-103 was 
added. Including:  
• Overall Study Design and Plan  
• Table 8: Design of Study VXA -NVV-103 
• Summary of safety  
• Table 9: Summary of Solicited symptoms of 
reactogenicity  
• Summary of Immunogenicity Analysis   Modified to include updated 
information.  
1.6  NV 
Challenge Dose 
Titration Study 
and Dose 
Justification  Additional information from the VXA -G11-201.1 
Study: 
• Table 14: Description of illness after challenge 
with two different doses of Norwalk virus 
(Study VXA-G11-201.1). Was updated with all 
compi[INVESTIGATOR_248375]  
• Clinical outcome was added  
• Table 15: Summary of the correlation between 
acute gastroenteritis and NV positivity by 
[CONTACT_9084]. Added  
• Table 16: Characterization of diarrhea in 
subjects with acute gastroenteriti s and NV 
positivity by [CONTACT_9084] (by [CONTACT_8477]). Added  Modified to include updated 
information.  
1.7  Summary of 
Clinical 
Experience with 
Vaxart Oral 
Vaccine Platform  Summary of Clinical Experience with Vaxart Oral 
Vaccine Platform section and Table 7 where updated to 
include recent completed studies.  
 Modified to include updated 
information.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 112 of 114 
Date: 25 May 2023  
 1.9 Potential 
Risks and 
Benefits  Additional of:  
“Since the initiation of the current protocol, multiple 
injected adenovirus vectored vaccines approved for use 
via Emergency Use Authorization (EUA) for the 
prevention of COVID -[ADDRESS_366344] reported severe events of 
thrombosis in combination with thrombocytopenia 
(thrombosis with thrombocytopenia syndrome, TTS), in 
some cases accompanied by [CONTACT_79602]. Though the TTS 
events were reported with adenovirus vectored 
vaccines for COVID -19, the FDA has asked Sponsors 
of adenovirus vectored vaccines for other indications to 
broadly monitor for these risks.  
Investigators should be alert to the signs and symptoms 
of thromboembolism and/or thrombocytopenia. Study 
participants should be instructed to seek immediate 
medical attention if they develop symptoms including, 
but not limited to , shortness of breath, chest pain, leg 
pain and/or swelling, persistent abdominal pain, severe 
or persistent headaches, blurred vision or other vision 
changes, mental status changes or seizures, petechia, 
purpura beyond the site of vaccination, and/or easy  
bruising/bleeding. The medical management of 
thrombosis with thrombocytopenia is different from the 
management of isolated thromboembolic diseases. 
Investigators should follow available guidelines for the 
assessment and treatment of thrombotic 
thrombocyto penia (e.g., American Society of 
Hematology 2021British Society for Haematology 
2021; CDC 2021). The use of heparin may be harmful 
and alternative treatments may be needed. Consultation 
with hematologists is strongly recommended”.  Because Vaxart’s VXA -G1.1-NN 
investigational vaccine utilizes an 
adenovirus vectored design, and per 
the direction of the FDA, information 
on the risks of thromboembolism and 
/or thrombocytopenia have been 
added to Section 1.9 of the protocol.   
1.9.2 Norovirus 
Challenge Risks  The amount of time expected to elicit acute watery 
diarrhea was changed to 12 -72 hrs from 18 to 48 hrs  Information was updated based on 
the findings in the GI.1 norovirus 
titration study (VXA -NVV-201.1). 
7.2 Visit 00: 
Screening Visit  Addition of  
•Blood Sample: coagulation tests, lab panel (PT/INR, 
aPTT and fibrinogen  
Subjects will be reminded to fast and refrain from 
ingesting solid food for at least [ADDRESS_366345] (rather than 8 hours) 
prior to study drug administration 
should be sufficient.  
7.3 Visit 01  : 
Study Day 1, 
Study Drug 
Administration  Addition of : 
Drug screen (urine and alcohol breath test)  A drug screen was added to study 
day 1 (prior to vaccination) as part of 
the screening process.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 113 of 114 
Date: 25 May 2023  
 7.5 Visit 03  : 
Study Day 28 
[+30 days], 1 day 
prior to challenge  Addition of :  
Any subject who is deemed ineligible will be 
discharged from unit prior to challenge. Subjects may 
return for re -evaluation of challenge eligibility within 
30 days of their original Day 28 Visit.  If they are 
assessed to be eligible for challenge at that time, they 
may be included for challenge with a subsequent 
cohort. A 30-day window was added to the 
pre-challenge visit (Day 28) to add 
flexibility for subjects that may not 
be eligible or available at the original 
visit timepoint. This change is not 
expected to impact the study 
immunogenicity and efficacy 
evaluations, however, will aid in 
reducing the screen failure rate for 
the challenge period.  
7.11.2 Early 
Termination (Day 
29 - Day 57;  
Challenge Phase  Addition of : 
Subjects who did not undergo challenge and 
discontinue between Days 29 and Day 57 do not need 
the above listed ET assessments, but rather should be 
managed as early terminations during the Safety 
Follow-up Period (see Section 7.11.3)  Informati on added for sake of 
clarification.  
7.13 
Immunogenicity 
Assessments  Addition of :  
Additional exploratory immunogenicity assays may 
also be performed to further evaluate the activity of the 
VXA-G1.1-NN vaccine candidate on samples stored for 
future use (wi th subjects’ consent).  Note that not all 
sample timepoints may be relevant for the some of the 
analysis, so not all assays will be performed at all 
timepoints  Information added for sake of 
clarification.  
11.4 Final 
Analysis Plan  Deletion of: 
A preliminary report will be prepared by [CONTACT_300090] [ADDRESS_366346] of this trial.   Information was deleted as not 
relevant for the clinical protocol.  
14.3 Informed 
Consent Process  Addition of : 
The Informed Consent Form explains the storage and 
future use of specimens, and subjects will be asked to 
consent for future testing of samples  Information added for sake of 
clarification.  
Appendix E  : List 
of Adverse 
Events of Special 
Interest Addition of : 
Coagulopathy  
• Acquired amegakaryocytic thrombocytopenia  
• Axillary vein thrombosis  
• Cerebral venous thrombosis  
• Disseminated intravascular coagulation  
• Hepatic vein thrombosis  
• Intracranial venous sinus thrombosis  
• Portal vein thrombosis  The list of AESI to be monitored 
under this protocol was updated 
based on the most recent list of 
events received by [CONTACT_300091]’s 
oral Ad5 vaccine candidates.  
Norwalk GI.1 Challenge                                                                                               Protocol Number: VXA-NVV-201 
___________________________________ ________ ___________________________ __________   
 
_________________________________ ____________________________________________ ____ 
Version 6.0                                                       Confidential                                      Page 114 of 114 
Date: 25 May 2023  
 • Pulmonary thrombosis  
• Severe fever with thrombocytopenia syndrome  
• Thrombocytopenia  
• Thrombotic thrombocytopenia purpura  
• Transverse sinus thrombosis  
• Vena cava thrombosis  
• Amegakaryocytic thrombocytopenia  
• Cavernous sinus thrombosis  
• Deep vein thrombosis  
• Embolism venous  
• Immune thrombocy topenia 
• Mesenteric vein thrombosis  
• Pulmonary embolism  
• Pulmonary venous thrombosis  
• Subclavian vein thrombosis  
• Thrombocytopenia purpura  
• Thrombosis  
• Vena cava embolism  
• Venous thrombosis   
Additional minor wording, spelling and/or formatting modifications have been incorporated 
for added clarity and consistency.  
 